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General introduction
In recent decades, the percentage of caesarean deliveries has increased in 
most developed countries. There are some well-known complications, such as 
uterine rupture and pathologically adherent placenta in future pregnancy.1,2 
Only recently, the presence of a niche at the site of a caesarean scar in the 
uterus has been observed.3-6 A niche is mainly a sonographic finding and has 
been defined as an indentation representing myometrial discontinuity at the 
site of the caesarean scar that communicates with the uterine or cervical cavity 
as seen on contrast-enhanced sonohysterography (SHG)7 (Figure 1). Alternative 
terms for a niche are caesarean scar defect3,8,9, deficient caesarean scar10, 
diverticulum11, pouch5 and isthmocele12. We believe that the terms ‘deficient’ or 
‘defect’ should be avoided, as they imply a relationship between the appearance 
of a niche and function13, particularly in a future pregnancy, and therefore we 
prefer the term niche. 
8 | Chapter 1
Figure 1: Longitudinal section of a uterus, performed with the use of contrast-enhanced sonohysterography. 
The black arrow shows the niche at the site of the caesarean scar. 
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Imaging
Until now, there is no gold standard for the detection and measurement of a niche. 
The niche is mostly evaluated with the use of transvaginal sonography (TVS)4,8-
10,14,15 and SHG4,15-19, and a minority is evaluated with the use of hysteroscopy5,12,16 
or hysterosalpingography11. TVS without contrast is a widely used method to 
identify niches, but SHG may facilitate their detection as it provides a more clear 
delineation of a niche as the uterine cavity is filled with a contrast medium18. Using 
saline as a contrast medium is called saline contrast sonohysterography (SCSH) 
and filling the uterine cavity with gel is called gel instillation sonohysterography 
(GIS). A problem that occurs during SCSH is unstable filling and inadequate 
distension of the uterine cavity owing to backflow of saline. As gel has a higher 
viscosity, GIS may produce a more stable filling of the uterine cavity.20 However, 
it is unknown if GIS is a better diagnostic method in comparison with the more 
regularly used SCSH for examination of the uterine cavity. 
 
No consensus exists regarding the gold standard for the detection and 
measurement of a niche. As a result, a wide range in niche prevalence has 
been reported up to now, and each study uses different methods for niche 
measurement. In addition, no studies have been performed yet in which the 
reproducibility of niche measurement was evaluated in non-pregnant women. 
 
Risk factors
As mentioned above, there is a wide range in the reported prevalence of a niche. 
For TVS, the prevalence varies between 42% and 70% in studies with a random 
population of women with a history of one or multiple caesarean sections 
(CSs)3,8,18 and the prevalence for SHG varies between 58% and 84% in studies with 
a random population.6,15,18 If also studies with a selected population of women 
with gynaecological symptoms are included, then there is even more variation 
in prevalence.9,10,16,17,21,22 We do know from these studies that not all women with 
a history of CS develop a niche. Therefore, it is relevant to study risk factors for 
the development of niches and risk factors for the development of symptoms in 
women undergoing a CS. 
Symptoms
There is growing interest in possible associations between the presence of a 
niche and various gynaecological symptoms, and in the mechanisms behind the 
development of these symptoms. Several studies reported that there is a relation 
between the presence of a niche and postmenstrual spotting.5,9,19 Different 
hypotheses have been postulated to explain the aetiology of bleeding disorders 
in relation to a niche. Postmenstrual spotting may be due to the retention of 
menstrual blood in the niche, which is intermittently expelled after the majority 
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of the menstruation has ceased.19,23 This may depend on poor contractility of the 
uterine muscle around the scar19 and the presence of (fibrotic) tissue below the 
niche, which may impair the drainage of menstrual flow through the cervix23. At 
the time of designing our two prospective cohort studies, large prospective cohort 
studies that consecutively included women with a history of CS and assessed the 
association between a niche and abnormal uterine bleeding, were lacking. Other 
reported symptoms in women with a niche are dysmenorrhea, chronic pelvic 
pain, dyspareunia and urinary symptoms.9 In addition, a pregnancy may develop 
in a niche, which is a rare form of ectopic pregnancy. The incidence of caesarean 
scar pregnancies (CSPs) ranges from 1:1800-1:2216 pregnancies and constitutes 
6.1% of all ectopic pregnancies in patients with a history of at least 1 caesarean 
delivery.24,25 Because a CSP can lead to uterine scar rupture and haemorrhage, a 
life threatening condition for both mother and child may occur if the pregnancy 
is allowed to continue, even in the first trimester.26 However, there is still no 
consensus about an optimal treatment modality for a CSP. 
Aim of this thesis
The aim of this thesis is to evaluate the diagnostics (part I), clinical consequences 
of a niche and risk factors (part II), and treatment modalities of a niche pregnancy 
(part III). The studies aim to answer the following questions:
Part I (diagnostics)
- What is the difference between saline contrast sonohysterography (SCSH) and 
gel instillation sonohysterography (GIS) as diagnostic method for the evaluation 
of the uterine cavity? Which technique is preferable?
- What is the reproducibility of the measurement of the size and volume of a 
niche, its residual myometrial thickness (RMT) and assessment of its shape, with 
the use of three-dimensional (3D) ultrasound volumes?
- What is the prevalence of a niche in women with a history of CS using both TVS 
and SHG?
Part II (gynaecological symptoms and risk factors)
- What is the relationship between the presence of a niche and abnormal uterine 
bleeding and urinary symptoms?
- Are sonographic features of a niche, such as niche size and volume, related to 
these symptoms?
- What are risk factors for the development of a niche?
Part III (niche pregnancy)
- What is the best treatment modality for a CSP?
500835-L-bw-Dieleman
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Outline of the thesis
The first part of this thesis focuses on sonographic evaluation of the uterus, 
including the niche. In the second part, risk factors for a niche and niche related 
symptoms are evaluated. In the last part of this thesis, treatment modalities for 
a niche pregnancy are described. 
Chapter 2 compares the effect of two different types of distension fluid, either 
saline or gel, on diagnostic features in the evaluation of intrauterine abnormalities 
and patient discomfort during SHG in a prospective cohort study. In chapter 3, 
the inter- and intraobserver agreement for the measurement and assessment of 
niches is evaluated using stored 3D TVS volumes. 
In Chapters 4 and 5, the prevalence of a niche and related symptoms are 
evaluated in two different cohort studies with different populations, using both 
TVS and GIS. In chapter 4, 3D SHG is also used for the assessment of niche 
volume. Chapter 6 is a systematic review of the medical literature, evaluating 
the prevalence of a niche using various diagnostic methods, potential risk factors 
for the development of a niche and niche-related gynaecological symptoms in 
non-pregnant women. 
Chapter 7 reports 4 cases of women with a CSP and their treatment and follow-
up. An overview of the literature is provided concerning treatment and follow-up 
of CSPs. Based on our experience and the literature, treatment recommendations 
for CSP are given. 
In Chapter 8, we discuss the results of our studies and clinical implications, and 
we will provide suggestions for future research. Finally, a summary of this thesis 
in English and Dutch is provided in Chapter 9.
500835-L-bw-Dieleman
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Abstract
Objective
To compare gel instillation sonohysterography (GIS) with saline contrast 
sonohysterography (SCSH) as diagnostic methods for the evaluation of the 
uterine cavity.
Methods
A prospective cohort study was performed at the Department of Obstetrics 
and Gynecology of the VU University Medical Center, Amsterdam, between 
September 2007 and April 2008. We included 65 women suspected of having 
an intrauterine abnormality with an indication for SCSH/GIS. First SCSH and 
subsequently GIS were performed in all women. Distension of the uterine cavity, 
image quality, visualization of intrauterine abnormalities and pain experienced 
on a visual analog scale (VAS score) were recorded for both procedures.
Results
The mean distension with GIS was 9.0 mm and with SCSH it was 8.5 mm (P = 0.15). 
The mean image quality, on a scale from 0 to 5, for SCSH was 4.0 and for GIS it 
was 3.6 (P = 0.01). No difference was found for the visualization of intrauterine 
abnormalities, and the VAS scores for pain experienced on SCSH and GIS were 
1.5 and 1.6, respectively (P = 0.62).
Conclusions
The image quality of SCSH is slightly better than that of GIS. This difference 
is likely to be attributable to the presence of air bubbles in the gel. The small 
difference in uterine cavity distension in favor of GIS and comparable stable 
distension during at least 4 min make GIS a suitable alternative for SCSH if air 
bubbles can be prevented.
16 | Chapter 2
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Introduction
Abnormal uterine bleeding is highly prevalent and an important factor in female 
health. Saline contrast sonohysterography (SCSH) is an appropriate technique 
for the detection of focally growing lesions such as polyps and fibroids1,2. With 
a sensitivity of 0.95 and a specificity of 0.88 it is an accurate diagnostic tool in 
the evaluation of the uterine cavity in premenopausal and postmenopausal 
women3. The uterine cavity is distended with physiological saline, which serves 
as a contrast medium and enables visualization of the endometrial surface. A 
problem that occurs during SCSH is unstable filling and inadequate distension of 
the uterine cavity owing to backflow of saline. In addition, patients experience 
discomfort owing to fluid leakage. In trying to overcome these disadvantages, 
the SCSH technique can be modified by instilling gel instead of saline. In one 
study hydroxyethyl glycerin gel was used, showing good distension and stable 
filling without backflow problems4. Comparison of both procedures has not 
been published yet. The purpose of this study was to compare gel instillation 
sonohysterography (GIS) with SCSH as diagnostic methods for the evaluation of 
the uterine cavity, with the focus on distension of the cavity.
Methods
This study was performed at our department of obstetrics and gynecology 
between September 2007 and April 2008. Women attending the department 
and suspected of having an intrauterine abnormality were asked to participate 
in the study. The following were used as inclusion criteria: all premenopausal 
women with abnormal uterine bleeding; postmenopausal women with abnormal 
uterine bleeding and endometrial thickness > 4 mm; women with infertility in 
combination with irregular endometrium and/or endometrial thickness > 10 
mm; women with a history of premature birth in combination with irregular 
endometrium and/or endometrial thickness > 10 mm. Because of logistic reasons 
inclusion was not possible on certain days, while on other days women who met 
the inclusion criteria were included consecutively. Exclusion criteria were risk 
of pelvic inflammatory disease, presence of cervical cancer, pregnancy or being 
premenopausal and in the luteal phase without use of contraception.
Gynecologists and sufficiently trained residents performed first SCSH and 
subsequently GIS with the Goldstein Sonohysterography Catheter, which is 26 
cm in length and 2.4 mm in diameter (Cook Medical, Spencer, USA). Most patients 
were pretreated with a non-steroidal anti-inflammatory drug (500 mg naprosine 
1 day and 1 h before the procedure). Before performing SCSH, sterile saline 
Comparison of SCSH with GIS | 17
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was flushed through the catheter to rid it of small amounts of air and the cervix 
was cleaned with povidone–iodine solution. The catheter was inserted through 
the cervical canal and the ‘acorn’ of the catheter was adjusted at the external 
cervical os to reduce leakage of instilled saline. The transvaginal transducer 
was introduced and real-time ultrasonographic imaging (Accuvix XQ, Medison, 
Korea) was performed with the simultaneous, continuous instillation of sterile 
saline solution (0.9% sodium chloride) into the uterine cavity. Distension was 
assessed by measuring the greatest distance between the anterior and posterior 
uterine walls in the midsagittal section. A score between 0 and 5 was given for 
image quality, with 0 expressing low image quality and 5 expressing high image 
quality with optimal visualization. The score was based on the following criteria: 
contrast, sharpness and brightness of the image; air bubbles and other artifacts; 
distension; visualization in case of an intrauterine abnormality (e.g. contrast 
around the abnormality, possibility of assessing the intracavitary protrusion). In 
case of an intrauterine abnormality, the sonographer recorded the nature (e.g. 
submucous fibroid, polyp, Müllerian duct anomaly or artifact). The women were 
asked to express the pain experienced during instillation of the fluid using a 
visual analog scale (VAS), which is a measure of pain intensity, with 0 equivalent 
to no pain and 10 equivalent to the worst pain imaginable.
Immediately after this procedure GIS was performed with the same catheter and 
with the use of Endosgel (Farco-Pharma, Köln, Germany) instead of saline solution. 
Endosgel is a sterile gel preparation, which has long been used by urologists 
for intraurethral instillation before cystoscopy, and contains chlorhexidine 
gluconate, sodium lactate, methyl hydroxybenzoate, propyl hydroxybenzoate, 
hydroxyethylcellulose and purified water. A syringe was connected to the base 
of the catheter, which was still located in the uterine cavity. A vacuum was 
created in the curette by withdrawing the plunger and negative pressure was 
applied until no fluid appeared in the catheter. A syringe was filled with Endosgel, 
connected to the base of the catheter and realtime ultrasonographic imaging 
was performed with the simultaneous instillation of gel. The instillation of gel 
was stopped when the patient felt slight menstrual-like cramps, backflow started 
or a maximum of 10 mL had been reached. The greatest distance between the 
anterior and posterior walls was measured, a score for the image quality and 
pain (VAS) during instillation of gel was given, and the presence of intrauterine 
abnormalities was recorded.
To evaluate the distension in time with GIS, distension curves were created. 
The distension in five consecutive women who were suspected of having an 
intrauterine abnormality was measured at different time points between 0 and 5 
min after the instillation of gel and removal of the catheter.
500835-L-bw-Dieleman
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Statistical analysis
The primary outcome was a difference in distension of the uterine cavity. 
A difference of 1.5 mm in distension was considered to be clinically relevant. 
Because of a lack of prior studies and in order to prevent an underpowered study, 
a standard deviation of 4.0 mm was chosen to perform a power calculation. To 
achieve 80% power and an alpha of 5%, 56 women would be needed to detect a 
difference of 1.5 mm in distension. Anticipating technical or procedural failures, 
we decided to include 65 patients.
The difference in distension between SCSH and GIS was evaluated with the paired 
samples t-test and the difference in visualization of intrauterine abnormalities 
was tested with the chi-square test. The Wilcoxon signed-rank test was used to 
evaluate the difference in quality of the ultrasound images and VAS score. All 
statistical analysis was performed two-sided using Statistical Packages for the 
Social Sciences software (SPSS, Inc., Chicago, IL, USA), and P of less than 0.05 was 
considered statistically significant.
Results
SCSH and GIS were performed in 65 women suspected of having an intrauterine 
abnormality, after they had given informed consent. Most women undergoing 
SCSH/GIS had complained of heavy and/or irregular menstrual bleeding (49%) 
or infertility (20%). The findings for SCSH and GIS are presented in Table 1. 
Distension after GIS was slightly higher than with SCSH (9.0 mm vs. 8.5 mm), 
but this difference did not reach statistical significance (P = 0.15). All relevant 
intrauterine abnormalities detected with SCSH were also identified using GIS 
(P = 1.00): 14 fibroids (22%), nine polyps (14%) and two Müllerian duct anomalies 
(3%). Four (6%) artifacts (not air bubbles) were seen with GIS, while three (5%) 
were seen with SCSH (P = 0.72). The mean image quality for SCSH and GIS was 4.0 
and 3.6, respectively, on a scale from 0 to 5 (P = 0.01). The pain experienced was 
comparable for SCSH and GIS, with mean VAS scores of 1.5 and 1.6, respectively 
(P = 0.62). Distension curves were created for five women, and show that the 
distension was stable during at least 4–5 min (Figure 1).
Discussion
Distension of the uterine cavity was 6% greater when using GIS than when using 
SCSH but this difference did not reach statistical significance. We expected more 
distension with GIS owing to the higher viscosity of the gel, but menstrual-like 
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Figure 1: Distension of the uterine cavity after instillation of gel and removal of the catheter in five different women. 
Table 1: Comparison of saline contrast sonohysterography (SCSH) with gel instillation sonohysterography (GIS) for 
distension, detection of intrauterine abnormalities, image quality and painscore.
SCSH GIS P
Distension of uterine cavity (mm, mean ± SD) (95% CI) 8.5 ± 4.2 (7.4-9.6) 9.0 ± 4.6 (7.8-10.1) 0.15
Women with uterine cavity abnormality (n (%)) 21 (32%) 21 (32%) 1.00
Women with submucous fibroid (n (%)) 14 (22%) 14 (22%) 1.00
Women with polyp (n (%)) 9 (14%) 9 (14%) 1.00
Women with Müllerian duct anomaly (n (%)) 2 (3%) 2 (3%) 1.00
Women with artifact (n (%)) 3 (5%) 4 (6%) 0.72
Image quality (mean ± SD) (95% CI)* 4.0 ± 1.1 (3.7-4.3) 3.6 ± 1.3 (3.3-3.9) 0.01
VAS score for pain (mean ± SD) (95% CI)† 1.5 ± 1.7 (1.0-1.9) 1.6 ± 2.1 (1.1-2.2) 0.62
*Quality assessed on a range from 0 (low quality) to 5 (high quality). 
†Pain assessed on a visual analog scale (0-10).
cramps and backflow may have limited the instilled gel volume. The distension 
of the cavity depends on the instilled volume, the instillation rate, the time of 
instillation, the backflow rate and the intracavitary pressure. Although instillation 
of saline solution and gel, and therefore distension, are partly operator 
dependent, we tried to standardize both procedures. Instillation of saline solution 
was always performed with the same pressure (80 mmHg) and instillation of gel 
was stopped when the patient felt slight menstrual-like cramps, backflow started 
or a maximum of 10 mL had been reached. Complete standardization of the two 
methods would have been impossible because of the difference in viscosity 
between the two fluids and the different instillation techniques used in clinical 
practice and therefore in this study (e.g. instillation of saline solution was with a 
continuous flow). The distension per milliliter is expected to be higher with gel 
since the instillation of saline solution was continuous, but we did not quantify 
this in the current study. The distension may also have been influenced by the 
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study design, since SCSH was always performed first and we did not succeed in all 
cases in removing the saline solution from the cavity completely. Nevertheless, 
it seems likely that the remainder of the saline solution was expelled by the gel 
through the cervix or Fallopian tubes.
It would have been appropriate to report the proportion of cases reaching a 
certain threshold volume using each technique, but the disadvantage with this 
approach is that the appropriate threshold volume is different for every woman 
and this would be difficult to assess. Our previous experience has suggested 
that greater distension results in better image quality and we therefore decided 
to compare the maximum uterine distension observed during each of the two 
procedures.
The image quality for SCSH was better than that for GIS. It must be noted that 
the score was a subjective impression, and therefore observer bias cannot be 
excluded. An important reason for the difference in quality is the presence of air 
bubbles in the gel. The currently used GIS technique may not be optimal in terms 
of avoiding air bubbles, because the syringe was filled manually with Endosgel. 
In addition, the catheter was not removed from the uterine cavity between 
SCSH and GIS in order to reduce inconvenience for the patient, although filling 
the catheter with gel before entering the uterine cavity may have reduced the 
occurrence of air bubbles. Another hypothesis is that the presence of air bubbles 
may have been promoted by rising temperature, negative pressure while filling 
the syringe, turbulence during gel instillation and dissolved molecules.
For better performance of GIS, commercial products are available containing gel 
with a smaller amount of dissolved molecules, no need to transfer the gel manually 
from one syringe to another and with a special cervical applicator preventing 
cervical backflow or leakage. It may be questioned whether a difference of 10% 
in image quality (4.0 vs. 3.6 on a scale from 0 to 5) should be considered clinically 
relevant, since intrauterine abnormalities could be visualized by SCSH as well as 
GIS in all cases. On the other hand, performing GIS after SCSH in all women may 
have caused review bias, because visualization of an abnormality with the first 
procedure makes it easier to recognize the same abnormality using the second 
procedure. Although it would have been appropriate to use a cross-over design, 
it appeared that it would be impossible to clear all the gel from the uterus and 
perform SCSH immediately afterwards. Alternatively, we could have chosen to 
perform GIS and SCSH at different times by different examiners, blinded to the 
results of the other test. However, we did not use this design for two reasons: 
inconvenience to the patient at having to undergo the same procedure twice; and 
interobserver variation. Future studies may overcome this problem by recording 
500835-L-bw-Dieleman
22 | Chapter 2
both SCSH and GIS for retrospective random assessment by independent 
examiners blinded to the results of the tests.
The mean VAS score for pain during fluid instillation was low and practically the 
same for both SCSH and GIS, which demonstrates that both procedures are well 
tolerated. In our experience, the introduction of the speculum and catheter causes 
more discomfort than the instillation of saline solution or gel. Because SCSH was 
always performed first, the pain score of SCSH may have been influenced by 
insertion of the catheter. Therefore, a cross-over design would have been more 
appropriate.
GIS is an easy diagnostic method to perform and the higher viscosity of the gel 
causes less fluid leakage. Although backflow could not be prevented completely, 
Figure 1 demonstrates that GIS gives stable distension during at least 4–5 min, 
which is sufficient to complete the ultrasound evaluation. Small fluctuations of 
the distension in time may be caused by contractions of the uterine muscle.
The introduction of three-dimensional (3D) ultrasound enhances visualization 
of the uterine cavity, and improves diagnostic accuracy of SCSH or GIS5. Gel is 
considered to be advantageous when performing 3D ultrasound. More stable 
filling of the uterine cavity without continuous flow of fluid allows extension of 
the observation time, resulting in better 3D sonohysterographic images with 
fewer artifacts and moving tissue elements4.
We have noticed that some women experience vasovagal cramps after GIS. To 
prevent this discomfort, the amount of gel should be as small as possible. With 
an average of 4 mL, an optimal distension of the uterine cavity can be achieved4.
In conclusion, a small but significant difference in image quality between GIS and 
SCSH was found in favor of SCSH, which may be caused by the presence of air 
bubbles while performing GIS. This disadvantage of GIS may be less prominent if 
another technique is used (e.g. use of commercially available prefilled gel syringes). 
With a comparable low level of experienced pain, the slightly higher distension 
with GIS makes it a suitable alternative to SCSH if air bubbles can be prevented. 
Moreover, a beneficial effect of GIS is expected for 3D ultrasonography and it 
must be questioned if GIS should replace SCSH when using two-dimensional (2D) 
imaging. Additional prospective studies should be performed to determine the 
diagnostic accuracy of 2D and 3D GIS in comparison with SCSH, in which both 
procedures are assessed independently and preferably blinded.
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Abstract
Objective
To evaluate the inter- and intraobserver agreement for measurement of the 
size and volume of a niche and assessment of the shape, with the use of three-
dimensional (3D) ultrasound.
Study design
In this reproducibility study, 20 3D ultrasound volumes of uteri with a niche were 
selected, based on complete visualisation of the uterus and niche in both the 
longitudinal and transversal plane. Niche measurements were performed off-
line twice by one observer and once by another observer. Niche measurements 
and assessment of shape were performed in the longitudinal and transversal 
plane, and niche volume in the longitudinal plane.
The mean difference, 95% limits of agreement, the intraclass correlation 
coefficient (ICC) and Cohen’s kappa were calculated to assess the inter- and 
intraobserver agreement.
Results
The interobserver agreement was excellent for all niche measurements (ICC 
>0.86), including depth and residual myometrial thickness (RMT), except for 
width at niche base in the transversal plane (ICC 0.74) and niche volume (ICC 
0.79), which were classified as good agreement. Wide limits of agreement and 
a high mean difference were found for maximal width in the transversal plane.
The intraobserver agreement was excellent for all measurements (ICC >0.80), 
except for RMT in the longitudinal and transversal plane, which were classified 
as good agreement (ICC 0.73 and 0.62, respectively). Wide limits of agreement 
were found for maximal width and width at niche base in the transversal plane.
The overall agreement in the transversal plane was lower than in the longitudinal 
plane, but still all in the range of good agreement. The inter- and intraobserver 
agreement was good to poor for the assessment of niche shape.
Conclusion
Using 3D ultrasound, various niche parameters, including depth (both 
perpendicular to niche base and maximal depth), maximal width, width at niche 
base, RMT and volume, can be measured with a high level of agreement, in 
particular if measured in the longitudinal plane.
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Introduction
Since the turn of the century, the interest for the uterine niche has increased. A 
niche can be observed during sonography at the site of the uterine caesarean 
scar and has been defined as any indentation representing myometrial 
discontinuity at the site of a caesarean scar that communicates with the uterine 
or cervical cavity [1]. The diagnostic method for the detection of a niche is mainly 
transvaginal sonography (TVS) and contrast-enhanced sonohysterography 
(SHG). The prevalence of a niche in a random population of women with a history 
of caesarean section (CS) differs between 24% and 70% for TVS and between 
56% and 84% for SHG [1].
Apart from the well-known complications, such as uterine rupture and caesarean 
scar pregnancy, there are indications that a niche is responsible for symptoms, 
such as postmenstrual spotting [2], [3], [4] and [5] and subfertility [3]. One study 
reported a relatively large volume of a niche in women with postmenstrual 
spotting [2] and another study reported a larger width of the niche in women 
with postmenstrual spotting, dysmenorrhea and chronic pelvic pain [5]. Interest 
is growing to learn which niches are responsible for symptoms. Therefore, 
different classifications for niches have been used, based on size [6] and [7] or 
shape [2]. However, there is no agreement about a definition for the various 
subgroups of niches, neither how to measure the niche.
In order to be able to compare studies concerning niche prevalence, classification, 
size and symptoms, we formulated definitions for the used niche parameters and 
methods for assessment that may be used for future studies. No studies have 
been performed up to now, in which the reproducibility of the measurement 
of a niche was evaluated in non-pregnant women. The objective of the current 
study is to evaluate the inter- and intraobserver agreement for measurement of 
the size and volume of a niche, and assessment of the shape, with the use of 3D 
ultrasound volumes.
Materials and methods
This inter- and intraobserver study was conducted in January 2014 at the 
Department of Obstetrics and Gynaecology of the VU University Medical Center 
in Amsterdam. Transvaginal ultrasound images of uteri without using contrast 
in women with a history of CS were stored for research purposes between 2007 
and 2012. The images were performed using an Accuvix ultrasound machine 
(Medison, Hoofddorp, The Netherlands; currently Samsung Medison) in women 
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with their bladder empty. Stored 3D volumes, acquired in the longitudinal 
plane, of uteri with a niche were selected for this inter- and intraobserver study. 
Informed consent of all women was obtained at the time of inclusion and the 
study was approved by the local research ethics committee.
From a data set of 150 anonymized volumes, the first 20 3D volumes with complete 
visualisation of the uterus and niche in both the longitudinal and transversal 
plane were selected for both the inter- and intraobserver study. The images 
were measured twice by one observer (M.B.) in a different random order, with a 
time interval between the two measurements of four weeks. For the evaluation 
of the interobserver agreement, another observer (I.L.) performed the same 
measurements once. The first measurements of the first observer were selected 
for assessment of interobserver variability and the observers were blinded to 
each other’s results. The measurements were performed off-line with the use of 
off-line software (Medison XI Viewer) in the longitudinal and transversal plane.
The most optimal midsagittal section of the uterus was obtained by rotating 
around the x- and y-axis. The lower uterine segment was examined in the 
longitudinal plane to identify the area likely to contain the niche. The section with 
the largest surface area of the niche was identified. In case of multiple previous 
CSs and multiple niches, measurements of the largest niche were recorded. 
The uterus was rotated around the z-axis to obtain the base of the niche in 
the horizontal position in order to simplify the measurements. The image was 
zoomed if necessary and the measurements were performed with the calliper 
placed on the inner border of the endometrium.
The following measurements were performed in the longitudinal plane with the 
Calliper function of the MultiSlice mode (Fig. 1):
- Residual myometrial thickness (RMT) (1): measured from the serosal surface of 
the uterus (without the white lining of the serosa) or if extraperitoneally where 
the myometrium ended, to the apex of the niche, perpendicular to niche base.
- Depth, perpendicular to niche base (2).
- Maximal depth (3): distance between apex of the niche and the estimated 
middle of the niche base.
- Maximal width (4): perpendicular to the line between middle of the niche base 
and apex (3).
- Width at niche base (5).
The niche shape was assessed according to a specified classification, which was 
also used for a previously published study [2]: triangle, semicircle, rectangle, 
circle, droplet and inclusion cysts (Fig. 2). The volume of the niche was measured 
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in the longitudinal plane with the use of the eXtended Imaging Virtual Organ 
Computer-aided Analysis program. The mode “manual 10—planes” was chosen 
and a diagram of 10 parallel sections of the niche was displayed on the screen. 
After manual outline of the external niche surface in all selected planes, the 
software automatically provided the volume of the niche (Fig. 3).
With the niche visible in the longitudinal plane and the blue dot located at the 
base of the niche, the transversal plane (B plane) was obtained. The section in 
which the niche had its maximal surface area was identified, and the uterus 
was rotated around the z-axis to obtain the endometrium (base of the niche) 
in the horizontal position in order to simplify the measurements. The same 
measurements as performed in the longitudinal plane were completed in the 
transversal plane (Fig. 4). In addition, the niche shape according to the same 
classification (Fig. 2) was recorded.
Figure	  1:	  Niche	  measurements	  in	  the	  longitudinal	  plane.	  1=residual	  myometrial	  thickness;	  
2=depth	  perpendicular	  to	  niche	  base;	  3=maximal	  depth;	  4=maximal	  width;	  5=width	  at	  niche	  
base.	  
Figure 1: Niche measurements in th  longitudinal plane.1=residual myometrial thickness; 2=depth perpendicular to 
niche base; 3=maximal d pth; 4=maximal width; 5=width at niche base.
Figure 2: Classification used to assess the shape of the niche.
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Statistics
Data were analysed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). For inter- 
and intraobserver agreement, the mean difference, 95% limits of agreement and 
the intraclass correlation coefficient (ICC) were calculated. Bland–Altman plots 
were used to determine whether the difference was influenced by the magnitude 
of the measurements [8] and [9]. Cohen’s kappa was calculated for the agreement 
for categorical variables (i.e. niche shape). For both ICC and kappa, values 
between 1.0 and 0.81 were considered to show excellent agreement, 0.80–0.61 
good, 0.60–0.41 moderate, 0.40–0.21 fair and 0.20–0.00 poor agreement [10].
Figure 4: Niche measurements in the transversal plane.1=residual myometrial thickness; 2=depth perpendicular to 
niche base; 3=maximal depth; 4=maximal width; 5=width at niche base.
Figure 3: Volume measurement of the niche, demonstrating manual outline of the niche of five of the ten sections, 
and the calculated volume.
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Table 1: Interobserver and intraobserver agreement for niche measurements in the longitudinal plane.
n Mean 
difference 
95% limits  
of agreement 
ICC*  
(95% CI)
Kappa 
coefficient
Interobserver agreement
Residual myometrial thickness (mm) 20 0.11 -0.96 to 1.18 0.97 (0.93-0.99)
Depth, perpendicular to niche base (mm) 20 -0.25 -2.74 to 2.24 0.92 (0.81-0.97)
Maximal depth (mm) 20 -0.30 -2.54 to 1.93 0.94 (0.86-0.98)
Maximal width (mm) 20 -0.20 -1.50 to 1.10 0.97 (0.93-0.99)
Width at niche base (mm) 20 -0.39 -3.06 to 2.28 0.90 (0.77-0.96)
Niche volume (mm3) 20 -26.50 -309.41 to 256.41 0.79 (0.54-0.91)
Niche shape 20 0.73
Intraobserver agreement
Residual myometrial thickness (mm) 20 -0.26 -3.71 to 3.20 0.73 (0.43-0.88)
Depth, perpendicular to niche base (mm) 20 0.19 -0.76 to 1.14 0.99 (0.97-1.00)
Maximal depth (mm) 20 0.16 -1.03 to 1.36 0.98 (0.95-0.99)
Maximal width (mm) 20 0.36 -2.20 to 2.93 0.87 (0.70-0.95)
Width at niche base (mm) 20 0.004 -2.86 to 2.86 0.87 (0.70-0.95)
Niche volume (mm3) 20 7.50 -153.73 to 168.73 0.87 (0.71-0.95)
Niche shape 20 0.33
*ICC=intraclass correlation coefficient (1.0-0.81 excellent, 0.80-0.61 good, 0.60-0.41 moderate, 0.40-0.21 fair and 
0.20-0.00 poor agreement).
Results
Interobserver agreement
Table 1 shows the interobserver agreement for niche measurements in 
the longitudinal plane, demonstrating excellent reproducibility for most 
measurements. The ICC for RMT was 0.97, with the Bland–Altman plot (Fig. 5) 
showing narrow 95% limits of agreement and all measurements situated around 
the mean. The ICC’s for depth perpendicular to niche base (ICC 0.92), maximal 
depth (ICC 0.94), maximal width (ICC 0.97) and width at niche base (ICC 0.90) 
were also excellent, although width at niche base had wider limits of agreement. 
The ICC for niche volume was 0.79 with wide limits of agreement (Fig. 6) and the 
kappa coefficient for niche shape was 0.73. Both values can be classified as the 
upper limit of good.
Table 2 demonstrates lower reproducibility for measurements in the transversal 
plane in comparison to the longitudinal plane, although the ICC was excellent for 
all niche measurements except for width at niche base with an ICC of 0.74 and 
wide limits of agreement. In addition, the mean difference of the maximal width 
was high with wide limits of agreement. The ICC for RMT in the transversal plane 
was lower (0.86) in comparison to the RMT in the longitudinal plane (0.97) with 
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Figure 5: Bland-Altman plots showing inter- and intraobserver agreement for residual myometrial thickness (RMT) 
for the longitudinal and transversal plane. Mean (——) and 95% limits of agreement  (------) are shown.
Figure 6: Bland-Altman plots showing inter- and intraobserver agreement for niche volume. Mean (——) and 95% 
limits of agreement  (------) are shown.
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Table 2: Interobserver and intraobserver agreement for niche measurements in the transversal plane.
n Mean 
difference 
95% limits  
of agreement 
ICC* (95% CI) Kappa 
coefficient
Interobserver agreement
Residual myometrial thickness (mm) 20 0.56 -2.56 to 3.67 0.86 (0.68-0.94)
Depth, perpendicular to niche base (mm) 20 -0.67 -2.44 to 1.10 0.96 (0.90-0.98)
Maximal depth (mm) 20 -0.41 -2.28 to 1.46 0.95 (0.89-0.98)
Maximal width (mm) 20 -1.35 -4.82 to 2.12 0.95 (0.87-0.98)
Width at niche base (mm) 20 -0.72 -7.14 to 5.69 0.74 (0.46-0.89)
Niche shape 20 0.50
Intraobserver agreement
Residual myometrial thickness (mm) 20 -0.71 -5.80 to 4.37 0.62 (0.26-0.83)
Depth, perpendicular to niche base (mm) 20 0.20 -2.20 to 2.61 0.91 (0.78-0.96)
Maximal depth (mm) 20 0.43 -2.56 to 3.43 0.86 (0.68-0.94)
Maximal width (mm) 20 0.18 -4.47 to 4.83 0.88 (0.73-0.95)
Width at niche base (mm) 20 0.25 -4.86 to 5.36 0.80 (0.57-0.92)
Niche shape 20 0.04
*ICC=intraclass correlation coefficient (1.0-0.81 excellent, 0.80-0.61 good, 0.60-0.41 moderate, 0.40-0.21 fair and 
0.20-0.00 poor agreement). 
wider limits of agreement (Fig. 5). The kappa coefficient for niche shape in the 
transversal plane was 0.50.
Intraobserver agreement
The intraobserver agreement in the longitudinal plane was excellent for depth 
perpendicular to niche base (ICC 0.99), maximal depth (ICC 0.98), maximal width 
(ICC 0.87), width at niche base (ICC 0.87) and volume (ICC 0.87). Maximal width 
and width at niche base had both rather wide limits of agreement (Table 1). 
The intraobserver agreement for RMT was good (ICC 0.73) with wide limits of 
agreement as shown by the Bland–Altman plot (Fig. 5). The kappa coefficient for 
niche shape was 0.33.
Also for the intraobserver analyses applies that measurements in the transversal 
plane were less reproducible than measurements in the longitudinal plane 
as shown by lower ICC values and wider limits of agreement (Table 2). The 
ICC for RMT was 0.62 with wide limits of agreement. All other intraobserver 
measurements in the transveral plane showed excellent agreement, although 
the limits of agreement were wide for maximal width and width at niche base. 
The kappa coefficient for niche shape was very low (0.04).
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Comment
Main findings
We demonstrated that both depth perpendicular to niche base and maximal 
depth can be measured with a high level of agreement. The level of agreement 
is also high for maximal width and width at niche base if measured in the 
longitudinal plane, but lower for the same measurements in the transversal 
plane. Measurement of RMT and volume are reasonably reproducible, as the 
intraobserver agreement for RMT and interobserver agreement for volume were 
moderate. Agreement on the assessment of niche shape was poor for both the 
inter- and intraobserver analyses.
Strengths and limitations of the study
As far as we know, this is the first study evaluating the reproducibility of niche 
measurements in non-pregnant women. This study is important for future 
research, because until now the parameters for niche measurement were different 
for most studies and therefore difficult to compare. We attempted to make clear 
definitions for all parameters, which may be used for future research. We did not 
assess the quotient of the myometrial thickness at the site of the niche and the 
adjacent normal myometrium, which may nevertheless be a useful parameter.
A limitation of this study is that the results are only applicable to offline analysis 
of 3D volumes of the niche, not to real-time 2D ultrasound examination. Another 
limitation is that only ultrasound images performed with TVS were included, 
and therefore nothing can be said about the reproducibility of SHG images. A 
number of only 20 included images may also have been a limitation. Finally, two 
examiners were involved and one of them had also performed the selection of 
the 20 volumes. Although there was a time gap between the selection of the 
images and the performance of the reproducibility study, the examiner who 
selected the 20 volumes might have had a slight advantage.
Interpretation of our findings
Concerning the interobserver study, the mean difference for measurements 
in the longitudinal plane was mostly negative (Table 1), which means that the 
measurements of the first observer were in general lower than the second one. 
After reviewing the measurements, we may explain this finding by the fact that 
not the largest surface area of the niche was chosen by the first observer for 
several volumes. However, the mean differences were small (less than 0.50 mm) 
and therefore acceptable. As it is subjective to estimate the largest surface area 
of the niche, we suggest measuring the depth and width of the niche three times 
and to continue measuring in the section with the largest surface area.
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The lower level of intraobserver agreement compared to the interobserver 
analyses for certain measurements is the opposite from expected, especially 
for RMT. In order to explain this finding, measurements of the RMT were 
reviewed and we found that the reproducibility was influenced by the difficulty 
to recognize the end of the myometrium in some cases, especially if the niche 
was located extraperitoneally. Although this does not explain the better ICC of 
the interobserver study in comparison to the ICC of the intraobserver study, this 
may explain the lower reproducibility in the transversal plane as the serosa and/
or end of the myometrium were more difficult to recognize in this plane. Lower 
reproducibility in the transversal plane in general may be caused by the fact that 
the resolution of the reconstructed plane (transversal plane) is inferior to that of 
the acquisition plane (longitudinal plane). In addition, the flection of the uterus 
in either anteverted or retroverted direction can make it difficult to determine 
the exact transversal plane perpendicular to the serosa at the site of the niche. 
A small variation in angle may induce a large effect on the niche depth and RMT.
The ICC values for width at niche base for the transversal plane were lower 
than the ICC values for the longitudinal plane, which may be explained by the 
observation that it is difficult to assess the base for the transversal plane in case 
of intracavitary fluid. The same was observed by O.V. Osser et al. [11], who did 
not measure the width of the niche in the transversal plane during SHG as they 
found delineating the niche in the transversal plane difficult.
The intraobserver agreement for niche volume is better in comparison with the 
interobserver agreement. Measuring a volume requires multiple activities, as 
the niche surface needs to be manually outlined in 10 different planes, which 
may introduce slight differences between observers. In addition, we found in 
retrospect that one observer systematically measured slightly smaller volumes.
The assessment of niche shape is not reproducible, which may be caused by the 
fact that the classification depends on the section in which the shape is assessed. 
A lot of niches have branches, which are only present in several sections. In 
addition, it is difficult to make use of a classification like we did, as a minority 
of niches meet with a certain predetermined shape. We had not performed 
any training of the examiners in advance. Training might have improved the 
reproducibility of the niche shape.
Comparison with other publications
Only one reproducibility study [12] on the niche has been published, performed 
in pregnant women with, similar to our study, niche measurements carried out 
off-line on stored images. According to the author of this study, RMT does not 
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vary across the trimesters of pregnancy and is therefore likely to be comparable 
with our results, although the presence of amniotic fluid in pregnant women acts 
as a contrast agent and therefore may improve visibility of the margins of the 
niche. An ICC of 0.71 was found for the interobserver and an ICC of 0.88 for the 
intraobserver agreement on the measurement of the RMT for all three trimesters 
combined [12]. Our interobserver agreement for RMT was higher with an ICC of 
0.97. Our intraobserver agreement was lower (ICC 0.73), which may be explained 
by the short delay of only 10 s between the two measurements of Naji et al.
Clinical implications
Our results indicate that parameters assessing niche size or RMT are highly 
reproducible in the longitudinal plane using 3D ultrasound. Some of these 
parameters may have clinical implications. Although still to be proven, they may 
be associated with the presence of symptoms [2], [5], [13] and [14] and uterine 
dehiscence or rupture in future pregnancies [15]. In addition, they may be of 
influence on therapeutical options. Hysteroscopic [16] and [17] or laparoscopic 
[18] treatment of the niche is performed in some women with gynaecological 
symptoms, which is dependant on RMT. The RMT must be at least 2–3 mm for 
hysteroscopic niche resection in order to prevent perforation of the uterus or 
bladder injury [14]. Based on our results, we suggest measurement of the RMT 
in both the longitudinal and transversal plane in the section in which the RMT is 
the smallest instead of taking the maximal surface area of the niche, and to use a 
volume of sufficient quality in order to be able to recognize the serosa.
Future research
As we have performed the first study evaluating the inter- and intraobserver 
agreement for niche measurement, future studies should confirm our results. We 
believe that the use of a consistent technique for analyzing the 3D volumes and 
optimization of image quality will improve inter- and intraobserver agreement. 
Image quality may be improved by adding contrast, and therefore future studies 
should also evaluate the inter- and intraobserver agreement for SHG images.
Based on the higher reproducibility of niche evaluation in the longitudinal plane, 
we suggest assessment of the niche in the longitudinal plane in general practice 
and future studies, except for RMT, which we believe should also be measured 
in the transversal plane. In addition, given the low reproducibility it may be 
considered to omit the evaluation of niche shape as performed in our study.
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Abstract
Objective
To evaluate the relationship between a niche and abnormal uterine bleeding, and 
to develop a sonographic classification of niches and evaluate its relationship to 
abnormal uterine bleeding.
Methods
An observational prospective cohort study was performed between October 
2007 and May 2009. All women who had a Cesarean section performed in 
our hospital were asked to participate. Two hundred and twenty-five women 
were included and examined with both transvaginal sonography (TVS) and gel 
instillation sonohysterography (GIS) 6–12 months after the Cesarean section. In 
case of a niche, the depth, volume and residual myometrium were measured, and 
the shape was assessed according to a specified classification. A questionnaire 
and pictorial blood loss assessment chart were filled in.
Results
The prevalence of a niche on evaluation with TVS and GIS was 24.0% and 56.0%, 
respectively. A niche was considered to be present if the depth was at least 1 mm 
visualized with GIS. Postmenstrual spotting was reported by 33.6% of women 
with a niche and 15.2% of women without a niche (P = 0.002). The niche volume 
was significantly different between women with and without postmenstrual 
spotting (P = 0.02). Most niches had a semicircular (50.4%) or triangular shape 
(31.6%). No significant relationship was identified between the shape of the niche 
and postmenstrual spotting (P = 0.19).
Conclusions
A niche is present in 56.0% of women with a history of Cesarean section when 
examined by GIS and is associated with postmenstrual spotting. Semicircular 
and triangular niches are most common, but the shape is not related to 
postmenstrual spotting.
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Introduction
In the 1970s the Cesarean section rate began to increase in most Western 
countries1, as a consequence of which the number of women with a uterine 
scar is rising. Apart from the well-known complications, such as uterine rupture 
and pathologically adherent placentas, the long-term effects of this widely used 
procedure have been poorly studied. Recently, researchers have observed the 
presence of a niche at the site of the Cesarean scar. A niche is a sonographic 
finding and is defined as a triangular, anechoic area at the presumed site of 
incision2. Uterine niches can be identified on transvaginal sonography (TVS), but 
saline contrast sonohysterography (SCSH) may facilitate their detection2,3, and 
provides a more clear delineation of scar defects4. An alternative to SCSH is gel 
instillation sonohysterography (GIS), which has the advantage of creating a more 
stable filling of the uterine cavity and reducing discomfort for the patient due to 
the prevention of fluid leakage during the procedure5.
Because of the high Cesarean section rate—15.0% in The Netherlands in 20056 
and 31.1% in the USA in 20067—it is important to learn more about the clinical 
consequences of a niche. Several small studies have demonstrated that a niche 
may be responsible for abnormal uterine bleeding in women with a previous 
Cesarean section. However, most studies included women with gynecological 
complaints2,8-10. No large prospective studies have yet been performed that 
focus on the relationship between the niche and abnormal uterine bleeding, and 
in which women with a history of Cesarean section were consecutively asked 
to participate. The aim of the current study was to evaluate the relationship 
between the presence of a niche and abnormal uterine bleeding in women with a 
history of Cesarean section, and to develop a sonographic classification of niches 
and evaluate its relationship to abnormal uterine bleeding.
Methods
An observational prospective cohort study was performed between October 
2007 and May 2009 at the Department of Obstetrics and Gynaecology of the 
VU University Medical Center, Amsterdam, which is a high-risk pregnancy 
referral center where about 450 Cesarean sections are carried out every year. 
The study was approved by the local research ethics committee. All women 
who had a Cesarean section performed in our hospital were consecutively 
asked to participate. The women were identified from a database in which all 
deliveries performed in our hospital are registered. Exclusion criteria were risk 
of pelvic inflammatory disease, cervical cancer or pregnancy. Women were 
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contacted by phone 3–9 months after their Cesarean section and after giving 
informed consent they visited the hospital 6–12 months after the operation. 
Medical records, especially details of the pregnancy and Cesarean section, were 
reviewed and a specific form was filled in, in order to have a complete clinical and 
obstetric record for each woman. All women underwent both TVS and GIS using 
an Accuvix ultrasound machine (Medison, Hoofddorp, The Netherlands) to study 
the presumed site of the uterine scar, performed by one experienced operator 
(A.B.) in a standardized way.
Except for those not using contraception—who were examined in the follicular 
phase of their cycle—the women were examined during a random phase of 
their menstrual cycle and the cycle day was recorded. Patients needed to 
have their bladder completely empty during the test. TVS was performed first 
and the following details of the uterus were recorded: position, length, width, 
endometrial thickness and presence of intracavitary fluid. The uterus was 
examined for a niche, defined as an anechoic area at the site of the Cesarean scar 
with a depth of at least 1 mm. If a niche could be detected, the depth of the niche 
(the vertical distance between the base and apex of the defect) and residual 
myometrium (from the serosal surface of the uterus to the apex of the niche) 
were measured (Figure 1), the niche shape was assessed according to a specified 
classification (Figure 2), and the volume of the niche was measured with the use 
of three-dimensional ultrasonography and the eXtended Imaging Virtual Organ 
Computer-aided Analysis program. Subsequently, GIS was performed with the 
use of an intrauterine insemination catheter (Repromed, IM Services BV, Zwolle, 
The Netherlands), which was first flushed with sterile gel to rid it of small amounts 
of air and then introduced into the uterine cavity. Gel was infused through the 
catheter until the patient felt slight menstrual cramps, backflow started or a 
maximum of 10 mL was reached5. If a niche with a depth of at least 1 mm could 
be detected, the same measurements as mentioned above were repeated in the 
distended uterus. In women without a niche, the thickness of the myometrium 
at the site of the Cesarean scar (if visible) was measured and recorded as the 
thickness of the residual myometrium. In patients with multiple niches, only the 
largest defect was measured. The uterine cavity was examined for the presence 
of other intrauterine abnormalities, such as submucosal fibroids or polyps.
When the ultrasound examination had been performed, all women were asked 
to fill in a questionnaire in order to detect abnormal uterine bleeding and 
especially postmenstrual spotting. Women were asked for the regularity and 
duration of their menstrual cycle, number of days of blood loss (including the 
number of days of brownish discharge just before and after the cycle), and the 
number of days of intermenstrual bleeding. In addition, they were asked to keep 
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a modified pictorial blood loss assessment chart (PBAC)11 to assess the amount 
of blood loss during their period. Postmenstrual spotting was defined as more 
than 2 days of brownish discharge at the end of menstruation with a total length 
of menstruation (including spotting) of more than 7 days, or intermenstrual 
bleeding which starts within 5 days after the end of menstruation. To prevent 
any bias patients were not informed about the presence of a niche and the 
sonographer was not informed about the menstrual pattern.
The primary outcome was the difference in the prevalence of postmenstrual 
spotting between women with and without a niche. The following secondary 
outcomes were also evaluated: niche classification based on the shape of the 
niche and its relationship with abnormal uterine bleeding, and the difference 
between women with and without a niche concerning other bleeding parameters 
(i.e. duration of menstruation, intermenstrual bleeding, PBAC score), pain during 
menstruation and urological symptoms.
In addition we evaluated possible confounders such as amenorrhea, lactation, 
polyps, smoking, use of oral contraceptives and levonorgestrel-releasing 
intrauterine system (LNG-IUS).
Statistical analysis
To analyze the relationship between the niche and uterine bleeding parameters 
and urological symptoms, we used logistic regression analysis, the chi-square 
test, Student’s t-test or the Mann–Whitney U-test, depending on the type and 
distribution of the parameter. The relationship between niche classification 
based on niche shape and postmenstrual spotting was evaluated using Fisher’s 
exact test. Logistic regression analysis was used to evaluate the influence of 
possible confounders on postmenstrual spotting in patients with or without a 
Figure 1: Schematic diagram demonstrating 
measurement of depth of the niche (1), thickness of 
the residual myometrium (2) and total myometrial 
thickness (3).
Figure 2: Schematic diagram demonstrating classification 
used to assess niche shape: triangle, semicircle, rectangle, 
circle, droplet and inclusion cysts.
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niche. Data were analyzed using Statistical Packages for the Social Sciences (SPSS, 
Inc., Chicago, IL, USA). Two-sided tests were used and P < 0.05 was considered 
statistically significant.
Based on a previous study12, a difference of 15% (from 10% to 25%) was expected 
in the prevalence of abnormal uterine bleeding between women with and 
without a niche, which was considered clinically relevant. To achieve 80% power 
with an alpha of 5%, 134 patients with a niche would be needed. Assuming a 
prevalence of the niche of 59.5% (as ascertained by Menada Valenzano et al.12) in 
women examined with GIS and with a history of Cesarean section, 225 women 
had to be included.
632 women underwent a
caesarean section during the
research period
132 women not contacted because of:
- history of radical vaginal trachelectomy (4)
- perinatal death (19)
- incorrect phone number (109)
275 women not able to participate:
- no possibility to visit the hospital (62)
- current pregnancy (22)
- refusal to undergo the examinations (191)
500 women 
contacted by
telephone
225 women
included
Figure 3: Flow chart of patients included in the study.
Results
We included 225 women with a history of Cesarean section with a mean age of 
34.9 (range, 22–44) years (Figure 3). These women used the following methods 
of contraception: no contraception, 28.4%; condom, 27.1%; oral contraceptives, 
21.8%; LNG-IUS, 10.7%; sterilization, 6.3%; and other methods, 5.7%. Eight 
women were breast-feeding totally and 10 women partially, of whom three and 
four, respectively, were amenorrheic. All women underwent TVS. In 16 women 
the GIS catheter could not be inserted in the uterus or insufficient distension of 
the uterine cavity was achieved, resulting in 209 patients examined with GIS. A 
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niche could be demonstrated by TVS in 54 out of 225 women (24.0%) and by GIS 
in 117 out of 209 women (56.0%).
For the following analyses, a niche was considered to be present if visualized with 
GIS with a depth of at least 1 mm. The baseline characteristics of the study group 
are demonstrated in Table 1 for women with and without a niche. A significant 
difference was found for parity (P = 0.01) and for the mean number of previous 
Cesarean sections (P = 0.001).
Table 1: Baseline characteristics with details of the Cesarean section preceding entry to the study. 
Parameter Niche on GIS 
(n = 117)
No niche on GIS 
(n = 92)
P
Age (years) 35.2 ± 4.0 34.5 ± 4.4 0.26
Parity 1.8 ± 0.9 1.5 ± 0.9 0.01
Number of Cesarean sections 1.5 ± 0.7 1.2 ± 0.5 0.001
Gestational age at the time of Cesarean section (weeks) 38.2 ± 3.3    37.5 ± 3.9 0.39
Indication for last Cesarean section 0.11
Failure of cervical dilation 21 (17.9%) 10 (10.9%)
Obstetric history* 21 (17.9%) 9 (9.8%)
Fetal distress 20 (17.1%) 30 (32.6%)
Breech or transverse presentation 19 (16.2%) 15 (16.3%)
Maternal condition (including placental problems) 19 (16.2%) 13 (14.1%)
Delayed second stage of labor 15 (12.8%) 11 (12.0%)
Patient request 2 (1.7%)  3 (3.3%)
Other 0 (0%) 1 (1.1%)
Induction of labour 16 (43.2%) 21 (56.8%) 0.09
Labor augmentation 32 (60.4%) 21 (39.6%) 0.46
Contractions at the time of Cesarean section†                            62 (53.9%) 53 (46.1%) 0.37
Dilation at the time of Cesarean section (cm) 3.3 ± 4.0 3.6 ± 4.1 0.68
Birth weight (g) 3253 ± 940 3061 ± 986 0.16
Time after last Cesarean section at the time of inclusion (weeks) 49.4 ± 4.7 50.1 ± 4.5 0.25
Data are given as mean ± SD or n (%). *Previous failure of labor, cephalopelvic disproportion, multiple 
Cesarean sections. †Six women excluded because presence of contractions not known. GIS, gel instillation 
sonohysterography.
Table 2: Sonographic characteristics of uteri of women in the study group.
Characteristic Niche on GIS                   
(n = 117) 
No niche on GIS   
(n = 92) 
P
On transvaginal sonography
Endometrial thickness (mm) 5.1 ± 2.9 5.3 ± 3.1 0.73
Uterine length (cm) 7.3 ± 1.2 6.9 ± 1.3 0.04
Uterine width (cm) 3.8 ± 0.7 3.8 ± 0.9 0.67
Intracavitary fluid* 13/98 (13.3%) 5/80 (6.3%) 0.12
On GIS
Myometrial thickness at site of Cesarean scar (mm) 7.0 ± 2.8 9.6 ± 3.0 <0.001
Data are given as mean ± SD or n (%). *Women between cycle day 1 and 5 of their menstrual cycle were excluded. 
GIS, gel instillation sonohysterography. 
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Sonographic characteristics of the uterus
Table 2 shows the characteristics of the uterus for women with and without a 
niche. The mean length of the uterus was slightly greater in women with a niche 
(7.3 cm) than in women without a niche (6.9 cm) (P = 0.04), while the width of the 
uterus was the same for both groups (3.8 cm). The myometrium at the site of the 
Cesarean scar during GIS was significantly thinner in women with a niche (7.0 
mm) than in women without a niche (9.6 mm) (P < 0.001). After excluding women 
at days 1–5 of their menstrual cycle (as they may have had menstrual blood in the 
uterine cavity), TVS demonstrated intracavitary fluid in 13 of 98 patients with a 
niche (13.3%) and in five of 80 women without a niche (6.3%) (P = 0.12). The mean 
depth of the niche was 4.9 mm in women with intracavitary fluid and 3.5 mm in 
women without intracavitary fluid (P = 0.07), and the mean volume of the niche 
in women with and without intracavitary fluid was 0.14 and 0.04 cm3, respectively 
(P = 0.01).
Uterine bleeding pattern and urological symptoms
The relationship between the presence of a niche and abnormal uterine bleeding 
is demonstrated in Table 3. Details of postmenstrual spotting were reported 
by 208 women; in one woman we were not able to determine the exact cycle 
pattern. Postmenstrual spotting was present in 39 women with a niche (33.6%) 
and 14 women without a niche (15.2%). Univariate logistic regression analysis 
demonstrated a relationship between the presence of a niche and postmenstrual 
spotting (coefficient = 1.04, odds ratio (OR) = 2.8 (95% CI, 1.4–5.6); P = 0.03). Using 
univariate analysis, no significant relationship with postmenstrual spotting could 
be detected for the following potential confounders: amenorrhea (P = 0.10), 
lactation (P = 0.45), polyps (P = 0.71), smoking (P = 0.44) and use of LNG-IUS (P = 
0.73). The only significant relationship was found for the use of oral contraceptives 
(P = 0.045). Using logistic regression analysis, the coefficient (1.14) changed 
sufficiently after inclusion of oral contraception as a covariable, confirming 
oral contraception to be a confounder. After correction for this confounder, the 
relationship between a niche and postmenstrual spotting became stronger (OR = 
3.1 (95% CI, 1.5–6.3); P = 0.002). If women with amenorrhea were excluded from 
the analyses, postmenstrual spotting was present in 39/110 (35.5%) women with 
a niche and 14/84 (16.7%) women without a niche (P = 0.004).
As already mentioned, a niche was defined as an anechoic area at the site of 
the Cesarean scar with a depth of at least 1 mm. Repeating logistic regression 
analysis with 2 mm as a cut-off value for the depth, the niche was still significantly 
related to postmenstrual spotting (OR = 2.0 (95% CI, 1.1–3.8); P = 0.03).
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Information about intermenstrual bleeding was obtained from 197 women, 
and this symptom was reported by 33 of 110 women with a niche (30.0%) and 
9 of 87 women without a niche (10.3%) (P = 0.001). The mean number of days of 
intermenstrual bleeding was 0.8 for the group with a niche and 0.3 for the group 
without a niche (P = 0.001). A PBAC was completely filled in by 90 patients, and 
the total estimated monthly blood loss was similar in both groups (P = 0.97). The 
pain experienced during menstruation, reported with the use of a visual analog 
scale (VAS) score, was similar for women with and without a niche (P = 0.95). 
Urological symptoms were also similar for both groups (Table 3). By using TVS for 
the detection of a niche, the prevalence of postmenstrual spotting was 29.6% in 
women with a niche and 22.2% in women without a niche (P = 0.24).
Table 3: Uterine bleeding pattern and urological symptoms of women in the study group.
Characteristic Niche on GIS          
(n = 117)                          
No niche on GIS       
(n = 92)
P
Postmenstrual spotting (n = 208) 39/116 (33.3%) 14/92 (15.2%) 0.002
Days of blood loss during menstruation (n = 194) 5.7 ± 2.8 5.8 ± 1.9 0.23
Intermenstrual bleeding (n = 197) 33/110 (30.0%) 9/87 (10.3%) 0.001
Days of intermenstrual bleeding (n = 197) 0.8 ± 1.7 0.3 ± 1.1 0.001
PBAC score (n = 90) 153 ± 161 154 ± 146 0.97
VAS score (0-10) (n = 196) 3.5 ± 2.7 3.4 ± 2.3 0.95
Incontinence (n = 207) 26/115 (22.6%) 23/92 (25.0%) 0.69
Stress incontinence (n = 207) 23/115 (20.0%) 18/92 (19.6%) 0.94
Urge incontinence (n = 207) 5/115 (4.3%) 7/92 (7.6%) 0.32
Data are given as n (%) or mean ± SD. GIS, gel instillation sonohysterography; PBAC, pictorial blood loss assessment 
chart; VAS, visual analog scale for menstrual pain.
Table 4: Niche classification by gel instillation sonohysterography and postmenstrual spotting.
Parameter Prevalence Postmenstrual 
spotting (n = 28)*
No postmenstrual 
spotting (n = 66)*
P
Niche classification 0.19
Semicircle 59 (50.4%) 14 (50.0%) 32 (48.5%)
Triangle 37 (31.6%) 11 (39.3%) 18 (27.3%)
Droplet 12 (10.3%) 1 (3.6%) 9 (13.6%)
Inclusion cyst(s) 8 (6.8%) 1 (3.6%) 7 (10.6%)
Other 1 (0.9%) 1 (3.6%) 0 (0%)
Depth of the niche (mm) 3.7 ± 1.9 3.5 ± 2.1 0.50
Volume of niche (cm³)† 0.08 ± 0.13 0.04 ± 0.10 0.02
Myometrial thickness at the site of Cesarean scar (mm)   7.5 ± 3.3 8.3 ± 3.2 0.34
Data are given as n (%) or mean ± SD.  
*As use of oral contraceptives was identified as a confounding factor, women using oral contraceptives (n = 22) were 
excluded from the analyses. One woman was additionally excluded due to uncertainty with respect to the presence 
of postmenstrual spotting.  
†Measured with the use of three-dimensional sonohysterography.
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Niche classification
The shape of the niche was assessed with GIS and resulted in the classification 
presented in Table 4. The most common shapes were semicircular (50.4%), 
triangular (31.6%), droplet-shaped (10.3%) and inclusion cysts (6.8%) (Figure 4). 
Women using oral contraceptives were excluded from the following analyses, as 
the use of oral contraceptives was identified as a confounding factor. No significant 
relationship was observed between the shape of the niche and postmenstrual 
spotting (P = 0.19). Both mean depth of the niche and the residual myometrium at 
the site of the Cesarean scar were not significantly different between the groups 
with and without postmenstrual spotting (P = 0.50 and 0.34, respectively). 
However, the niche volume was larger in women with postmenstrual spotting 
(0.08 cm3) than in women without postmenstrual spotting (0.04 cm3) (P = 0.02).
Figure 4: Ultrasound scans showing the most common niche shapes: the semicircular niche (a), triangular niche (b), 
droplet-shaped niche (c) and inclusion cysts (d). 
Discussion
To the best of our knowledge, this is the first prospective cohort study focusing 
on the niche and its relationship to abnormal uterine bleeding, in which women 
were consecutively included 6–12 months after Cesarean section. In order to 
prevent selection bias, all women who underwent a Cesarean section were 
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included independently of their obstetric history. The prevalence of a niche 
on TVS was 24.0% in our population, which is comparable with that of 19.4% 
in a previous study using the same method13. Other authors reported a much 
lower prevalence of 6.9%10. This difference may have been caused by variation in 
definitions, level of awareness and methods used. Using GIS, the prevalence in our 
study increased to 56.0%, which is comparable with other studies3,12. Our findings 
confirm that the detection rate of niches increases using sonohysterography and 
that most scar defects appear to be larger with this technique than with TVS.
We have demonstrated a significant relationship between the presence of a niche 
as seen using GIS and postmenstrual spotting in women with a previous Cesarean 
section. One in three women with a niche had complaints of postmenstrual 
spotting, while one in seven women without a niche had these complaints. The 
relationship between a niche and postmenstrual spotting was independent of 
amenorrhea, lactation, polyps, smoking, LNG-IUS and oral contraception use. 
The latter was demonstrated to be a confounder, and after controlling for 
this factor using logistic regression analysis, the relation between a niche and 
postmenstrual spotting was even stronger.
Most previous studies included only a selected group of women, who underwent 
TVS8,10 or SCSH2,9 because of gynecological complaints. This may explain the high 
prevalence of postmenstrual spotting in these studies, varying between 63.8 
and 100%. Only one study has been performed in an unselected population, 
including 217 women with a history of vaginal delivery or Cesarean section and 
undergoing both TVS and SCSH. In this study no relationship was found between 
the presence of a niche and abnormal uterine bleeding, with a prevalence of 
24.6% for abnormal uterine bleeding in women with a niche12. We have no clear 
explanation for why no relationship was found, but three possible explanations 
may be proposed. First, women were evaluated between 3 months and 10 
years after the Cesarean section, and only 17 were examined 3–12 months after 
the Cesarean section (as were our study population). Secondly, women with 
multiple parity were excluded, while our study demonstrated that patients with 
multiple Cesarean sections are at higher risk for the development of a niche. 
This could be because women with a history of multiple Cesarean sections 
may have more fibrotic tissue in the myometrium and may be more prone to 
obstruction of menstrual blood and associated menstrual spotting. Thirdly, 
although sonohysterography was used in both studies, the method of niche 
assessment may have been different. The importance of the method used for 
niche assessment is emphasized by our results of niche evaluation with TVS, as 
no significant difference for postmenstrual spotting between women with and 
without a niche was found when TVS was used instead of GIS. Fewer niches 
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were identified on TVS and therefore GIS should be used to exclude a niche in 
cases of postmenstrual spotting. Some selection may have occurred in our study 
since women with complaints are generally more willing to participate in a study. 
However, women were not informed whether or not a niche was observed to 
prevent possible bias in reporting their bleeding pattern.
The ideal moment for sonographic evaluation is probably the early follicular phase, 
assuming that a thin endometrium may improve the identification of a niche and 
measurement of its depth and size. Although standardized measurement during 
the early follicular phase was not possible for our participants due to their private 
schedules, no difference in mean endometrial thickness and cycle day between 
the groups with and without a niche was found. Women will be followed for a 
period of 5 years, which should allow identification of patients with later onset 
of postmenstrual spotting, but these follow-up data are not yet available. It has 
been suggested that the frequency of abnormal uterine bleeding—defined as 
spotting after the end of menstruation and/or noncyclic bleeding not related to 
menstruation—is higher in women who were evaluated after a longer period12.
Several hypotheses have been postulated to explain the etiology of bleeding 
disorders in relation to the niche. It has been assumed that abnormal uterine 
bleeding may be due to the retention of menstrual blood in the niche, which is 
intermittently expelled after the majority of the menstruation has ceased, causing 
postmenstrual spotting9,14. Thurmond et al.9 reported that this condition may 
depend on poor contractility of the uterine muscle around the scar. In addition, 
the presence of fibrotic tissue below the niche may impair the drainage of 
menstrual flow through the cervix14. It cannot be ruled out that the accumulated 
blood is produced in situ, as suggested by Morris15 based on the presence of free 
blood cells in the endometrial stroma, suggesting recent hemorrhage.
The positive relationship between niche volume and postmenstrual spotting 
indicates an increased capacity to collect blood and underlies the theories 
mentioned above. Our hypotheses that the depth and shape of the niche may 
be related to abnormal uterine bleeding could not be confirmed, which may be 
explained by the group size being insufficient to test these secondary outcome 
parameters. The presence of intracavitary fluid seemed to be more frequent in 
women with a niche than in women without a niche, but a larger study group 
will be needed to assess this. In addition, the volume of the niche was higher 
in women with intracavitary fluid. We propose that the presence of a niche, 
especially one with a large volume, may be associated with intracavitary fluid, 
which affects postmenstrual spotting. It has been suggested that subfertility 
after a Cesarean section might be caused by the presence of a niche14. More 
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research should be undertaken to study the relationship between the niche, 
intracavitary fluid and infertility.
In conclusion, we have performed the first prospective study in which the 
prevalence of the niche and its relationship to abnormal uterine bleeding 
were evaluated. Our results demonstrate that 56.0% of women with a history 
of Cesarean section have a niche when examined by GIS and that a niche is 
associated with postmenstrual spotting. Therefore, we encourage gynecologists 
to include the niche as a differential diagnosis in patients with postmenstrual 
spotting and a previous Cesarean section. Future research should increase our 
knowledge about the etiology of a niche.
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Abstract
Objective
To study the prevalence of niches in the caesarean scar in a random population, 
and the relationship with postmenstrual spotting and urinary incontinence.
Design
A prospective cohort study.
Setting
A teaching hospital in the Netherlands.
Population
Non-pregnant women delivered by caesarean section.
Methods
Transvaginal ultrasound (TVU) and gel instillation sonohysterography (GIS) 
were performed 6–12  weeks after caesarean section. Women were followed 
by questionnaire and menstruation score chart at 6–12 weeks, 6 months, and 
12 months after caesarean section.
Main outcome measures
Prevalence of a niche 6–12  weeks after caesarean section, using TVU and 
GIS. Secondary outcomes: relation to postmenstrual spotting and urinary 
incontinence 6 and 12 months after caesarean section; and niche characteristics, 
evaluated by TVU and GIS.
Results
Two hundred and sixty-three women were included. Niche prevalence was 49.6% 
on evaluation with TVU and 64.5% with GIS. Women with a niche measured by 
GIS reported more postmenstrual spotting than women without a niche (OR 5.48, 
95% CI 1.14–26.48). Women with residual myometrium at the site of the uterine 
scar measuring <50% of the adjacent myometrial thickness had postmenstrual 
spotting more often than women with a residual myometrial thickness of >50% 
of the adjacent myometrial thickness (OR 6.13, 95% CI 1.74–21.63). Urinary 
incontinence was not related to the presence of a niche.
Conclusions
A niche is present in 64.5% of women 6–12  weeks after caesarean section, when 
examined by GIS. Postmenstrual spotting is more prevalent in women with a niche and 
in women with a residual myometrial thickness of <50% of the adjacent myometrium.
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Introduction
Concern regarding the association between delivery by caesarean section and 
long-term maternal morbidity is growing, as the rate of caesarean section 
continues to increase. In the Netherlands the caesarean section rate increased 
from 7.4 to 15.8% during the period 1990–2008,1 and in the USA it increased 
from 21.2 to 32.8% from 1990 to 2011.2 The long-term complications of 
caesarean section in relation to future reproduction have been comprehensively 
examined.3,4 In the past decade several articles have described a defect that 
can be seen on ultrasound at the site of the caesarean section scar, known as 
a ‘niche’.5,6 A niche is defined as a triangular anechoic structure at the site of 
the scar or a gap in the myometrium of the anterior lower uterine segment at 
the site of a previous caesarean section.7,8 Niche prevalence depends on the 
method used for evaluation and the population investigated.9-16 In non-pregnant 
women the scar is visible with transvaginal ultrasonography (TVU) and contrast 
sonohysterography using either saline (saline infusion sonohysterography, SIS) 
or gel (gel instillation sonohysterography, GIS).5,6 There have been several reports 
of an association between abnormal bleeding and a niche.8,10-12,15 In particular, 
postmenstrual spotting seems to be a predominant symptom in women with 
a niche10,11; however, most of these studies included symptomatic patients, 
resulting in a possible selection bias. Given the proximity of the niche to the 
bladder, it has been postulated that the local accumulation of fluid and scarring 
might disturb bladder function11; however, prospective studies assessing both 
bleeding symptoms and urinary symptoms in relation to the presence of a niche 
in a random population of women with a history of caesarean section are scarce. 
As far as we are aware, none of the reported studies asked women to participate 
at the time of caesarean section. The aim of our study was to determine the 
prevalence of niches in the caesarean section scar in a random population of 
women enrolled immediately after caesarean section, using both TVU and GIS 
6–12 weeks after caesarean section, and to examine the relationship between 
the niche and postmenstrual spotting and urinary incontinence.
Methods
Study design and population
We conducted a prospective observational cohort study. The trial was registered 
in the Dutch trial register (trial number NTR-2887). The study was performed in St 
Antonius Hospital, Nieuwegein: a teaching hospital in the Netherlands. The protocol 
was approved by the local medical ethics committee (VCMO NL18722.100.07 
R-07.14A/SCAR.). Participants were recruited between November 2007 and 
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September 2010. Specially trained midwives asked all women over 18  years 
of age who underwent a caesarean section at St Antonius Hospital during the 
inclusion period to participate, within 3 days of the caesarean section. Exclusion 
criteria were twin pregnancies, known uterine anomalies, or the suspicion of 
a uterine infection, defined as a positive culture or fever and abdominal pain 
with discharge. After providing written informed consent, all participants were 
evaluated by TVU followed by GIS 6–12 weeks after the caesarean section. A GIS 
was not performed when there were suspected placental remnants, intrauterine 
haematomas, intrauterine fluid accumulation, or a possible pregnancy (i.e. a visit 
during the midluteal phase in women not using adequate contraception). Women 
were followed by questionnaires and menstruation score charts at 6–12 weeks, 
6 months, and 12 months after the caesarean section.
Transvaginal ultrasound
All TVU and GIS procedures were performed at St Antonius Hospital by three 
experienced examiners (L.V., S.V., and M.S.). TVU was performed using a 7.5–
MHz transducer (Philips Sonicare HD 11.XE, Philips Medical Systems, Eindhoven, 
the Netherlands). Women were examined after emptying their bladder. The 
uterus, uterine scar, and niche, if present, were examined in a standardised 
way. The position, length, and width of the uterus and double thickness of the 
endometrium were registered in the midsagittal plane. A niche was defined as 
an anechoic space (with or without fluid) at least 2 mm deep at the presumed 
site of the caesarean section scar. The uterus was screened for the presence of 
caesarean section scar(s) using parallel sagittal planes going from left to right, 
until the plane with the largest niche depth was defined. The uterus was also 
scanned in the transverse plane. When a niche was identified, it was measured 
in the sagittal plane in which the niche had the greatest depth; the depths of 
the niche and of the residual myometrium at the site of the scar and of the 
adjacent normal myometrium were measured in real time (see Figure 1). In cases 
when more than one caesarean section scar was present the largest niche was 
measured.
Figure 1. Schematic presentation of niche 
measurement. The following measurements were 
performed: (1) niche depth (in the sagittal plane); (2) 
residual myometrium (RM), from the serosal surface of 
the uterus (without the white lining of the serosa) to the 
apex of the niche, perpendicular to the endometrium 
(in sagittal plane); (3) adjacent myometrial thickness 
(AMT). Adapted from Bij de Vaate et al.11!!
!
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Gel instillation sonography
A speculum was inserted and a catheter (SIS Rudigoz Catheter, CCD International, 
Paris, France) was placed inside the uterus. Gel (Endosgel, Farco-Pharma GmbH, 
Köln, Germany) was flushed inside the uterine cavity and cervix while retracting 
the catheter. A maximum volume of 10 cm3 was instilled, or less if uterine cramps 
occurred or reflux was observed from the cervix. The speculum was removed, the 
vaginal probe was reinserted, and the presence of a niche was recorded in the 
sagittal plane where the niche had the greatest depth. Niche characteristics were 
measured and recorded as described above (Figure 1). The shape was classified 
according to the previous classifications published by Bij de Vaate et  al.11  The 
presence of uterine polyps, fibroids, or other intrauterine abnormalities was 
noted.
Data collection
The characteristics of participants, including contraceptive use, breastfeeding, 
bleeding characteristics before pregnancy, and detailed obstetric history 
(dates ofprevious caesarean section, indication, and characteristics of the last 
pregnancy and caesarean section) were noted immediately after informed 
consent was given. Current contraceptive use and bleeding pattern were recorded 
at 6–12 weeks after the caesarean section. Women completed and returned a 
questionnaire at 6 and 12 months after the caesarean section. The questionnaire 
included questions on current medication or contraceptive use, breastfeeding, 
bleeding pattern (including duration of menstruation, postmenstrual spotting, 
vaginal discharge, and urinary incontinence). They were also asked to complete a 
validated menstrual score chart: the Pictorial Blood Assessment Chart (PBAC).17 
All data were recorded in a web-based database by two research nurses. The 
results of the ultrasound scans were not recorded in the case notes, and women 
and their doctors were not informed of the ultrasound findings. All women who 
underwent TVU were included in the analyses. Only women who underwent 
both TVU and GIS were included in the comparison of TVU and GIS measurement 
outcomes.
The primary outcome was the prevalence of a niche as measured by TVU and 
GIS 6–12 weeks after caesarean section. Secondary outcome measures included 
details of the bleeding pattern, including postmenstrual spotting (defined as 
more than 2 days of brownish discharge after the end of the menstrual period), 
number of days of menstrual bleeding, urinary incontinence at 6 and 12 months 
after caesarean section, and the relationship of these with a niche, and niche 
characteristics (i.e. depth, residual myometrium, and the ratio of the residual 
myometrium divided by the total thickness of the adjacent anterior myometrium), 
identified by TVU and GIS.
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Statistical analyses
Data were analysed using the spss 20 (SPSS Inc., Chicago, IL, USA). Differences in 
baseline characteristics were compared using the chi-square test, Fisher’s exact 
test, Student’s t–test, or the Mann–Whitney U–test, depending on the type and 
distribution of the variables. Logistic regression analysis was planned to analyse 
the relationship between the presence of a niche and postmenstrual spotting. 
Potential confounding factors were predefined, and included age, breastfeeding, 
body mass index (BMI), BMI above 25 kg/m2, oral contraceptive use, and use of 
the levonorgestrel intrauterine system (LNG-IUS). These potential confounding 
factors were tested using univariate analysis. All tests were two-sided. A two-
tailed P < 0.05 was considered to be statistically significant.
Results
Between November 2007 and September 2010, 350 women gave informed consent 
to participate in the study within 3 days of their caesarean section at St Antonius 
Hospital. Of these, 276 were willing to receive a TVU at 6–12 weeks, and 263 women 
could be included. TVU was used to examine 263 women, and 197 underwent both 
TVU and GIS (see Figure 2). Two women underwent a second caesarean section 
during the study period, but only the results of the first caesarean section and 
the related TVU and GIS were included in the study. TVU and GIS were performed 
at a mean of 7.6 ± 1.7 (SD) weeks after caesarean section. In total, 72% (191/263) 
of all women who underwent a TVU completed the questionnaire at 6 months, 
and 69% (172/249) of the women who received a questionnaire at 12  months 
after the caesarean section completed it. Of all the women who completed 
the questionnaire at 12  months, 45 were pregnant again. Of the women who 
underwent both a TVU and GIS the response rate was 73% at 12 months. Baseline 
characteristics and sonography results at 6–12 weeks after caesarean section are 
shown in Table 1. The majority of the women (71%) analysed had had only one 
previous caesarean section. Sixty-four (24%) had had two and eleven (4%) had 
had three previous caesarean sections. One caesarean section was carried out 
by a J–shaped or ‘hockey stick’ incision. All other women had a transverse lower 
segment incision. The uterus was closed in two layers in four women and in one 
layer in all others. Most caesarean sections (55%) were performed because of an 
emergency. During the sonographic evaluation at 6–12  weeks after caesarean 
section, 55% of the women were breastfeeding and 77% were amenorrhoeic. At 
6–12 weeks, the women reported using the following methods of contraception: 
no contraception, 36%; oral contraceptives, 10%; progesterone only pill, 3%; 
sterilisation, 4%; condoms, 42%; and other, 5%. The difference in contraceptive 
use was not statistically significant between patients with or without a niche.
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Figure 2.  Flow diagram of study participants.
  
  
 
Excluded  (n  =  87):  
• Women  not  willing  to  undergo  TVU  
at  6–12  weeks  after  CS  (74)  
•   Twin  pregnancy  (6)  
•   Uterus  anomaly  (1)  
•   New  pregnancy  (2)  
•   >  12  weeks  after  CS  (1)  
•   Pelvic  inflammatory  disease  (1)  
•   Woman’s  2nd  CS  during  study-­‐
period  (2)  
  
  
Transvaginal  ultrasound  (TVU)    
(n  =  263)  
Excluded  from  GIS  (n  =  66):  
•   Placental  remnant/haematoma  (8)  
•   Pelvic  inflammatory  disease  (6)  
•   Woman's  request  (6)  
•   Unprotected  intercourse  (3)  
•   Failed  GIS  (no  distension)  (11)  
•   Failed  GIS  (pain)  (12):    
•   Intrauterine  fluid  (13)  
•   0ther  (7)  
Gel  instillation  sonography  (GIS)  
  (n  =197)  
Questionnaire  completed  12  months  after  CS  
(n  =172)  
Nonresponders  (77)  
Lost  to  follow-­‐up  (14)  
• Incorrect  address/moved  (12)    
• Refusal  to  continue  the  study  (2)  
Women  willing  to  
participate  
(n  =  350)  
There were no differences regarding the rate of primary or emergency caesarean 
section, age, or parity between women who were included in our analyses and 
those who refused to participate, those who did not undergo a GIS, or those who 
did not complete the questionnaire at 12 months.
Niche prevalence and characteristics
Niche prevalence was 49.6% when evaluated by TVU and 64.5% when evaluated 
by GIS. In three women it was not possible to identify the scar in the uterus 
with TVU. With GIS all scars were visible. In women with one caesarean section, 
62% who underwent GIS had a niche, compared with 68.2% of women with 
two caesarean sections and 77.8% of women with three caesarean sections. 
Sonographic characteristics of the uterus are shown in Tables 1 and 2. The 
length and width of the uterus were no different between women who had or 
did not have a niche. The niche was deeper when examined by GIS than by TVU 
(2.32  ±  3.35 and 3.03  ±  3.1  mm, respectively; P  <  0.001). The thickness of the 
residual myometrium at the site of the uterine scar was approximately 2  mm 
less in women with a niche compared with those without a niche, as measured 
by TVU and GIS (P < 0.001 and P = 0.005, respectively; see Table 1). The mean 
500835-L-bw-Dieleman
60 | Chapter 5
Ta
bl
e 
1.
 C
ha
ra
ct
er
is
tic
s 
of
 th
e 
st
ud
y 
pa
rt
ic
ip
an
ts
.
 
A
ll 
w
om
en
  
( n
 =
 2
63
)
N
ic
he
 (T
VU
)  
(n
 =
 1
29
)
N
o 
ni
ch
e 
(T
VU
)  
(n
 =
 1
31
)
P*
N
ic
he
 (G
IS
) 
(n
 =
 1
27
)
N
o 
ni
ch
e 
(G
IS
) 
(n
 =
 7
0)
P*
*
Ba
se
lin
e 
ch
ar
ac
te
ris
tic
s 
 
 
 
Ag
e 
(y
ea
rs
), 
m
ea
n 
(±
SD
)
32
.4
6 
(±
4.
15
)
32
.6
6 
(±
4.
16
)
32
.2
6 
(±
4.
15
)
0.
44
32
.5
1 
(±
4.
11
)
32
.7
3 
(±
3.
85
)
0.
72
Pa
ri
ty
, m
ea
n 
(±
SD
)
1.
54
 (±
0.
70
)
1.
55
 (±
0.
73
)
1.
54
 (±
0.
68
)
0.
96
1.
57
 (±
0.
78
)
1.
50
 (±
0.
68
)
0.
52
BM
I (
kg
/m
2 ),
 m
ea
n 
(±
SD
)
25
.7
0 
(±
5.
58
)
26
.1
5 
(±
5.
48
)
25
.2
8 
(±
5.
66
)
0.
28
25
.9
8 
(±
5.
83
)
24
.9
8 
(±
5.
19
)
0.
29
N
um
be
r 
of
 c
ae
sa
re
an
 s
ec
tio
ns
, m
ea
n 
(±
SD
)
1.
33
 (±
0.
56
)
1.
35
 (±
0.
57
)
1.
31
 (±
0.
54
)
0.
55
1.
35
 (±
0.
59
)
1.
26
  (
±0
.5
0)
0.
26
Vi
si
t a
t 6
–1
2 
w
ee
ks
 a
ft
er
 c
ae
sa
re
an
 s
ec
tio
n
 
 
 
W
ee
ks
 a
ft
er
 c
ae
sa
re
an
 s
ec
tio
n,
 m
ea
n 
(±
SD
)
7.
58
 (±
1.
74
)
7.
40
 (±
1.
40
)
7.
74
 (±
2.
01
)
0.
12
7.
66
 (±
1.
77
)
7.
72
 (±
1.
92
)
0.
82
Br
ea
st
fe
ed
in
g,
 n
um
be
r 
(p
er
ce
nt
ag
e)
**
* 
 
14
2 
(5
5%
)
67
 (5
2%
)
75
 (±
59
%
)
0.
38
64
 (5
3%
)
41
 (6
1%
)
0.
29
U
ltr
as
on
og
ra
ph
ic
 re
su
lts
 a
t 6
–1
2 
w
ee
ks
 a
ft
er
 c
ae
sa
re
an
 s
ec
tio
n
 
 
 
D
ou
bl
e 
en
do
m
et
ri
al
 th
ic
kn
es
s 
TV
U
 (m
m
), 
m
ea
n 
(±
SD
)
5.
49
 (±
3.
80
)
5.
61
 (±
3.
85
)
5.
36
 (±
5.
77
)
0.
61
5.
36
 (±
3.
57
)
4.
86
 (±
3.
33
)
0.
34
U
te
ru
s 
le
ng
th
 T
VU
 (c
m
), 
m
ea
n 
(±
SD
)
7.
18
 (±
1.
43
)
7.
29
 (±
1.
52
)
7.
07
 (±
1.
32
)
0.
23
7.
09
 (±
1.
38
)
7.
11
 (±
1.
47
)
0.
92
U
te
ru
s 
w
id
th
 T
VU
 (c
m
), 
m
ea
n 
(±
SD
)
4.
23
 (±
0.
94
)
4.
26
 (±
0.
81
)
4.
19
 (±
1.
07
)
0.
59
4.
27
 (±
0.
84
)
4.
17
 (±
1.
20
)
0.
49
Th
ic
kn
es
s 
of
 m
yo
m
et
ri
um
 a
t s
ite
 o
f C
S 
sc
ar
 (m
m
), 
m
ea
n 
(±
SD
)
9.
59
 (±
4.
18
)
8.
51
 (±
3.
90
)
10
.7
3 
(±
4.
18
)
<0
.0
01
8.
59
 (±
3.
81
)
10
.2
0 
(±
3.
59
)
0.
00
5
BM
I, 
bo
dy
 m
as
s 
in
de
x;
 T
VU
, t
ra
ns
va
gi
na
l u
ltr
as
ou
nd
; G
IS
, g
el
 in
st
ill
at
io
n 
so
no
hy
st
er
og
ra
ph
y.
*P
 v
al
ue
 b
et
w
ee
n 
ni
ch
e 
an
d 
no
 n
ic
he
 d
ur
in
g 
TV
U
.
**
P 
va
lu
e 
be
tw
ee
n 
ni
ch
e 
an
d 
no
 n
ic
he
 d
ur
in
g 
G
IS
.
**
*N
o 
in
fo
rm
at
io
n 
on
 b
re
as
tf
ee
di
ng
 fo
r 
13
 p
at
ie
nt
s 
at
 6
–1
2 
w
ee
ks
 a
ft
er
 C
S.
500835-L-bw-Dieleman
Niche prevalence and abnormal uterine bleeding | 61
5
ratio between the thickness of the residual myometrium at the site of the niche 
and the thickness of the adjacent myometrium was 0.74 ± 0.58 in all women who 
underwent GIS. The ratio was <0.5 in 22% of these women. Most niches detected 
by GIS had a semicircular shape (55%); 24% had a triangular shape, 10% had a 
droplet shape, 6% were inclusion cysts, and 7% had another shape.
Table 2. Comparison of transvaginal ultrasound (TVU) and gel instillation sonohysterography (GIS) results (n = 197)*.
TVU GIS P (95%CI)
Niche depth of all women, mean (±SD)** 2.32 (±3.35) 3.03 (±3.1) <0.001 (0.38–1.02)
Niche depth of women with niche on GIS, mean (±SD)** 3.43 (±3.67) 4.77 (±2.64) <0.001 (0.92–1.79)
Residual myometrial thickness of all women, mean (±SD) 9.58 (±4.39) 9.11 (±3.8) 0.06 (–0.24–0.96)
Residual myometrial thickness of women with niche on GIS, 
mean (±SD)
9.30 (±4.67) 8.59 (±3.75) 0.03 (0.09–1.38)
*Of the 263 women in total, only the 197 women who underwent both TVU and GIS were included in this table.
**Niche depth was recorded as 0 when no niche was observed.
Bleeding pattern and urological symptoms
The questionnaire at 6 months was completed by 191 women. Information on the 
menstrual cycle was available for only 59 women. Given the large proportion of 
women who were still breastfeeding or who did not yet have a regular menstrual 
cycle we decided not to analyse the outcomes at 6 months. The questionnaire at 
12 months was completed by 172 women. The menstrual pattern could not be 
analysed in 45 of these women because of a subsequent pregnancy. Ten of these 
women completed the information on the basis of their menstruation pattern 
before pregnancy. Information on the menstrual cycle and contraceptive use 
was available for 137 women, of whom 17 were amenorrhoeic because of LNG-
IUD or another hormonal contraceptive. Postmenstrual spotting was reported 
by 13 out of 45 (28.9%) women with a niche detected by GIS, compared with two 
women out of 29 (6.9%) without a niche detected by GIS (OR 5.48, 95% CI 1.14–
26.48; Table  3). Including only primiparae, again postmenstrual spotting was 
reported more frequently in women with a niche detected by both TVU or GIS 
compared with those without a niche (31 versus 4% for TVU and 32 versus 0% 
for GIS; OR 9.7, 95% CI 1.1–85.6). Women with a ratio of residual myometrium of 
less than half of the adjacent myometrium (ratio <0.5) measured by TVU or GIS 
reported postmenstrual spotting more often than women with a ratio of >0.5 
(OR 7.2, 95% CI 1.74–21.62, and OR 6.1, 95% CI 1.94–26.70, respectively; Table 4).
Using univariate analyses none of the predefined confounding factors or 
baseline characteristics were related to postmenstrual spotting: all had P > 0.1 
(LNG-IUD use, P = 0.11; oral contraceptive use, P = 0.24; breastfeeding, P = 1.0; 
age, P = 1.0; BMI, P = 1.0; BMI > 25 kg/m2, P = 0.40), and therefore the planned 
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logistic regression was not performed. We did not find any significant differences 
between women with or without a niche concerning the existence of (combined) 
urinary incontinence, urge incontinence, or stress incontinence (see Table 3).
Discussion
Main findings
All caesarean section scars could be identified using GIS. Using this technique the 
prevalence of niches at the site of these caesarean section scars was high (64.5%) 
in a random population. Comparing the results of GIS with TVU, niche prevalence 
was higher, measured niche depth was greater, and residual myometrium was 
thinner when detected by GIS. Postmenstrual spotting 1  year after caesarean 
section was strongly related to the presence of a niche detected by both TVU and 
GIS. One out of three women with a niche detected by GIS reported postmenstrual 
spotting, compared with one out of ten women without a niche. Postmenstrual 
spotting was related to a residual : adjacent myometrium ratio of <50%, which 
might indicate that this is a relevant parameter for niche size. The prevalence of 
urinary incontinence was not related to the presence or absence of a niche.
Strengths and limitations of the study
To the best of our knowledge this is the first study that has recruited participants 
at a very early stage after their caesarean section (within 3  days), followed 
by early examination (within 3  months) by both TVS and GIS, and with the 
sequential completion of menstrual questionnaires up to 1  year after the 
caesarean section. Only two prospective studies have evaluated niches in an 
unselected population.11,18 Both these studies recruited patients at 6–12 months 
after caesarean section. The Bij de Vaate et al.11 study was carried out by our 
study group, but in a different population and with the examinations performed 
by a different examiner. In the present study, early scanning (3  months after 
the caesarean section) meant that the vast majority of the women were still 
amenorrhoeic, so the influence of abnormal uterine bleeding on the willingness 
of women to participate (selection bias) is expected to be limited. An additional 
advantage of early sonographic evaluation is that, because of amenorrhoea in 
most patients, the potential confounding effect of variations in timing of the 
measurements during the menstrual cycle and related endometrial thickness 
is limited. In addition, women were consecutively asked to participate by 
research midwives, and the registration of the results was independent of 
clinical considerations. Women and their doctors were not informed whether 
or not a niche was observed to prevent possible bias in reporting their bleeding 
pattern. Although complete post-caesarean section scar healing may take up 
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to 6  months6, we do not know the exact time needed to develop a niche. We 
defined a niche as an anechoic space (with or without fluid) with a depth of at 
least 2 mm at the presumed site of the caesarean section scar. This should not be 
confused with the caesarean section scar itself. As demonstrated in this study, 
a scar is almost always visible and is reflected as a hypoechoic indentation of 
the myometrium at the location of the caesarean section. We expect the uterine 
scar to continue to heal beyond 6–12 weeks, and this might differ in performance 
with time. However, we consider it very unlikely that niches (i.e. discontinuations 
and fluid-stained spaces in the myometrium) will heal after this period. However, 
changes in a niche over time are not unlikely. Sustained accumulation of fluid 
may, in theory, increase niche size over time, but no data are currently available 
to confirm this theory.
A possible limitation of our study is that not all women who were delivered by 
caesarean section during the study period were asked to participate. Women 
were asked consecutively by trained midwives during their day and night shifts, 
but these midwives were not always present. Because the absence of the 
midwives was randomly distributed over the week, we consider this potential 
effect on selection bias to be minor. This is underlined by the lack of differences 
in baseline characteristics between women who were asked to participate 
and those who were not, with regards to elective or emergency caesarean 
section, age, and parity. In addition, we did not observe any differences in these 
parameters between included and excluded women, or those who were not 
willing to undergo a GIS or who did not complete the questionnaire.
Patients with a previous twin pregnancy or a known uterine anomaly were 
excluded in order to assemble a homogeneous group and to prevent undesired 
effects of unknown confounding factors; however, whether these factors would 
in fact introduce significant confounding effects is a topic for further discussion. 
We also decided not to perform a GIS in patients with a placental remnant, 
haematoma, or fluid in the uterine cavity detected by TVU. Consequently, a 
relatively small proportion of all patients who provided informed consent were 
analysed. Whether it is correct to exclude women with intrauterine fluid collection 
from examination by GIS should be further discussed. This was decided before 
the start of the study, and was included in the study protocol; however, it can be 
postulated that this group might have been particularly symptomatic and prone 
to postmenstrual spotting. We could not observe any relationship between 
niches and urinary incontinence, but we did not report other urinary symptoms, 
such as urgency. An additional shortcoming of the study is that we did not 
measure the niche width in the sagittal plane or the niche length in the transverse 
plane, as recently proposed by Naji et al.5 (our study had already begun before 
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that publication). Therefore, we could not analyse the relationship between 
these parameters and niche symptomatology. We also did not determine the 
reproducibility of our measurements.
Clinical implications of the findings and relation to published data
We were able to identify the caesarean section scar with GIS in 100% of the 
women. This is in line with another study examining women within 3 months of 
a caesarean section.19 The observed niche prevalence rate of 49.6% using TVU is 
comparable with the reported prevalence (42%) in a prospective cohort study of 
an unselected population.9 Different prevalence rates (28 and 61%) were reported 
in prospective studies in populations evaluated at 6 months and at 6–12 months 
after a caesarean section.11,13 Different definitions of a niche and different timing 
after the caesarean section may both affect the niche detection rate. Vikhareva 
Osser et al.13 used the definition ‘any visible defect’, and Bij de Vaate et al.11 used 
‘any indentation of at least 1  mm’. We used a cut-off level of 2  mm; however, 
consensus on the exact cut-off levels is lacking. Early scanning may facilitate the 
recognition of the location of the caesarean section scar in the uterine wall as a 
result of incomplete scar healing, and this may increase the detection of small 
niches. In addition, the related thin endometrium resulting from breastfeeding in 
the majority of the women may also improve niche recognition and measurement.
We used the same terminology as that suggested by Naji et al.5, and measured 
the depth and residual myometrial thickness in the sagittal plane as described. 
Niche prevalence using GIS was 64.5% in our study, which is comparable with the 
reported prevalence using GIS or SIS in random, unselected populations (56, 59.5, 
59, and 78%).10,11,14,18 Niche prevalence was higher using GIS than with TVU only. 
These findings are in line with the reported findings of three studies comparing 
GIS or SIS with TVU.10,11,18 These studies showed a higher niche prevalence with 
sonohysterography than with TVU without contrast, and thus GIS may be more 
accurate at detecting niches. Although the niches that were detected using GIS but 
were missed using TVU were smaller than those detected by both TVU and GIS, they 
can be clinically relevant. This is underlined by the strong relationship we found 
between postmenstrual spotting and niches on GIS.11 An additional argument 
for using GIS rather than TVU is that the residual myometrium measured using 
GIS was significantly thinner. The residual myometrium is considered to be the 
main limiting factor for eventual hysteroscopic niche resections to treat related 
bleeding symptoms. Most publications report a required residual myometrium 
of 2–3 mm for hysteroscopic niche resection, given the risk of perforation and/or 
bladder injury.20 In order to prevent undesired complications during hysteroscopic 
niche resections we propose that a GIS or SIS be used rather than TVU for the 
preoperative evaluation of the residual myometrium. Several previous studies 
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indicated a relationship between large niches and postmenstrual spotting. Bij de 
Vaate et al.11 reported the niche volume to be related to postmenstrual spotting. 
We were not able to calculate niche volume because of the lack of stored three-
dimensional volumes. In order to assess the relationship between large niches 
and postmenstrual spotting, we decided not to take an absolute measurement 
of residual myometrium, but to relate it to the adjacent myometrium. We defined 
large niches as those with a residual myometrium with thickness of <50% of 
that of the adjacent myometrium. This parameter was significantly related to 
postmenstrual spotting. This parameter and cut-off level were also used by Ofilli-
Yebovi et al.15, who reported a high prevalence of women with a ratio of less of 
than 50% in a population with gynaecological symptoms. A potential relationship 
between niche size and postmenstrual spotting is in line with the hypothesis that 
spotting is induced by the accumulation of blood inside the niche.6,7 A depth of 
more than half the myometrial thickness makes the anterior part of the niche 
possibly large enough to obstruct the direct outflow of menstrual blood. This, 
in combination with lower contractility as a result of fibrosis, may induce the 
accumulation of blood in a niche.
One out of three women with a niche observed by GIS reported postmenstrual 
spotting. This is in line with the previous reported prevalence of postmenstrual 
spotting in patients with a niche.10,11 Given the high prevalence of postmenstrual 
spotting after caesarean section, this should be part of routine counselling 
before elective caesarean section.
Future perspectives
Future research should focus on the relationship of niches to subsequent fertility, 
obstetric complications such as uterine rupture, and on the impact of a niche 
on a woman’s well-being. There is a lack of information on the impact of niche-
related bleeding disorders on women’s quality of life, their sexual function, and 
their willingness to undergo treatment for related symptoms.
Conclusion
In conclusion, the caesarean section scar was visible in all women at 6–12 weeks 
after caesarean section using GIS. The prevalence of niches detected by GIS 
is high after caesarean section (64.5%), and more niches are detected using 
GIS than using TVU, with a larger observed niche size and reduced residual 
myometrial thickness. The presence of a niche is related to postmenstrual 
spotting. Postmenstrual spotting is more frequent in patients with large niches 
(defined as a residual myometrium of thickness <50% of that of the adjacent 
myometrium) than in patients with smaller niches.
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Abstract
Objective
To review systematically the medical literature reporting on the prevalence of a 
niche at the site of a Cesarean section (CS) scar using various diagnostic methods, 
on potential risk factors for the development of a niche and on niche-related 
gynecological symptoms in non-pregnant women. 
Methods
The PubMed and EMBASE databases were searched. All types of clinical study 
reporting on the prevalence, risk factors and/or symptoms of a niche in non-
pregnant women with a history of CS were included, apart from case reports and 
case series.
Results
Twenty-one papers were selected for inclusion in the review. A wide range in the 
prevalence of a niche was found. Using contrast-enhanced sonohysterography in 
a random population of women with a history of CS, the prevalence was found 
to vary between 56% and 84%. Nine studies reported on risk factors and each 
study evaluated different factors, which made it difficult to compare studies. 
Risk factors could be classified into four categories: those related to closure 
technique, to development of the lower uterine segment or location of the 
incision or to wound healing, and miscellaneous factors. Probable risk factors are 
single-layer myometrium closure, multiple CSs and uterine retroflexion. Six out 
of eight studies that evaluated niche-related symptoms described an association 
between the presence of a niche and postmenstrual spotting.
Conclusions
The reported prevalence of a niche in non-pregnant women varies depending 
on the method of detection, the criteria used to define a niche and the study 
population. Potential risk factors can be categorized into four main categories, 
which may be useful for future research and meta-analyses. The predominant 
symptom associated with a niche is postmenstrual spotting. 
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Introduction
In recent decades, the percentage of Cesarean section (CS) deliveries has 
dramatically increased in most developed countries. An average rate of 21.1% 
for developed countries has been reported, with a range between 6.2% and 
36%1. There are some well-known complications, such as uterine rupture and 
pathologically adherent placenta in future pregnancy2,3, but there is now an 
increasing interest in the long-term effects of this procedure. Recently, the 
presence of a niche at the site of a CS scar has been observed4-7. A niche is mainly 
a sonographic finding and has been defined as a triangular anechoic area at the 
presumed site of incision8. However, a generally accepted definition of a niche 
is still under debate. Alternative terms for a niche are Cesarean scar defect4,9,10, 
deficient Cesarean scar11, diverticulum12, pouch6 and isthmocele13. Interest in the 
potential clinical relevance of a niche has increased in the last few years and a 
growing number of studies on the subject have been published. Various methods 
to detect and measure a niche have been described. The majority of papers have 
evaluated the niche with the use of transvaginal sonography (TVS)5,9-11,14,15 and 
contrast-enhanced sonohysterography (SHG)5,8,15-18, but a minority have used 
hysteroscopy6,13,16 or hysterosalpingography12. At present there is no consensus 
regarding the gold standard for the detection and measurement of a niche. As 
not all women with a history of CS develop a niche, it is of interest to identify the 
risk factors that may predict their development. In addition, there is growing 
interest in possible associations between the presence of a niche and various 
gynecological symptoms, and in the mechanisms behind the development 
of these symptoms. A common symptom reported to be associated with the 
presence of a niche is postmenstrual spotting5,6,10,18. 
The objective of the current review was to give a systematic overview of the 
available literature on the prevalence of a niche using various diagnostic methods, 
on potential risk factors for the development of a niche and on niche-related 
gynecological symptoms in non-pregnant women.
Methods
Search strategy
In February 2013, we searched the PubMed and EMBASE databases for 
words in the title or abstract and MeSH terms. All possible combinations of 
known terms for niche (cicatrix, scar, isthmocele, anechoic, pouch, wound 
dehiscence, diverticulum), uterus (uterine diseases, myometrium, endometrium, 
myoendometrium) and CS (Cesarean, caesarean, c section, abdominal delivery, 
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postCesarean, postcaesarean) were used. The complete electronic search 
strategy is provided in Appendix S1. Reference lists of the studies were cross-
checked to identify cited articles not captured by the electronic search.
Study selection criteria
We included all types of clinical study reporting on the prevalence, risk factors 
and/or symptoms of a niche in non-pregnant women, using TVS, SHG or 
hysteroscopy. Studies in the English language published as full papers in peer-
reviewed journals were included. Case reports or small case series were excluded. 
Given the limited number of cohort studies or randomized controlled trials, we 
did not apply additional methodological filters for paper selection. The types of 
study we expected to find were randomized controlled trials, prospective cohort 
studies (following a group of similar individuals over time), retrospective cohort 
studies (comparison of patients’ medical records for a particular outcome), 
cross-sectional studies (observation of a population at one specific point in time) 
and case–control studies (comparing subjects who have a certain condition with 
patients who do not, in order to identify a factor that may contribute to this 
condition).
Studies were selected in a two-stage process by two researchers ( J.H. and A.B.). 
First, eligibility was assessed based on the titles and abstracts. Full manuscripts 
were obtained for all selected studies. In the second step, the decision for final 
inclusion was made after examination of the full papers. The outcomes of this 
review are the prevalence of a niche in women with a history of CS, risk factors 
for the development of a niche and symptoms related to the presence of a niche.
Presentation of data
The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
analyses) statement was used for reporting the methods, results and discussion 
sections of the current review and the STROBE (Strengthening the Reporting 
of Observational Studies in Epidemiology) statement was used to obtain an 
impression of the quality of the included studies19,20. Included papers were ordered 
in the tables according to the outcome of the most relevant items of the STROBE 
checklist, such as clear definition of the study population and clear description 
of the method of evaluation. The extended STROBE checklist, including all 
STROBE items, is provided in Appendix S2. The QUADAS (Quality Assessment of 
Diagnostic Accuracy) checklist was used for assessing the methodological quality 
of the studies reporting on the accuracy of diagnostic tests21.
The included studies were divided into papers reporting on niche prevalence, risk 
factors and symptoms. The tables were subdivided into two sections: a section 
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with studies performed in a random population of women with a history of CS, and 
a section with studies performed in a population of women with gynecological 
symptoms. All studies were assessed for potential risk of bias. Papers were ranked 
based on methodological criteria, which means that randomized controlled trials 
and studies with a clear definition of study population and method of evaluation 
were placed at the top of the tables. In the table reporting on risk factors, studies 
including women with one previous CS and in which multivariate analysis was 
used were placed in the first few columns.
Results
Literature identification
The electronic search in PubMed and EMBASE generated 2953 records. Four 
additional records were identified through cross-checking. After screening 
2957 abstracts, 27 papers were thought to meet the inclusion criteria and were 
selected for full assessment. Six papers were excluded for the following reasons: 
study design (two case reports), three publications did not meet the outcome 
measures and in one study women were examined at 14–16 weeks’ gestation. We 
included two studies that were subgroups of a study by Vikhareva Osser et al.9 
as new outcome parameters were tested17,22. The final study included 21 papers 
(Figure 1).
1370 records identified 
through searching 
Pubmed 
4 additional records 
identified through 
cross-checking
2957 records screened
2930 
records 
excluded
21 studies included
6 publications excluded:
-2 case reports
-3 publications did not meet the outcome 
measures 
-In 1 publication women were examined 
at 14-16 weeks’ gestation
1583 records identified 
through searching 
Embase 
(Pubmed results were 
excluded)
27 full-text articles 
assessed for 
eligibility
Figure 1: Flow diagram of literature search for articles on uterine niches following Cesarean section.
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Table 1: Methodological characteristics, based on the STROBE-statement, of included studies performed either 
in a random population of women with a history of Cesarean section (CS) or in women with a history of CS and 
gynecological symptoms (i.e. subject to selection bias).
Study Design Clear 
definition of 
study 
population
Clear  
description of 
niche  
assessment
Clear  
description of 
assessment of 
all outcomes
Description  
of missing 
data
Correction for 
confounders
Random population
Yazicioglu, 
200626
RCT Yes Yes No Yes Yes
Vikhareva 
Osser,  
201022
Prosp. cohort Yes Yes Yes NA Yes
Bij de Vaate, 
20115
Prosp. cohort Yes Yes Yes Yes Yes
Hayakawa, 
200625
Prosp. cohort Yes Yes Yes NA Yes
Valenzano, 
200615
Case-control Yes Yes Yes NA No
Vikhareva 
Osser,  
201017
Prosp. cohort Yes Yes Yes NA No
Vikhareva 
Osser,  
20099
Case-control Yes Yes Yes NA No
Ceci,  
201223
Prosp. cohort Yes Yes Yes Yes No
Armstrong, 
20034
Case-control Yes Yes Yes NA No
Regnard,  
20047
Prosp. cohort No Yes Yes NA No
Chen,  
199014
Prosp. cohort No No No NA No
Glavind,  
201224
Retro. cohort Yes Yes Yes NA No
Women with gynecological symptoms
Ofili-Yebovi, 
200811
Prosp. cohort Yes Yes Yes Yes Yes
El-Mazny,  
201116
Cross-sectional Yes Yes Yes NA No
Monteagudo, 
20018
Prosp. cohort Yes Yes Yes NA No
Wang,  
200910
Cross-sectional No Yes Yes NA Yes
Chang,  
200927
Prosp. cohort No Yes No NA No
Uppal,  
201128
Prosp. cohort No No Yes No Yes
Borges,  
201013
Prosp. cohort No No No NA No
Thurmond, 
199918
Prosp. cohort No No No NA No
Fabres,  
20036
Retro. cohort No Yes No NA No
Only first author is listed for each study. Prosp., prospective; RCT, randomized controlled trial; Retro., retrospective. 
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The niche was evaluated in a random population of women with a history of CS in 
12 studies4,5,7,9,14,15,17,22-26. In these studies, women with a history of CS were included 
regardless of the presence of symptoms. The other nine studies evaluated women 
who were referred for a variety of gynecological symptoms, such as abnormal 
uterine bleeding or infertility6,8,10,11,13,16,18,27,28. The included studies with a random 
population and those with a population of women with symptoms are reported 
in Table 1. The diagnostic methods used for evaluation of the uterine cavity were 
TVS in 16 studies4-6,9-11,14,15,17,22-28, SHG in eight studies5,7,8,15-18,22 and hysteroscopy in 
four studies6,13,16,23.
Prevalence
The prevalence of a niche was reported in 15 papers. Seven studies were 
performed in a random population of women with a history of CS (Table 2) and 
eight in a population of women with gynecological symptoms (Table 3).
Using TVS, the reported prevalence of a niche varied between 24% and 70% in 
four studies with a random population of women with a history of one or multiple 
CSs4,5,9,17. All four studies met the STROBE criteria in terms of a clear description 
of study population and method of evaluation. Using SHG, the prevalence of a 
niche varied between 56% and 84% in three studies with a random population 
that met the STROBE criteria5,15,17. The prevalence of a niche as ascertained by 
hysteroscopy was only evaluated in populations of women with gynecological 
symptoms13,16 (Table 3).
Two studies meeting the STROBE criteria and conducted in a random population 
of women with a history of CS reported the prevalence of a niche using both TVS 
and SHG5,17. Vikhareva Osser et al.17 reported a niche prevalence of 84% with SHG 
and 70% with TVS, with a niche defined as any indentation or other defect in the 
scar. The same authors found that the length and height of Cesarean scar defects 
were greater when evaluated using SHG than when evaluated using TVS, and 
that more scars were seen and classified subjectively as large by SHG without a 
change being noted in the shape. Bij de Vaate et al.5 found a niche prevalence of 
56% with SHG and 24% with TVS, and defined a niche as an anechoic area at the 
site of the CS scar with a depth of at least 1 mm.
Another study performed in women with gynecological symptoms compared the 
accuracy of SHG with hysteroscopy as the reference technique and demonstrated 
that SHG is comparable to hysteroscopy for the diagnosis of a niche as shown by 
the sensitivity (87%), specificity (100%), positive predictive value (100%), negative 
predictive value (95%) and overall accuracy (96%)16. This study did not meet 
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two criteria of the QUADAS checklist21. First, the study population consisted of 
women with gynecological symptoms. Second, the hysteroscopy findings were 
interpreted with prior knowledge of the SHG results. Another study reported 
that hysteroscopy as the reference technique showed 100% correlation with TVS 
in the detection of a niche6. However, this study did not meet the QUADAS criteria 
either, as it was a retrospective study in women with a niche assessed using 
TVS, and hysteroscopy was performed in a subgroup of women who wanted to 
become pregnant (verification bias).
Niche shape
Five studies reporting on niche shape evaluated the shape in the sagittal plane 
with TVS or SHG5,6,9,14,17. Most authors described the niche as being triangular 
in shape with TVS6,9,14. Vikhareva Osser et al.9 reported that 83% of niches 
were triangular, 2% were round, 4% were oval and 10% showed no remaining 
myometrium over the defect. The same group demonstrated that the shape 
did not change when evaluated by SHG17. Another study demonstrated that the 
niche was visualized as a triangular anechoic area in all women6. In addition, it 
was reported that a wedge defect was present in 21% of women with a history 
of CS, inward protrusion (internal surface of the scar bulging toward the uterine 
cavity) in 6%, outward protrusion (external surface bulging toward the bladder or 
abdominal cavity) in 15%, hematoma (echogenic mass adjacent to the wound site 
of the anterior wall of the lower uterine segment) in 4% and inward retraction 
(external surface of the scar dimpled toward the myometrial layer) in 4%14. Bij de 
Vaate et al.5, using SHG, found that 50% of niches were semicircular, 32% were 
triangular and 10% were droplet-shape; inclusion cysts accounted for 7%.
If we consider only the methodologically well-performed studies according 
to the STROBE criteria with a random population of women with a history of 
CS, triangular and semicircular are found to be the most commonly described 
shapes 5,9.
Niche size
Eight studies evaluated niche size, but the studies describing large niches 
used different definitions for this5,7,9,11,16,17,27,28. Vikhareva Osser et al.9 
classified a niche as large or as a total defect based on subjective evaluation 
in a random population of women with a history of CS examined by TVS. 
At least one defect was classified as large in 14%, 23% and 45% of the women 
with one, two and at least three CSs, respectively. At least one total defect (with 
no remaining myometrium over the defect) was observed in 6%, 7% and 18% of 
the women with one, two and at least three CSs, respectively. In another study 
by the same authors, a niche was defined as large if the remaining myometrium 
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measured ≤ 2.2 mm in thickness using TVS and ≤ 2.5 mm using SHG in women 
with one previous CS17. According to the authors, these cut-off values were the 
measurements that best discriminated between defects estimated subjectively 
as being large or not in women with a history of one CS. Regnard et al.7 reported 
that two out of 19 niches (11%) had a depth of at least 80% of the anterior 
myometrium, which was demonstrated with SHG in a random population of 
women with a history of CS. Ofili-Yebovi et al.11 demonstrated that, when using 
TVS in a group of women with gynecological symptoms, half of them had a large 
niche, i.e. one involving more than 50% of the myometrial thickness.
The abovementioned studies demonstrate that there is currently no uniform 
definition of a large niche. The definitions used for a large niche were a niche 
penetrating to a depth of at least 50% or 80% of the anterior myometrium, or the 
remaining myometrial thickness ≤ 2.2 mm when evaluated by TVS and ≤ 2.5 mm 
when evaluated by SHG. A total defect was defined as no remaining myometrium 
over the defect.
Risk factors
Risk factors that are associated with the presence or size of a niche were evaluated 
in nine studies (Table S1). Various risk factors were investigated, but none of the 
papers studied exactly the same ones. In addition, some factors are known to 
be mutually related. For example, several indications for CS (duration of labor, 
oxytocin augmentation) affect cervical dilatation or the development of the 
lower uterine segment22. For this reason, we classified all risk factors into four 
main categories: factors related to closure technique, development of the lower 
uterine segment or location of the incision, wound healing and miscellaneous 
factors (Table 4). In addition, studies were classified according to their design, 
with studies including only one previous CS and/or those using multivariate 
analysis presented first. Three studies were performed in a population of women 
with a history of only one CS and analyzed with the use of multivariate analysis, 
and will be discussed below22,25,26.
Closure technique
Two studies evaluated the relationship between closure technique and 
the presence of a niche25,26. A randomized controlled trial reported a lower 
frequency of a niche in women treated by full thickness suturing (including the 
endometrial layer) in comparison with split thickness suturing (excluding the 
endometrial layer)26, while a prospective cohort study reported a reduced risk 
of niche development after double-layer myometrium closure or single-layer 
myometrium closure with endometrial suture in comparison with single-layer 
myometrium closure without endometrial suture25. Another prospective cohort 
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study reported large niches more frequently in women with one-layer uterine 
closure (90.9%) in comparison with two-layer closure (9.1%), but this was not a 
statistically significant difference22. A niche was classified as large in the latter 
study if the remaining myometrium measured ≤ 2.2 mm in thickness using TVS 
and ≤ 2.5 mm in thickness using SHG.
Development of lower uterine segment or scar location
Three studies reported a relationship between the presence or size of a niche and 
the factors potentially affecting the development of the lower uterine segment 
or scar location (Table 4)22,25,26. In one of these studies, the risk of a large niche 
increased if the station of the presenting part of the fetus at CS was below the 
pelvic inlet, cervical dilatation was ≥ 5 cm or duration of labor was ≥ 5 h22. Another 
study, on the other hand, reported that an increased risk for the presence of a 
niche was related to less cervical dilatation26. Hayakawa et al.25 reported that 
an increased risk was associated with premature rupture of membranes and 
increased gestational age at delivery, while Yazicioglu et al.26 found that there 
was no relationship with gestational age. Emergency CS and the presence of 
labor were reported not to be risk factors for the presence of a niche25,26.
Wound healing
One study reported a relationship between uterine retroflexion and a large niche, 
and another reported a relationship between pre-eclampsia and the presence 
of a niche22,25. We classified these risk factors as ones with a potential negative 
effect on wound healing. Other factors that were classified in this category 
(infection or maternal body mass index) were not related to the presence of a 
niche25. In a study performed in women with a history of one or multiple CSs, 
multivariate analysis demonstrated a relationship between the presence of a 
niche and multiple CSs or uterine retroflexion11.
Symptoms
The identification of niche-related symptoms was evaluated in eight studies, 
using TVS, SHG or hysteroscopy for niche assessment (Table S2). Two studies 
were performed in a random population of women with a history of CS5,15; both 
studies fulfilled the STROBE criteria, except for the correction for confounders 
in one study15. Bij de Vaate et al.5 reported postmenstrual spotting in 34% of 
women with a niche using SHG, which was significantly higher than in women 
without a niche. Menada Valenzano et al.15 did not find an association between 
the presence of a niche identified with SHG and abnormal uterine bleeding, 
defined as spotting after the end of menstruation and/or non-cyclic bleeding 
not related to menstruation. However, the same authors found that abnormal 
uterine bleeding was more frequent in women with diverticula (anechoic round 
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structures) and deformation of the cervical canal at the scar site, identified on 
TVS. In addition, abnormal bleeding was more frequent in women with a history 
of CS than in women with a previous vaginal birth in this study, indicating some 
relationship between the presence of a CS scar and postmenstrual spotting.
Six studies were performed in a population of women with gynecological 
symptoms (Table S2), and a high prevalence of postmenstrual spotting in 
women with a niche compared with women without a niche was reported in 
three studies6,10,18. In one cross-sectional study the prevalence of postmenstrual 
spotting in women with a niche examined by TVS for various gynecological 
reasons was 64%10. In a very small prospective cohort study all women with a 
niche demonstrated by SHG had postmenstrual spotting18. A retrospective study 
of all TVS examinations conducted for a variety of gynecological reasons reported 
abnormal bleeding in 83% and postmenstrual spotting in 76% of premenopausal 
women with a niche6.
Three studies reported an association between the size of a niche and 
postmenstrual spotting5,10,28. In one study, performed in a random population of 
women with a history of CS, the depth and shape of the niche were not significant 
factors, while a larger niche volume was described in women with postmenstrual 
spotting5. The other two studies, performed in a population of women with 
gynecological symptoms, demonstrated that niches were significantly wider in 
women with postmenstrual spotting, dysmenorrhea or chronic pelvic pain, and 
that the prevalence of postmenstrual spotting or prolonged menstrual bleeding 
was higher with a larger diameter of the niche10,28. Other reported symptoms in 
women with a niche were dysmenorrhea (53.1%), chronic pelvic pain (36.9%) and 
dyspareunia (18.3%)10.
Discussion
In a random population of women with a history of CS, the prevalence of a 
niche ranged from 24% to 70% and 56% to 84% when assessed by TVS and SHG, 
respectively. Probable risk factors are single-layer myometrium closure, multiple 
CSs and retroflexed uterus. The predominant symptom related to a niche is 
postmenstrual spotting.
The ideal study reporting on symptoms would be performed in a random 
sample of women with a history of CS in order to prevent selection bias, but also 
including a group of patients who had only experienced vaginal birth in order to 
distinguish the effects of CS and niche. Only one study performed in a random 
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population described a positive relationship between a niche and postmenstrual 
spotting5. This association was not found by Menada Valenzano et al.15, who did 
report a relationship between postmenstrual spotting and a previous CS. The 
discrepancy in the findings of these two studies can be explained by variations 
in methodology, such as definition of a niche, timing of the ultrasound scans and 
exclusion of multiple CSs in the population of Menada Valenzano et al. In the 
majority of the studies evaluating niches in women with gynecological symptoms, 
selection bias is likely to play a role, which is underlined by the higher prevalence 
of postmenstrual spotting in these women than in a random population of 
women with a history of CS6,10,13,18,28. Several hypotheses have been put forward 
to explain the etiology of abnormal uterine bleeding in women with a niche, such 
as poor contractility of the uterine muscle around the niche, which may result in 
retention of menstrual blood within it18.
Two studies report that closure technique during CS affects niche development. 
It seems to be more appropriate to use double-layer or full thickness suturing, a 
finding that should be confirmed in future studies25,26. Although the results of the 
current review are inconclusive, we hypothesize that potential factors affecting the 
development of the lower uterine segment (such as duration of labor, dilatation, 
stage of the presenting part) may influence development of a niche. It has been 
postulated that the characteristics of the myometrium alter during labor and 
that, for example, a thinner myometrium may be less well vascularized, which 
may lead to insufficient wound healing and niche development29. In addition, a 
lower position of the CS incision, in particular in the cervical part of the uterus, 
may be more prone to the development of a niche9.
The current review is the first systematic review to give an overview of the 
available literature relating to the prevalence of a niche, potential risk factors 
and symptoms associated with a niche. Given the inconsistency in methodology 
between the studies, we were not able to perform meta-analyses. However, we 
ranked the included papers based on criteria for quality assessment in order to 
improve the interpretation of the current reported evidence.
The lack of consistency in methodology is based on three aspects. The principal 
issue was the method of niche detection. Although TVS has been considered 
an accurate method for detecting a niche, SHG may facilitate their detection 
and measurement, an idea that is supported by the higher prevalence and 
identification of larger niches with SHG than with TVS in two comparative 
studies5,17. Application of saline or gel contrast enables differentiation between 
niches that communicate with cervical wall defects and cervical (mucous) cysts. 
In addition, small indentations or defects at the site of the scar can be identified 
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more precisely if contrast is used. Therefore, we propose SHG in non-pregnant 
patients as the gold standard in future studies on niche prevalence.
The second major issue is the lack of agreement about the definition of a niche. 
First of all, it is important to distinguish a niche from the CS scar itself. Naji 
et al.30 described a standardized measurement technique and registration 
method for the evaluation of CS scars using TVS in pregnant and non-pregnant 
women. However, there is no agreement about how to define the margins of a 
niche, whether cervical diverticula should be included or if there is a minimal 
size to the anechoic area for it to qualify as a niche. We propose the following 
definition: any indentation representing myometrial discontinuity at the site of 
the Cesarean scar that communicates with the uterine or cervical cavity as seen 
on SHG. The problem with reporting on risk factors for a large niche is the lack of 
predefined definitions for them. In one study, the cut-off value for a large niche 
was based on study outcome, and therefore has a risk of data-driven definition22. 
We propose the use of predefined cut-off values for a large niche based on 
interquartile ranges or standard deviations, or on the ratio of niche depth 
and total thickness of adjacent myometrium, e.g. a ratio of more than 50%11. 
Finally, there is significant heterogeneity in the patient populations reported, 
consisting of women with a history of CS who were assessed for a variety of 
gynecological symptoms or women with a history of CS (and vaginal birth), 
independent of their symptoms.
As the CS rate increases, the potential morbidity associated with CS scars is likely 
to become increasingly important. If we are to understand the relevance of the 
presence of a niche, it is essential that agreed criteria and definitions are used 
in future studies as well as standardized outcomes. In addition, identification of 
potential risk factors provides insight into etiology, but more importantly it would 
be useful for the prevention of future niche development and related symptoms.
At present we do not know the importance of a niche in future pregnancies and it 
must be questioned whether it is appropriate to report on the morphology of CS 
scars using ultrasound in view of the fact that we do not know how to act on this 
information. It seems increasingly likely that niches may be a cause of abnormal 
uterine bleeding, and we await good interventional trials to see if correction in 
these circumstances is effective. The possible impact of a niche on fertility is an 
important subject, but we have little information on this topic to guide us.
In conclusion, niches are frequently identified after CS and are related to 
postmenstrual spotting. A uniform definition of a niche and a method for 
500835-L-bw-Dieleman
90 | Chapter 6
assessment should be formulated in order to enable future meta-analyses. 
We propose to use SHG and define a niche as any indentation representing 
myometrial discontinuity at the site of the Cesarean scar that communicates 
with the uterine or cervical cavity. More well-designed research on risk factors 
is needed in order to obtain tools to prevent future niche development.
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Appendix S1:  
Literature search
PubMed February 2013
Search Query Results
#4 #1 AND #2 AND #3 1370
#3 “Cesarean Section”[Mesh] OR cesarea*[tiab] OR caesarea*[tiab] OR “c section”[tiab] 
OR “c sections”[tiab] OR (abdominal[tiab] AND deliver*[tiab]) OR postcesarea*[tiab] 
OR postcaesaria*[tiab]
54595
#2 “Uterus”[Mesh] OR “Uterine Diseases”[Mesh] OR uterus[tiab] OR uterine[tiab] 
OR myometri*[tiab] OR endometri*[tiab] OR endomyometri*[tiab] OR 
myoendometri*[tiab]
266584
#1 “Cicatrix”[Mesh] OR cicatr*[tiab] OR scar[tiab] OR scars[tiab] OR scarring[tiab] OR 
isthmocele*[tiab] OR niche[tiab] OR niches[tiab] OR anechoic[tiab] OR pouch*[tiab] 
OR diverticul*[tiab]
119394
Embase February 2013
Search Query Results
#5 #1 AND #2 AND #3 AND [embase]/lim 1583
#4 #1 AND #2 AND #3 2057
#3 ‘cesarean section’/exp OR cesarea*:ab,ti OR caesarea*:ab,ti OR ‘c section’:ab,ti OR 
‘c sections’:ab,ti OR (abdominal:ab,ti AND deliver*:ab,ti) OR postcesarea*:ab,ti OR 
postcaesarea*:ab,ti
66719
#2 ‘uterus’/exp OR ‘uterus disease’/exp OR uterus:ab,ti OR uterine:ab,ti 
OR myometri*:ab,ti OR endometri*:ab,ti OR endomyometri*:ab,ti OR 
myoendometri*:ab,ti
485605
#1 ‘wound dehiscence’/exp OR ‘scar formation’/exp OR ‘scar’/exp OR cicatr*:ab,ti OR 
scar:ab,ti OR scars:ab,ti OR scarring:ab,ti OR isthmocele*:ab,ti OR niche:ab,ti OR 
niches:ab,ti OR anechoic:ab,ti OR pouch*:ab,ti OR diverticul*:ab,ti
151943
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 d
ef
ec
ts
.
D
efi
ni
tio
n:
 D
et
ec
ta
bl
e 
m
yo
m
et
ri
al
 
th
in
ni
ng
 a
t t
he
 s
ca
r 
si
te
.    
       
       
       
       
       
       
       
       
     
M
et
ho
d:
 T
VS
A 
hi
st
or
y 
of
 m
ul
tip
le
 C
Ss
 (O
R 
1.
9 
[9
5%
 C
I 
1.
3-
2.
9]
; p
=0
.0
01
), 
ut
er
in
e 
re
tr
ofl
ex
io
n 
(O
R 
2.
4 
[9
5%
 C
I 1
.3
-4
.8
]; 
p=
0.
01
) a
nd
 th
e 
in
ab
ili
ty
 
to
 v
is
ua
liz
e 
al
l c
es
ar
ea
n 
sc
ar
s 
in
 w
om
en
 w
ith
 
a 
hi
st
or
y 
of
 m
ul
tip
le
 C
Ss
 (O
R 
0.
31
 [9
5%
 C
I 
0.
13
-0
.7
5]
; p
=0
.0
1)
 w
er
e 
as
so
ci
at
ed
 w
ith
 th
e 
pr
es
en
ce
 o
f c
es
ar
ea
n 
sc
ar
 d
ef
ec
ts
.
re
po
rt
in
g 
ab
ou
t f
ac
to
rs
 a
ss
oc
ia
te
d 
w
ith
 n
ic
he
 s
iz
e:
W
an
g 
 
et
 a
l. 
    
    
    
    
   
20
09
10
Cr
os
s-
se
ct
io
na
l 
st
ud
y
20
7
W
om
en
 w
ith
 a
 
hi
st
or
y 
of
 o
ne
 
or
 m
ul
tip
le
 C
Ss
, 
ex
am
in
ed
 w
ith
 
TV
S 
fo
r 
va
ri
ou
s 
gy
na
ec
ol
og
ic
al
 
in
di
ca
tio
ns
, 
di
ag
no
se
d 
w
ith
 
a 
ce
sa
re
an
 s
ca
r 
de
fe
ct
.
As
so
ci
at
io
n 
be
tw
ee
n 
th
e 
si
ze
 o
f c
es
ar
ea
n 
sc
ar
 
de
fe
ct
s,
 u
te
ri
ne
 p
os
iti
on
 
an
d 
th
e 
nu
m
be
r 
of
 C
Ss
.
D
efi
ni
tio
n:
 H
yp
oe
ch
og
en
ic
 a
re
a 
w
ith
in
 th
e 
m
yo
m
et
ri
um
 o
f t
he
 
lo
w
er
 u
te
ri
ne
 s
eg
m
en
t, 
at
 th
e 
si
te
 
of
 a
 p
re
vi
ou
s 
ce
sa
re
an
 in
ci
si
on
.         
               
               
               
               
 
M
et
ho
d:
 T
VS
Th
e 
m
ea
n 
w
id
th
 a
nd
 d
ep
th
 o
f t
he
 s
ca
r 
de
fe
ct
 
w
er
e 
la
rg
er
 in
 w
om
en
 w
ho
 h
ad
 u
nd
er
go
ne
 
m
ul
tip
le
 C
Ss
 (p
=0
.0
01
 a
nd
 p
=0
.0
02
) a
nd
 th
e 
m
ea
n 
w
id
th
 w
as
 la
rg
er
 in
 w
om
en
 w
ith
 a
 
re
tr
ofl
ex
ed
 u
te
ru
s 
(p
<0
.0
01
). 
M
on
te
ag
ud
o 
et
 a
l. 
 2
00
18
Pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
44
W
om
en
 w
ith
 a
 
hi
st
or
y 
of
 o
ne
 
or
 m
ul
tip
le
 C
Ss
, 
w
ho
 u
nd
er
w
en
t 
SH
G
 fo
r 
a 
va
ri
et
y 
of
 g
yn
ae
co
lo
gi
c 
in
di
ca
tio
ns
. 
As
so
ci
at
io
n 
be
tw
ee
n 
th
e 
nu
m
be
r 
of
 C
Ss
 a
nd
 
th
e 
si
ze
 o
f t
he
 n
ic
he
 a
nd
 
th
ic
kn
es
s 
of
 th
e 
re
si
du
al
 
m
yo
m
et
ri
um
.
D
efi
ni
tio
n:
 T
ri
an
gu
la
r 
an
ec
ho
ic
 s
tr
uc
tu
re
 a
t t
he
 s
ite
 
of
 a
 p
re
vi
ou
s 
ce
sa
re
an
 s
ca
r.
           
           
           
           
           
           
           
   
M
et
ho
d:
 S
H
G
Th
er
e 
w
as
 n
o 
as
so
ci
at
io
n 
be
tw
ee
n 
th
e 
nu
m
be
r 
of
 C
Ss
 a
nd
 th
e 
de
pt
h 
of
 th
e 
ni
ch
e 
or
 
th
e 
th
ic
kn
es
s 
of
 th
e 
re
si
du
al
 m
yo
m
et
ri
um
. 
CS
=c
es
ar
ea
n 
se
ct
io
n;
 T
VS
=t
ra
ns
va
gi
na
l s
on
og
ra
ph
y;
 S
H
G
=s
on
oh
ys
te
ro
gr
ap
hy
.
500835-L-bw-Dieleman
Prevalence of niche, risk factors and symptoms | 103
6
Ta
bl
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: S
ym
pt
om
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as
so
ci
at
ed
 w
ith
 th
e 
pr
es
en
ce
 o
f a
 n
ic
he
.
Le
ad
in
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au
th
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D
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n
Po
pu
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on
O
ut
co
m
e
D
efi
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it
io
n
 o
f 
n
ic
h
e 
an
d
 
m
et
ho
d 
of
 e
va
lu
at
io
n
Sp
ec
ifi
ca
ti
on
 o
f 
b
le
ed
in
g 
di
so
rd
er
 a
nd
 m
et
ho
d 
of
 
ev
al
ua
ti
on
Re
su
lt
s
N
o 
se
le
ct
io
n 
bi
as
, r
an
do
m
 s
am
pl
e 
of
 w
om
en
 w
ith
 a
 h
is
to
ry
 o
f C
S:
Bi
j d
e 
Va
at
e 
et
 a
l. 
   
   
   
   
   
20
11
5
Pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
22
5
Co
ns
ec
ut
iv
e 
in
cl
us
io
n 
of
 w
om
en
 
6-
12
 m
on
th
s 
af
te
r 
a 
CS
.
Re
la
tio
ns
hi
p 
be
tw
ee
n 
ni
ch
e 
an
d 
ab
no
rm
al
 
ut
er
in
e 
bl
ee
di
ng
.
D
efi
ni
tio
n:
 A
ne
ch
oi
c 
ar
ea
 a
t t
he
 s
ite
 o
f t
he
 
ce
sa
re
an
 s
ca
r 
w
ith
 a
 
de
pt
h 
of
 a
t l
ea
st
 1
 m
m
.         
              
           
M
et
ho
d:
 S
H
G
Po
st
m
en
st
ru
al
 s
po
tt
in
g:
 
M
or
e 
th
an
 2
 d
ay
s 
of
 
br
ow
ni
sh
 d
is
ch
ar
ge
 
at
 th
e 
en
d 
of
 th
e 
m
en
st
ru
at
io
n 
w
ith
 a
 to
ta
l 
le
ng
th
 o
f m
en
st
ru
at
io
n 
of
 m
or
e 
th
an
 7
 d
ay
s,
 o
r 
in
te
rm
en
st
ru
al
 b
le
ed
in
g 
w
hi
ch
 s
ta
rt
s 
w
ith
in
 5
 
da
ys
 a
ft
er
 th
e 
en
d 
th
e 
en
d 
of
 th
e 
m
en
st
ru
at
io
n.
                        
             
M
et
ho
d:
 Q
ue
st
io
nn
ai
re
 
an
d 
PB
AC
.
Po
st
m
en
st
ru
al
 s
po
tt
in
g 
w
as
 
re
po
rt
ed
 b
y 
34
%
 o
f w
om
en
 
w
ith
 a
 n
ic
he
 a
nd
 1
5%
 w
ith
ou
t 
a 
ni
ch
e 
(p
=0
.0
02
). 
La
rg
er
 n
ic
he
 
vo
lu
m
e 
w
as
 s
ee
n 
in
 w
om
en
 
w
ith
 p
os
tm
en
st
ru
al
 s
po
tt
in
g 
th
an
 w
ith
ou
t p
os
tm
en
st
ru
al
 
sp
ot
tin
g 
(p
=0
.0
2,
) a
nd
 
no
 r
el
at
io
n 
w
as
 fo
un
d 
be
tw
ee
n 
ni
ch
e 
sh
ap
e 
an
d 
po
st
m
en
st
ru
al
 s
po
tt
in
g.
Va
le
nz
an
o 
et
 a
l. 
   
   
   
   
20
06
15
Ca
se
-c
on
tr
ol
 
st
ud
y
11
6 
w
ith
 
pr
ev
io
us
 
CS
 
(n
 =
 2
17
)
Ra
nd
om
 s
el
ec
tio
n 
of
 w
om
en
 w
ho
 g
av
e 
bi
rt
h 
fo
r 
th
e 
fir
st
 
tim
e 
be
tw
ee
n 
19
95
 
an
d 
20
04
: v
ag
in
al
 
bi
rt
h 
(n
 =
 1
01
) o
r 
CS
 
(n
 =
 1
16
).
As
so
ci
at
io
n 
be
tw
ee
n 
m
or
ph
ol
og
ic
al
 
ch
an
ge
s 
of
 th
e 
lo
w
er
 
ut
er
in
e 
se
gm
en
t a
ft
er
 
CS
 a
nd
 th
e 
fr
eq
ue
nc
y 
of
 a
bn
or
m
al
 u
te
ri
ne
 
bl
ee
di
ng
.
D
efi
ni
tio
n:
 T
ri
an
gu
la
r,
 
an
ec
ho
ic
 a
re
a 
at
 th
e 
pr
es
um
ed
 s
ite
 o
f i
nc
is
io
n.
                           
M
et
ho
d:
 T
VS
, a
nd
 o
nl
y 
ni
ch
es
 w
ith
 S
H
G
Ab
no
rm
al
 u
te
ri
ne
 
bl
ee
di
ng
: S
po
tt
in
g 
bl
ee
di
ng
 
af
te
r 
th
e 
en
d 
of
 th
e 
m
en
st
ru
at
io
n 
an
d/
or
 n
on
-
cy
cl
ic
 b
le
ed
in
g 
no
t r
el
at
ed
 
to
 th
e 
m
en
st
ru
at
io
n.
         
         
         
         
  
M
et
ho
d:
 Q
ue
st
io
ns
 w
er
e 
as
ke
d.
Ab
no
rm
al
 b
le
ed
in
g 
w
as
 
m
or
e 
fr
eq
ue
nt
 in
 th
e 
CS
 
gr
ou
p 
as
 c
om
pa
re
d 
w
ith
 th
e 
va
gi
na
l b
ir
th
 g
ro
up
 (p
=0
.0
41
). 
N
o 
as
so
ci
at
io
n 
w
as
 fo
un
d 
be
tw
ee
n 
ab
no
rm
al
 b
le
ed
in
g 
an
d 
th
e 
pr
es
en
ce
 o
f a
 n
ic
he
 
(p
=0
,8
18
), 
bu
t a
n 
as
so
ci
at
io
n 
w
as
 fo
un
d 
w
ith
 d
iv
er
tic
ul
a 
(p
=0
.0
12
) a
nd
 d
ef
or
m
at
io
n 
of
 
th
e 
ce
rv
ic
al
 c
an
al
 (p
=0
.0
31
), 
w
hi
ch
 w
as
 m
or
e 
si
gn
ifi
ca
nt
 
in
 w
om
en
 w
ho
 h
ad
 a
 C
S 
5-
10
 
ye
ar
s 
ag
o.
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th
or
D
es
ig
n
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Po
pu
la
ti
on
O
ut
co
m
e
D
efi
n
it
io
n
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n
ic
h
e 
an
d
 
m
et
ho
d 
of
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va
lu
at
io
n
Sp
ec
ifi
ca
ti
on
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f 
b
le
ed
in
g 
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so
rd
er
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nd
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et
ho
d 
of
 
ev
al
ua
ti
on
Re
su
lt
s
Se
le
ct
ed
 p
op
ul
at
io
n 
co
ns
is
tin
g 
of
 w
om
en
 w
ith
 g
yn
ae
co
lo
gi
ca
l s
ym
pt
om
s:
U
pp
al
 
et
 a
l. 
   
   
   
   
   
  
20
11
28
Pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
71
 w
ith
 
pr
ev
io
us
 
CS
 
(n
 =
 3
18
)
W
om
en
 r
ef
er
re
d 
fo
r 
gy
na
ec
ol
og
ic
al
 
ul
tr
as
ou
nd
. 7
1 
w
om
en
 h
ad
 a
 
hi
st
or
y 
of
 C
S.
As
so
ci
at
io
n 
be
tw
ee
n 
ce
sa
re
an
 s
ca
r 
de
fe
ct
s 
an
d 
ab
no
rm
al
 
va
gi
na
l b
le
ed
in
g.
D
efi
ni
tio
n:
 F
lu
id
 
fil
le
d 
de
fe
ct
 in
 th
e 
hy
st
er
ot
om
y 
in
ci
si
on
.           
                 
                 
                 
 
M
et
ho
d:
 T
VS
Ab
no
rm
al
 b
le
ed
in
g 
pa
tt
er
n:
 p
er
io
ds
 lo
ng
er
 
th
an
 7
 d
ay
s 
an
d/
or
 
sp
ot
tin
g 
af
te
r 
th
e 
pe
ri
od
.                          
                            
M
et
ho
d:
 Q
ue
st
io
nn
ai
re
 
an
d 
re
co
rd
s 
of
 th
e 
w
om
en
 
w
er
e 
re
vi
ew
ed
.
Th
e 
pr
es
en
ce
 o
f a
 c
es
ar
ea
n 
sc
ar
 d
ef
ec
t w
as
 s
ig
ni
fic
an
tly
 
as
so
ci
at
ed
 a
bn
or
m
al
 b
le
ed
in
g 
(O
R 
1.
96
 [9
5%
 C
I 1
.1
6-
3.
32
]; 
p<
0.
05
). 
Th
e 
la
rg
er
 th
e 
de
fe
ct
, 
th
e 
hi
gh
er
 w
as
 th
e 
in
ci
de
nc
e 
of
 a
bn
or
m
al
 v
ag
in
al
 b
le
ed
in
g.
Th
ur
m
on
d 
et
 a
l.
19
99
18
Pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
31
0
W
om
en
 r
ef
er
re
d 
fo
r 
ab
no
rm
al
 u
te
ri
ne
 
bl
ee
di
ng
, w
ho
 w
er
e 
ev
al
ua
te
d 
w
ith
 S
H
G
, 
in
de
pe
nd
en
t o
f t
he
ir
 
ob
st
et
ri
c 
hi
st
or
y.
D
es
cr
ip
tio
n 
of
 a
 
ca
us
e 
of
 a
bn
or
m
al
 
va
gi
na
l b
le
ed
in
g 
re
la
te
d 
to
 a
 h
is
to
ry
 
of
 C
S.
D
efi
ni
tio
n:
 A
 g
ap
 in
 th
e 
an
te
ri
or
 lo
w
er
 u
te
ri
ne
 
se
gm
en
t m
yo
m
et
ri
um
 
at
 th
e 
ex
pe
ct
ed
 s
ite
 
of
 th
e 
sc
ar
 fr
om
 p
ri
or
 
ce
sa
re
an
 d
el
iv
er
ie
s.
     
     
     
     
 
M
et
ho
d:
 S
H
G
Po
st
m
en
st
ru
al
 
sp
ot
tin
g:
 2
 to
 1
2 
da
ys
 
of
 p
os
tm
en
st
ru
al
 
di
sc
ha
rg
e 
of
 d
ar
k 
re
d 
or
 b
ro
w
n 
m
at
er
ia
l.  
          
          
          
          
          
  
M
et
ho
d:
 N
ot
 s
pe
ci
fie
d.
9 
w
om
en
 w
ith
 a
 h
is
to
ry
 o
f C
S 
de
m
on
st
ra
te
d 
a 
ni
ch
e 
an
d 
al
l 
th
es
e 
w
om
en
 h
ad
 a
 h
is
to
ry
 o
f 
2 
to
 1
2 
da
ys
 o
f p
os
tm
en
st
ru
al
 
sp
ot
tin
g.
 
W
an
g 
et
 a
l. 
   
   
   
 
20
09
10
Cr
os
s-
se
ct
io
na
l 
st
ud
y
20
7
W
om
en
 w
ith
 a
 
hi
st
or
y 
of
 C
S,
 
ex
am
in
ed
 w
ith
 
TV
S 
fo
r 
va
ri
ou
s 
gy
na
ec
ol
og
ic
al
 
in
di
ca
tio
ns
, 
di
ag
no
se
d 
w
ith
 
a 
ce
sa
re
an
 s
ca
r 
de
fe
ct
.
Th
e 
pr
ev
al
en
ce
 
of
 v
ar
io
us
 c
lin
ic
al
 
sy
m
pt
om
s 
in
 p
at
ie
nt
s 
w
ith
 c
es
ar
ea
n 
sc
ar
 
de
fe
ct
s 
an
d 
th
e 
as
se
ss
m
en
t o
f t
he
 
as
so
ci
at
io
n 
be
tw
ee
n 
th
e 
si
ze
 o
f t
he
 
ce
sa
re
an
 s
ca
r 
de
fe
ct
 
an
d 
sy
m
pt
om
s.
D
efi
ni
tio
n:
 H
yp
oe
ch
og
en
ic
 
ar
ea
 w
ith
in
 th
e 
m
yo
m
et
ri
um
 o
f t
he
 
lo
w
er
 u
te
ri
ne
 s
eg
m
en
t, 
at
 th
e 
si
te
 o
f a
 p
re
vi
ou
s 
ce
sa
re
an
 in
ci
si
on
.       
           
           
           
           
           
        
M
et
ho
d:
 T
VS
Bl
ee
di
ng
 d
is
or
de
r 
no
t d
efi
ne
d.
     
     
     
     
     
     
     
     
     
    
M
et
ho
d:
 M
ed
ic
al
 
hi
st
or
ie
s 
w
er
e 
re
vi
ew
ed
. 
Q
ue
st
io
nn
ai
re
s 
an
d 
m
is
si
ng
 d
at
a 
w
er
e 
ob
ta
in
ed
 b
y 
di
re
ct
 p
ho
ne
 
co
nt
ac
t. 
Pr
ol
on
ge
d 
po
st
m
en
st
ru
al
 
sp
ot
tin
g 
w
as
 th
e 
m
os
t 
co
m
m
on
 s
ym
pt
om
 (6
4%
), 
fo
llo
w
ed
 b
y 
dy
sm
en
or
rh
ea
 
(5
3%
), 
ch
ro
ni
c 
pe
lv
ic
 p
ai
n 
(4
0%
) a
nd
 d
ys
pa
re
un
ia
 (1
8%
). 
Th
e 
m
ea
n 
de
fe
ct
 w
id
th
 w
as
 
si
gn
ifi
ca
nt
ly
 la
rg
er
 in
 w
om
en
 
w
ith
 p
os
tm
en
st
ru
al
 s
po
tt
in
g 
(p
<0
.0
01
), 
dy
sm
en
or
rh
ea
 
(p
=0
.0
01
) a
nd
 c
hr
on
ic
 p
el
vi
c 
pa
in
 (p
<0
.0
01
). 
N
o 
as
so
ci
at
io
n 
be
tw
ee
n 
de
pt
h 
or
 th
ic
kn
es
s 
of
 
th
e 
re
si
du
al
 m
yo
m
et
ri
um
 a
nd
 
sy
m
pt
om
s 
w
as
 fo
un
d.
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6
Re
tr
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pe
ct
iv
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co
ho
rt
 s
tu
dy
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Pr
em
en
op
au
sa
l 
w
om
en
 w
ith
 a
 
hi
st
or
y 
of
 C
S 
an
d 
a 
po
uc
h 
at
 th
e 
si
te
 
of
 th
e 
ce
sa
re
an
 
sc
ar
 d
em
on
st
ra
te
d 
w
ith
 T
VS
, w
ho
 w
er
e 
as
se
ss
ed
 fo
r 
ot
he
r 
gy
na
ec
ol
og
ic
al
 
re
as
on
s.
As
so
ci
at
io
n 
be
tw
ee
n 
th
e 
pr
es
en
ce
 o
f t
he
 
po
uc
h 
an
d 
bl
ee
di
ng
 
di
st
ur
ba
nc
es
.
D
efi
ni
tio
n:
 A
 fi
lli
ng
 d
ef
ec
t 
of
 th
e 
ut
er
in
e 
ca
vi
ty
 
lo
ca
te
d 
in
 r
el
at
io
n 
to
 
th
e 
an
te
ri
or
 is
th
m
us
.   
    
    
   
M
et
ho
d:
 T
VS
Bl
ee
di
ng
 d
is
or
de
r 
an
d 
m
et
ho
d 
no
t d
efi
ne
d.
   
   
  
83
%
 o
f t
he
 w
om
en
 w
ith
 
a 
po
uc
h 
ha
d 
ab
no
rm
al
 
ut
er
in
e 
bl
ee
di
ng
. A
m
on
g 
th
es
e 
w
om
en
, 7
6%
 h
ad
 
po
st
m
en
st
ru
al
 s
po
tt
in
g,
 1
6%
 
m
id
cy
cl
e 
m
et
ro
rr
ha
gi
a 
an
d 
6%
 b
ot
h 
sy
m
pt
om
s.
M
on
te
ag
ud
o 
et
 a
l.
20
01
8
Pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
44
W
om
en
 w
ith
 a
 
hi
st
or
y 
of
 C
S,
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Abstract
We describe our experience with the treatment of 4 caesarean scar pregnancies 
and provide an overview of current literature. Four women diagnosed with a 
caesarean scar pregnancy in our hospital between 1996 and 2007 were treated 
with local or systemic methotrexate and had a steady decline of the serum 
ß-hCG level. The uterus was preserved in all women and 3 of them had an 
uneventful subsequent pregnancy and delivery. We suggest that transcervical 
needle aspiration of amniotic fluid followed by intra-amniotic injection of 
methotrexate should be the treatment of choice, followed by surgical treatment 
only if methotrexate fails.
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Introduction
Pregnancy developing in a scar from a caesarean section (CS) is the rarest form 
of ectopic pregnancy. In that case, the pregnancy is located outside the uterine 
cavity and is completely surrounded by myometrium and the fibrous tissue of 
the scar. Invasion of the conceptus into the myometrium is believed to occur 
through a defect in the caesarean scar. This defect may be due to fibrosis and poor 
vascularity, resulting in impaired postoperative healing.1 Because a caesarean 
scar pregnancy (CSP) can lead to uterine scar rupture and hemorrhage, a life-
threatening condition for both mother and child may occur if the pregnancy is 
allowed to continue, even in the 1st trimester.2
Since the 1970s the CS rate has dramatically increased in most Western 
countries.3 The consequence is an increase in the incidence of CSPs. Currently, 
the incidence ranges from 1:1,800–1:2,216 pregnancies and constitutes 6.1% 
of all ectopic pregnancies in patients with a history of at least 1 caesarean 
delivery.1,4 Because of the low frequency of CSPs, no clinical trials are available 
that can help determine the optimal clinical management. Therefore, there is 
no consensus on the most preferred treatment modality. The purpose of this 
report is to describe our experience with the treatment and follow-up of 4 
CSPs, summarized in Table 1, and to provide an overview of current literature. 
Therefore, the Medline database was searched with all known terms for CSP in 
combination with all known terms for methotrexate treatment, and reference 
lists were cross-checked. Based on our experience and the literature search, we 
suggest treatment recommendations for CSP.
Case descriptions
Case 1
A 36-year-old woman, gravida 5 para 3, presented with lower abdominal pain 
and a positive pregnancy test at a gestational age of 6 weeks and 6 days (GA 
6+6) according to her last menstrual period. The obstetric history included 
2 uneventful caesarean deliveries, 1 spontaneous abortion, and 1 induced 
delivery because of intra-uterine fetal death. Sonography (US) revealed an empty 
uterine cavity and the serum ß-human chorionic gonadotrophin (ß-hCG) level 
was 2,018 mIU/ml. Expectant management with regular measurements of the 
serum ß-hCG level and US examinations was proposed. After 8 days (GA 8+0), she 
presented with lower abdominal pain and slight vaginal bleeding. US examination 
using an Aloka SSD 3500 scanner with a 2–6-MHz curved-array transducer 
(Aloka, Wallingford, CT) demonstrated a gestational sac (GS) in the anterior 
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isthmic wall of the uterus, containing an embryo with fetal cardiac activity and 
a crown-rump length corresponding to 6 weeks and 2 days gestation (Figure 1) 
with a serum ß-hCG level of 40,000 mIU/ml. US-guided transcervical aspiration of 
the GS, followed by intra-amniotic injection of 50 mg methotrexate (1 mg/kg body 
weight), was performed successfully. Intermittent bleeding and abdominal pain 
improved after a few weeks followed by normal menstrual periods, and serum 
ß-hCG levels dropped below 2 mIU/ml after 5 months (Figure 2).
Figure 1: Transvaginal ultrasound image of a longitudinal section of retroverted uterus showing a ceasarean scar 
pregnancy (arrow).
Figure 2: Graphic representation of the serum ß-hCG levels after treatment in the 4 cases of caesarean scar 
pregnancy.*Local injection of methotrexate **Systemic injection of methotrexate
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Case 2
A 38-year-old woman, gravida 6 para 1, presented with vaginal spotting after a 
positive pregnancy test at 4 weeks and 1 day gestation (GA 4+1). The obstetrical 
history included 2 induced abortions, 1 primary CS because of a breech 
presentation, an evacuation of a missed abortion, and 1 tubal pregnancy followed 
by right salpingectomy. In vitro fertilization was performed because of tubal factor 
infertility and she became pregnant after the 1st attempt. The 1st transvaginal US 
examination at 5 weeks and 1 day gestation (GA 5+1) revealed an empty uterine 
cavity and suspicion of a pregnancy in the caesarean scar. Three days later (GA 
5+4), she presented with profuse vaginal bleeding and the serum ß-hCG level was 
14,000 mIU/ml. US-guided transcervical aspiration of the GS and intra-amniotic 
injection of 75 mg methotrexate (1 mg/kg body weight) were performed. Vaginal 
bleeding stopped 1 day after the procedure and the patient was discharged in 
good condition. Regular measurements of serum ß-hCG showed a steady decline, 
and the ß-hCG level was undetectable (<2 mIU/ml) 3 months after methotrexate 
injection (Figure 2). Two months later, transvaginal US showed almost complete 
regression of the GS. She started again with in vitro fertilization therapy 5 months 
after the procedure, resulting in a pregnancy after the 6th attempt and a primary 
CS after 37 weeks and 4 days gestation.
Case 3
A 31-year-old woman, gravida 3 para 1, presented with minimal vaginal blood 
loss at 6 weeks and 6 days gestation (GA 6+6) according to her last menstrual 
period. Her obstetrical history included 1 secondary CS because of failure to 
progress during labor and a curettage after incomplete abortion. US examination 
revealed an empty uterine cavity and a hypoechoic structure (11 mm in diameter) 
located in the right side of the uterus. The serum ß-hCG level was 21,100 mIU/
ml. The patient was admitted with a suspicion of ectopic pregnancy. However, 
diagnostic laparoscopy showed a normal abdomen and uterus without signs of 
a tubal, adnexal, or intra-abdominal pregnancy. The US was repeated after 4 
days (GA 7+3) and revealed a GS (22 x 23 x 19 mm) containing an embryo with 
fetal cardiac activity implanted in the anterior wall of the uterus, protruding into 
the vesico-uterine space. MRI confirmed the CSP. Transcervical aspiration of the 
amniotic fluid and intra-amniotic injection of 50 mg methotrexate (1 mg/kg body 
weight ) under US guidance was performed successfully. The serum ß-hCG levels 
decreased steadily, and the ß-hCG level was below the detection limit (<2 mIU/
ml) 4 months after the procedure (Figure 2). Nine weeks after methotrexate 
treatment, US still showed a hypoechoic structure with a hyper-echoic wall (24 
x 23 x 14 mm) between the uterus and bladder. Diagnostic hysteroscopy was 
performed and an extracavitary space with trophoblastic tissue was seen in the 
anterior wall of the uterus, close to the internal os. Laparotomy was performed 
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8 months after methotrexate treatment to remove pregnancy debris and repair 
the anterior uterine wall. There were no intra- or postoperative complications 
and the patient became pregnant 3 months after laparotomy. An elective CS was 
performed at a gestational age of 37 weeks and 4 days.
Case 4
A 38-year-old woman, gravida 3 para 1, had her 1st US examination at 8 weeks and 
3 days gestation (GA 8+3) according to her last menstrual period. Her obstetrical 
history included 1 CS because of pre-eclampsia and suspicion for placental 
abruption and 1 vacuum evacuation because of a missed abortion. US evaluation 
showed a fetus with a crown-rump length of 8 mm without fetal cardiac activity 
located in the scar from the CS. Management options and risks were explained, 
and the patient decided to wait for a spontaneous abortion. After 16 days without 
a sign of spontaneous abortion, a single injection of 50 mg methotrexate (1 mg/kg 
body weight) was administered intramuscularly. The serum ß-hCG levels declined 
from 75,000 mIU/ml 7 days before methotrexate treatment to 12,000 mIU/ml 7 
days after injection. Although serum ß-hCG levels declined steadily (Figure 2), 
the GS was still visible by US 3 weeks after methotrexate treatment. Laparotomy 
was performed 2 months after the procedure to resect the gestational tissue 
from the anterior uterine wall and the caesarean scar defect was repaired. The 
patient had an uneventful postoperative recovery and serum ß-hCG levels were 
below the detection limit 3 months after methotrexate treatment (Figure 2). She 
became pregnant 6 months after laparotomy, resulting in an uneventful CS at 38 
weeks and 2 days gestation.
Discussion
No general treatment guidelines for a CSP have been established to date and 
evidence-based data are lacking. A treatment policy should preferentially not 
be based on anecdotal reports only, but given the infrequent event of CSP, 
much is to be learned from each report. Current data indicate that expectant 
management is rarely successful and particularly unsuitable for women with 
vital scar pregnancies.1,5 In a hemodynamically stable patient, 2 options may be 
considered , medical or surgical, both aimed to eliminate the GS and retain the 
patient’s fertility.5
Medical Treatment
The administration of local or systemic methotrexate for this indication has 
shown high success rates. All reported cases of CSP treated with methotrexate, 
including our patients (no. 1–4), are summarized in Table 2. Systemic 
methotrexate in general is described as safe and effective, and virtually without 
500835-L-bw-Dieleman
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side effects.6 A single intramuscular dose of 50 mg/m2 followed by expectant 
management can be used for CSPs with a gestational age of less than 6–8 weeks 
without fetal cardiac activity.7 Some authors reported systemic methotrexate 
to be more effective in women with serum ß-hCG levels below 5,000 mIU/
ml.4,8 Systemic treatment with methotrexate was reported in 25 cases and 
successful in 9 cases (Table 2). In 13 cases7,9–17 complementary medical or surgical 
treatment was indicated because of rising ß-hCG levels, persistence of cardiac 
motion, increase of the GS, or prolonged vaginal bleeding. In 1 case18 dilation 
and curettage was performed because of vaginal bleeding, which resulted 
in copious hemorrhaging. Laparatomy was performed in 2 cases because of 
increasing size of the viable fetus and profuse vaginal bleeding, and 1 of these 
cases resulted in a hysterectomy.19 One of our patients with a CSP without fetal 
cardiac activity was treated with systemically injected methotrexate. Despite a 
rapid decline of serum ß-hCG levels, US did not show regression of the GS. It 
can be debated whether systemic methotrexate is the treatment of choice, since 
fibrous tissue may be involved in placentation. Due to impaired vascularization of 
this tissue, the penetration of methotrexate to the fetal sac may be insufficient.16 
For this reason, others advocate local injection of methotrexate,20 which can be 
injected into the GS by a transabdominal or transvaginal route. The transvaginal 
approach may be preferable because of the shorter distance to the GS.4 Local 
treatment with methotrexate was reported in 22 cases and successful in 18 cases 
(Table 2). In 8 cases with detectable embryonic cardiac activity, embryocide was 
performed 1st by the intracardiac injection of potassium chloride (KCl). Jurkovic et 
al1 reported 18 CSPs diagnosed in a period of 4 years, and 6 of these cases were 
treated with local injection of 25 mg methotrexate and intra-cardiac injection of 
0.1–0.2 nmol potassium chloride (KCl) in case of detectable embryonic cardiac 
activity. Four women were treated successfully with a serum ß-hCG resolution 
time between 6 and 10 weeks. Two women with vital pregnancies corresponding 
to 6 and 8 weeks’ gestation required additional surgical intervention and blood 
transfusion due to heavy vaginal bleeding. The women who did not receive 
medical treatment were managed either surgically, which was successful in all 
cases, or expectantly, which was successful in 1 of 3 cases. Lai et al21 reported an 
emergency laparotomy after local treatment because of active vaginal bleeding 
and pelvic pain. Complementary medical treatment was indicated in 1 case22 
because of increase of the GS and rising ß-hCG level. The uterus was preserved 
in all women treated with local methotrexate. Combined local and systemic 
methotrexate treatment was performed in 8 women and was successful in 7 cases 
(Table 2). Smorgick et al23 evaluated combined local and systemic methotrexate 
treatment in 31 patients with a viable ectopic pregnancy, which was successful 
in all CSP cases (n = 5). Although a 2nd dose was required in 4 of 5 cases of CSP, 
surgical intervention could be avoided.
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Figure 2 shows that in our 4 cases the serum ß-hCG level initially increased after 
local treatment with methotrexate, which was followed by a steady decline. In 
contrast, systemic methotrexate caused an immediate decline of the serum 
ß-hCG level.
On rare occasions, rupture of the scar and heavy bleeding may occur after medical 
treatment. This may even happen 15 days following methotrexate treatment.21 
Therefore, some authors propose a combination of the medical approach with 
bilateral uterine artery embolization to minimize the risk of such complications.24
Surgical Treatment
Because of the persistence of pregnancy tissue after medic al treatment, 2 of 
our patients underwent laparotomy with good results. Several authors consider 
laparotomy to be the preferred option as primary treatment,2,25–27 allowing the 
simultaneous removal of the pregnancy and repair of the defect. Resection of 
the old scar and new closure may reduce the risk of recurrence of a CSP.26 Others 
advocate laparotomy only if conservative medical or laparoscopic treatment fails, 
if the patient presents late, or if facilities and expertise for operative endoscopy 
are not available. Laparotomy is mandatory when uterine rupture is suspected. 
Removal of pregnancy tissue during laparotomy results in a rapid decline of 
serum ß-hCG levels within 1 or 2 weeks28 but has the drawbacks of a larger 
surgical wound, longer hospitalization, and longer recovery time in comparison 
to medical treatment.29
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A minimally invasive alternative is endoscopic surgery. An operative hysteroscopic 
approach should be chosen for a CSP that grows toward the uterine cavity, 
whereas laparoscopy is more appropriate for a deeply implanted pregnancy 
growing toward the abdominal cavity and the bladder.28,30 Hysteroscopy enables 
the identification of the embryonic sac and the distribution of vessels at the 
implantation site. The embryonic sac can be separated from the uterine wall and 
the vessels can be electrocoagulated to achieve hemostasis. The success rate of 
hysteroscopy is encouraging, but the number of cases are too small to draw solid 
conclusions.28
Laparoscopy is suitable if the woman is hemodynamically stable and appropriate 
facilities are available with a trained surgeon. The pregnancy mass in the 
caesarean scar is incised and the pregnancy tissue is removed in an endobag.28 
For the prevention of massive operative blood loss, blocking uterine perfusion 
with bilateral occlusion of the uterine arteries can be performed at the beginning 
of the procedure.29
In the study of Wang et al,29 laparoscopic treatment was performed in 4 women 
and hysteroscopic treatment in 6 women, and 1 woman underwent combined 
treatment with laparoscopy and hysteroscopy. No complications occurred and 
serum ß-hCG levels declined to a normal limit within 4 weeks after surgery.
Curettage should not be considered as the 1st choice of therapy, because the 
trophoblastic tissue will not always be reached due to its location and because of 
the risk of scar rupture and severe hemorrhage.2
Follow-up
The proposed follow-up protocol for CSP is a weekly outpatient clinical 
assessment and measurement of serum ß-hCG levels until they are below the 
detection limit. US examination is performed on a monthly basis to evaluate the 
size of the retained products of conception until no further pregnancy tissue can 
be detected.1 Follow-up in our patients consisted of 1 or 2 weekly out-patient 
clinical assessments and measurements of serum ß-hCG. Even though serum 
ß-hCG levels had declined under the detection limit, the trophoblastic tissue 
in 2 patients persisted for many weeks and was resected by laparotomy. One 
possible explanation for the persistence of pregnancy tissue is that the scanty 
venous flow within the fibrous scar tissue makes the absorption of residual 
gestational tissue difficult. A 2nd explanation might be related to the proliferation 
of fibrous tissue in the isthmic portion of the uterus in response to myometrial 
injury induced by placental villi invasion.4
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It can be questioned if it was necessary to remove the persisting pregnancy tissue 
in 2 of our patients, because the women had no complaints and the tissue might 
have disappeared spontaneously in the following months. It was also found by 
several authors4,16,28 that it is hard to predict when the gestational mass completely 
resolves, and that aspiration of the gestational tissue may be required because 
of the slow absorption. Wang et al31 performed a prospective cohort study with 
71 cases of CSP and reported that methotrexate treatment followed by dilation 
and curettage results in a shorter time to resolution of the CSP and serum ß-hCG. 
Dilation and curettage was offered when serum ß-hCG levels decreased to <50 
mIU/ml, no subtrophoblastic blood flow could be detected, and a connection 
between the GS and the uterine cavity was demonstrated on transvaginal US.
Although there are little data to suggest any danger in conceiving soon after a CSP, 
an interval of 3–6 months up to 2 years has been advised.4,32 The low prevalence 
of recurrent CSPs indicates that implantation into the scar is more likely to be 
a chance event, rather than the result of a particular affinity of a pregnancy 
for implanting into the scar.33 To date only 3 cases of recurrent CSP have been 
reported.28 Ben Nagi et al33 reported a case with 3 recurrences and suggested that 
the risk of scar implantation might be directly related to the size of the anterior 
uterine wall defect. In our case series, 3 of 4 patients had a successful pregnancy 
after the CSP; the 4th patient has no desire for a pregnancy yet.
In conclusion, based on literature and our own experience, we believe that 
transcervical needle aspiration of the GS and intra-amniotic injection of 
methotrexate, which may be combined with systemic methotrexate, should be 
the preferred treatment option. This treatment can avoid unnecessary surgery 
and preserve the woman’s fertility but requires time and patience for the serum 
ß-hCG levels to drop to normal and the pregnancy tissue to resolve completely. If 
medical treatment fails, additional surgical treatment can be chosen. Depending 
on the localization of the pregnancy tissue and the available experience, this may 
be by laparoscopy, laparotomy, or hysteroscopy.
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Main findings
Imaging
Various methods for the detection and measurement of a niche have been 
described, but most often transvaginal sonography (TVS) or sonohysterography 
(SHG) are used. In Chapter 6, we propose SHG in non-pregnant women as the 
gold standard for the detection of a niche and assessment of the prevalence 
for future studies. In case SHG is used, we demonstrated in Chapter 2 that gel 
instillation sonohysterography (GIS) is a suitable alternative for saline contrast 
sonohysterography (SCSH). Although the image quality of SCSH was slightly better 
than that of GIS, which was likely to be attributable to the presence of air bubbles in 
the gel, the small difference in uterine cavity distension in favour of GIS and stable 
distension during at least 4 minutes make GIS a suitable alternative for SCSH if 
air bubbles can be prevented. More stable filling of the uterine cavity with gel is 
especially an advantage when performing 3D ultrasound. For our reproducibility 
study in Chapter 3, we used 3D TVS. The results of this study demonstrated that 
a niche could be measured with a high level of agreement with the use of 3D 
ultrasound, in particular if measured in the longitudinal plane. 
Naji et al.1 suggested a standardized approach to describe niches by measuring 
the width, depth and residual myometrial thickness (RMT) in the longitudinal 
plane and length in the transverse plane. We propose the same measurements, 
but we defined our measurements in more detail and performed some additional 
measurements in both the longitudinal and transversal plane in the section 
with the greatest surface area of the niche: depth (perpendicular to niche base), 
maximal depth (distance between apex of the niche and the estimated middle of 
the niche base), maximal width (perpendicular to the line between middle of the 
niche base and apex) and width at niche base (Chapter 3). In addition, we suggest 
measuring niche volume in the longitudinal plane, and the RMT in both the 
longitudinal and transversal plane in the section in which the RMT is the smallest. 
Prevalence
In Chapter 4, a niche was defined as an anechoic area with a depth of at least 
1 mm, which resulted in a niche prevalence of 24% for TVS and 56% for GIS. In 
Chapter 5, a niche depth of at least 2 mm was used, resulting in a prevalence of 
50% for TVS and 65% for GIS. Chapter 6 shows that each study found a different 
niche prevalence, varying between 56% and 84% for a random population of 
women with a history of caesarean section (CS) examined with the use of SHG. 
126 | Chapter 8
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Risk factors
In our systematic review (Chapter 6), we describe that possible risk factors for the 
presence or size of a niche are single-layer myometrium closure, multiple CSs and 
retroflected uterus. The problem with reporting on risk factors for a large niche 
is the lack of predefined definitions, resulting in different cut-off values for a large 
niche for each study. As each study evaluated different risk factors and some risk 
factors are interdependent, we propose to categorize risk factors into four main 
categories: factors related to closure technique, development of the lower uterine 
segment or location of the incision, wound healing and miscellaneous factors. 
This may be helpful for future research, including meta-analyses. 
Symptoms
This thesis contains two prospective cohort studies reporting on symptoms 
associated with a niche (Chapter 4 and 5). We demonstrated that women with 
a niche more often report postmenstrual spotting in comparison to women 
without a niche after a CS and that niche size is related to postmenstrual spotting 
as well. In Chapter 4 was demonstrated that women with postmenstrual spotting 
have a larger niche volume. In Chapter 5, we demonstrated that women with 
a RMT measuring <50% of the adjacent myometrial thickness have more often 
complaints of postmenstrual spotting than women with a RMT >50% of the 
adjacent myometrial thickness (Chapter 5). A systematic review of the literature 
showed that our results are in line with the findings of other studies (Chapter 6). 
Six out of eight studies that evaluated niche-related symptoms demonstrated an 
association between the presence of a niche and postmenstrual spotting. 
A rare but serious complication of a subsequent pregnancy after a CS is a 
caesarean scar pregnancy (CSP). Chapter 7 describes four cases of CSP and a 
literature review reporting on the options for treatment. 
Strengths and limitations
The strength of this thesis is that it contains two prospective cohort studies 
reporting on niche prevalence and related symptoms (Chapter 4 and 5). In 
addition, the literature was reviewed in Chapter 6 on the same subject, and we 
evaluated the reproducibility of niche measurements and tried to define clear 
definitions for various niche parameters (Chapter 3).
However, the studies of this thesis have some limitations as well. The niche 
prevalence using TVS in the study reported in Chapter 4 was rather low compared 
with the study in Chapter 5 (24% versus 50%), which was not expected as a niche 
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was defined as an anechoic space of at least 1 mm in Chapter 4 and at least 2 
mm in Chapter 5. The prevalence of 50% reported in Chapter 5 is comparable 
with the reported prevalence in other studies (Chapter 6). One explanation for 
the higher prevalence in Chapter 5 may be a difference in timing of scanning, 
as the women of Chapter 5 were scanned only 6-12 weeks after their CS and 
the women of Chapter 4 6-12 months after their CS. Shortly after a CS, the scar 
in the myometrium has a more transonic aspect, improving the visualization of 
the niche. In addition, the endometrium is thinner shortly after a CS as most 
women are still breast-feeding, which may also improve the visibility of a niche. 
Another explanation is that the sonographer of Chapter 5 was more experienced 
in comparison with the sonographer of Chapter 4, resulting in a higher detection 
rate in Chapter 5. However, the latter is not underlined by the comparable niche 
detection rates in both studies using GIS. These prevalences (56% for Chapter 4 
and 65% for Chapter 5) were also comparable with other studies, and showed no 
outliers (Chapter 6). In both Chapters 4 and 5 was reported that postmenstrual 
spotting is the main symptom related to a niche, which was confirmed by the 
systematic review in Chapter 6. 
Another limitation of this thesis is that only TVS was evaluated in our reproducibility 
study of Chapter 3, even though we postulated in Chapters 4, 5 and 7 that the 
performance of SHG is preferable to TVS. In our prospective cohort studies 
(Chapters 4 and 5), the niche was only evaluated in the longitudinal plane. We also 
wanted to include measurements in the transversal plane for our reproducibility 
study. However, we learned that it was difficult to delineate the niche in the 
transversal plane using SHG in several cases, and therefore we decided to start 
using only TVS for evaluating the inter- and intraobserver agreement. 
A third limitation is that for the comparison of GIS versus SCSH in Chapter 2, 
niche detection and measurement were not included. However, one may expect 
that more stable distension with GIS is also an advantage for niche detection 
and measurement, and therefore also preferable for the evaluation of a niche, in 
particular if 3D ultrasound is used. We did not repeat this study in patients with 
a niche before we designed our prospective studies in Chapter 4 and 5.
Comparison to literature
Niche
In a recently published review2, it was postulated that the ‘disorder’ caused 
by a niche is a syndrome that should be defined by the associated symptoms. 
The authors propose that a previous caesarean scar defect is the formation of 
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a pouch at the site of an old caesarean incision at the anterior lower uterine 
segment, uterine isthmus or in the upper segment of the cervical canal 
with (among other symptoms) prolonged menstruation, dysmenorrhoea, 
intermenstrual spotting, the presence of a fluid-filled pouch and infertility. We 
do not agree with this definition, as we believe that a niche can exist without the 
presence of symptoms, and therefore we also prefer to avoid the term ‘defect’. 
In the same review was suggested that niches with ‘valves’ are the ones that 
lead to symptoms, as the ‘valve’-like lower edge impedes menstrual flow and 
allows for the accumulation of fluid in the niche. Although we found that a larger 
niche volume (Chapter 4) and RMT <50% of the adjacent myometrium (Chapter 
5) are related to postmenstrual spotting, we believe that the exact mechanism 
that leads to symptoms is still under debate and an issue for future research. 
For example, one may hypothesize that postmenstrual bleeding is induced by 
abnormal vessel formation in the niche, including fragile vessels that are prone 
to bleeding. 
Another recently published review article3 reported that a number of factors 
contribute to the varying niche prevalence between studies. These factors 
include heterogeneity of the studied populations, no accepted guidelines 
for the diagnostic criteria of a niche, and niches even with symptoms being 
unrecognized because of lack of knowledge of the condition. Like mentioned in 
our Letter to the Editor4, several of the populations reported in this review3 were 
selected based on gynaecological symptoms, which may bias the prevalence. In 
addition, no distinction was made between TVS and SHG while reporting the 
prevalence. The authors of this review proposed a staging system for the niche 
based on RMT, ratio RMT to the adjacent total myometrial thickness, number 
of scars, number of previous CSs and menstrual pattern.3 We agree with a 
standard approach for describing the niche, according to Naji et al.1. In addition, 
we support the suggestion to classify the morphological appearance of a niche 
as mild, moderate and severe based on the mean values3. We propose to add 
volume to the variables of this classification, as we found that it was associated 
with postmenstrual spotting (Chapter 4). However, instructions and training are 
necessary in order to obtain reproducible 3D volume measurements (Chapter 
3). In addition, we suggest to consider the addition of some extra dimensions 
described in our reproducibility study (Chapter 3), measured in the longitudinal 
plane, in order to map the niche more accurately. RMT should be measured 
in both the longitudinal and transversal plane, as women with gynaecological 
complaints are treated with either hysteroscopy or laparoscopy based on the 
RMT. A value between 2 and 3 mm should be chosen as cut-off value in the 
classification3, as this is the lower limit for hysteroscopic resection of the niche in 
order to prevent perforation of the uterus or bladder injury5. 
500835-L-bw-Dieleman
130 | Chapter 8
Caesarean scar pregnancy
Many case reports, case series and reviews on a CSP and its treatment were 
published, but there are still no universal treatment guidelines for the 
management of CSPs. A difference should be made between CSPs protruding 
towards the uterine cavity (type 1) and CSPs protruding towards the bladder 
(type 2). In addition, it is relevant to measure the RMT, ß-human chorionic 
gonadotrophin (ß-hCG) level and vascularity since this may affect the success 
rate of different therapies and the complication rates. Several recent studies will 
be discussed below. 
We report in Chapter 7 that we believe that transcervical needle aspiration of the 
gestational sac and intra-amniotic injection of methotrexate may be the treatment 
of choice. However, there is still no evidence for the optimal treatment modality. 
In one review6, the authors advocated medical treatment with methotrexate 
alone (local, systemic or combined) or in conjunction with aspiration, in women 
who are hemodynamically stable with an unruptured CSP of less than 8 weeks’ 
gestation and a myometrial thickness of less than 2 mm between the gestational 
sac and the bladder. In a recent retrospective case series7, 19 patients with a 
CSP were successfully treated with 25 mg of methotrexate into the area of the 
embryo, 25 mg into the placental area and an additional 25 mg was administered 
intramuscularly. The authors found after the treatment an initial increase in 
the serum ß-hCG level followed by a steady decline, just as we observed in our 
three patients treated with local methotrexate (Chapter 7). In another recent 
review8, it was reported that the lowest complication rates were achieved 
with intra-amniotic injection of methotrexate or potassium chloride as well as 
hysteroscopic resection. Based on these results, hysteroscopic removal may be 
considered in certain cases, but only if a CSP grows toward the uterine cavity with 
a sufficient thick residual myometrium. Hysteroscopic removal was reported to 
be associated with less bleeding and complications if it was performed after a 
decrease in ß-hCG after pretreatment with local methotrexate or uterine artery 
embolization.9 Despite the higher ß-hCG levels and thinner residual myometrium 
in the pretreated groups, the outcomes were equal or better in comparison with 
immediate hysteroscopic removal of the CSP. Although it is not always needed 
to perform surgical removal of a CSP after medical treatment, some publications 
reported that ß-hCG levels resolve quicker.10-12 Therefore we suggest to consider 
hysteroscopy in patients with a sufficient thick myometrium after pretreatment 
with local methotrexate if medical treatment fails, i.e. in case of persistent 
symptoms, ß-hCG and/or pregnancy tissue. However, one should take into 
account that it may take 30 to 140 days before ß-hCG levels and the vascularity of 
a CSP are non-detectable after local methotrexate treatment, and disappearance 
of the CSP tissue may even take longer.7 In case the CSP grows towards the 
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bladder and medical treatment fails, laparoscopic13-15 or vaginal16 removal of the 
pregnancy may be considered, which has the advantage of closing the niche in 
the same session. These therapies may be combined with temporary occlusion 
of the uterine arteries to reduce bleeding or after local methotrexate therapy. 
Clinical implications
Until now, the awareness for the presence of a niche is low. However, we 
demonstrated that a niche is present in a majority of women with a history of CS 
(Chapters 4 and 5) and that a niche may have serious long-term consequences. 
First of all, about a third of the women with a niche have complaints of 
postmenstrual spotting (Chapters 4 and 5). Dysmenorrhea, chronic pelvic pain 
and dyspareunia were also reported to be associated with a niche (Chapter 6). 
Secondly, a pregnancy may develop in a niche, which can lead to a life-threatening 
condition if the pregnancy is allowed to continue (Chapter 7). Thirdly, there are 
indications that a niche may lead to subfertility. In a recent review and meta-
analysis was reported that women with a history of CS had approximately 10% 
lower pregnancy rates compared to women with a previous vaginal delivery. 
However, it must be noted that studies controlling for maternal age or those 
that were least prone to bias found smaller effects.17 The relation between a 
niche and subfertility has not been studied yet. Two proposed mechanisms that 
may contribute to subfertility are the persistence of menstrual blood or fluid 
in the niche and uterus, impairing sperm penetration through cervical mucus 
and embryo implantation, and a chronic inflammatory state.3 In one prospective 
cohort study, 41 women with a niche, secondary infertility and postmenstrual 
spotting were included. Hysteroscopic niche resection and coagulation of niche 
vessels resulted in a spontaneous pregnancy and resolution of postmenstrual 
spotting in all patients.18 Finally, one may hypothesize that the presence of a 
(large) niche is a risk factor for uterine scar dehiscence or rupture in a future 
pregnancy, but only one small study has evaluated this association. The authors 
of this prospective cohort study with 156 women with a history of CS suggested 
that an association is likely between large niches detected by TVS and uterine 
rupture or dehiscence.19  
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Future research
It is important for future research that a uniform definition and standard method 
for niche assessment is used. In our review (Chapter 6), we propose the following 
definition for a niche: any indentation representing myometrial discontinuity at 
the site of the caesarean scar that communicates with the uterine or cervical 
cavity seen on SHG. However, for standardization reasons we suggest to define 
a niche as an indentation of at least 1 mm. A cut off value of 1 mm was also 
used in Chapter 4, and this study demonstrated that even niches with a depth 
between 1 and 2 mm were associated with postmenstrual spotting. However, 
additional research is needed to set the exact threshold for a niche, which should 
be based on related symptoms and its impact on patients. As mentioned in the 
proposed definition, SHG should be used for detection and measurement of a 
niche. In addition, we suggest to use the measurements described in Chapter 3, 
both in the longitudinal and transversal plane, to describe the niche accurately. 
A standard classification should be used, which includes at least niche volume 
and RMT. We believe that more uniformity will result in a smaller range in the 
prevalence of a niche.
The focus for future research should be on the aetiology of the development 
of a niche and related symptoms. If more is known about the aetiology of the 
development of a niche, the prevalence of niches may be reduced. Possible 
risk factors contributing to niche development, such as location of the incision 
and suturing method of the uterine scar, need to be studied. We know that full 
thickness suturing (including the endometrium) partly prevents the development 
of a niche (Chapter 6). However, randomized controlled trials (RCTs) need to be 
performed to determine whether single- or double-layer closure, using unlocked 
sutures, is superior in preventing niches and related symptoms. There are also 
indications that a niche is related to factors affecting development of lower 
uterine segment (LUS) during labour. One study reported that the risk of a large 
niche increased if the station of the presenting part of a foetus at CS was below 
pelvic inlet, cervical dilatation was ≥5 cm or duration of labour was ≥5 hours 
(Chapter 6). If these findings can be confirmed in future studies, it is relevant to 
learn if this relation is caused by a thin LUS during CS, by the low uterine incision 
or both. Also factors with potential negative influence on wound healing should 
be evaluated in future studies, as there are indications that a retroflected uterus, 
pre-eclampsia and multiple CSs are related to a niche (Chapter 6). 
We should learn more about the aetiology of symptoms, in order to be able to 
treat the niche effectively. In Chapter 4, we report that several hypotheses have 
been postulated to explain the aetiology of postmenstrual spotting. It may be 
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due to the retention of menstrual blood in the niche, which may depend on 
poor contractility of the uterine muscle around the scar and/or fibrotic tissue 
below the niche impairing the drainage of menstrual flow. Another hypothesis 
is that accumulated blood is produced in situ as was demonstrated by Morris20, 
which may be further elucidated by microscopic research on caesarean scar 
tissue. Research on scar tissue should also demonstrate if there is a condition of 
chronic inflammation at the site of a niche. 
More research is needed to confirm if there is a relation between a niche and 
subfertility, to learn more about the mechanism behind this and to find out if 
a niche affects future pregnancies. No studies were published that evaluated 
the relation between a niche and subfertility. One prospective cohort study 
found no increase in spontaneous abortion rates in the CS group compared to 
the non-CS group. However, in eight pregnancies in which the implantation site 
crossed the scar, seven of them resulted in a spontaneous abortion.21 A small 
study did indicate that there may be a relation between a large niche and uterine 
dehiscence or rupture19. As a growing number of women with large niches are 
treated to prevent uterine rupture or dehiscence, a large prospective study 
should be performed to confirm this result. 
Minimally invasive therapies are used to treat the symptoms related to the 
niche. One review22 included twelve studies, reporting on hysteroscopic niche 
resection, laparoscopic repair, (laparoscopic assisted) vaginal repair and oral 
contraceptives. Abnormal uterine bleeding improved in the vast majority of the 
patients after these interventions. However, the methodological quality of the 
papers was considered to be moderate to poor and therefore well-designed 
RCTs, which should include expectant management, are needed. In addition, 
studies with a long-term follow-up are needed, as not much is known about the 
chance for recurrence of a niche on the long term after treatment.
It is important that the awareness for the presence of a niche in women with 
a history of CS increases among doctors and patients, as a niche can cause 
complaints that can be treated successfully. Both small and large niches can 
cause symptoms. Women need to be informed about the risk to develop a niche 
and the related symptoms during the counselling for a primary CS. We need to 
learn more about the risk factors for a niche to enable surgeons to prevent the 
development of a niche during a CS. Therapies must be improved in order to treat 
women with a niche and symptoms successfully, and more research should be 
performed to get to know the optimal treatment modality and to tailor treatment 
to individual needs. 
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Summary
This thesis is about the niche, defined as an indentation of at least 1 mm 
representing myometrial discontinuity at the site of the caesarean scar that 
communicates with the uterine or cervical cavity, and mainly diagnosed using 
sonography and in particular with contrast-enhanced sonohysterography (SHG). 
Part I reports on diagnostics of the niche, part II on gynaecological symptoms 
and risk factors associated with a niche, and part III on niche pregnancy.
Chapter 1 is a general introduction and describes the outline of this thesis. 
The caesarean section (CS) rate is rising, and with that also the niche prevalence 
and interest for the niche. The niche is mostly evaluated with the use of 
transvaginal sonography (TVS) and SHG, but up to now there is no gold standard 
for the detection and measurement of a niche. As a result, a wide range in niche 
prevalence has been reported. In the first part of this thesis, we tried to learn 
more about the diagnostics and prevalence of a niche. 
We do know that not all women with a history of CS develop a niche, and therefore 
it is relevant to study the risk factors for the development of a niche. In addition, 
there are indications that a niche is associated with symptoms, especially with 
postmenstrual spotting. In the second part we tried to identify symptoms and 
risk factors associated with a niche.
Furthermore, caesarean scar pregnancies (CSPs) have been described in the 
literature. In the third part, we aimed to report favourable treatment modalities 
for CSPs. 
Part I
SHG is a widely used method for the assessment of the uterine cavity and for the 
detection and measurement of a niche. In Chapter 2, we compared gel instillation 
sonohysterography (GIS) with saline contrast sonohysterography (SCSH) for the 
evaluation of the uterine cavity. First SCSH and subsequently GIS were performed 
in 65 women suspected of having an intrauterine abnormality. Distension of the 
uterine cavity, image quality, visualization of intrauterine abnormalities and pain 
were recorded for both procedures. We found that the image quality of SCSH was 
slightly better than that of GIS, which was likely to be attributable to the presence 
of air bubbles in the gel. We concluded that the small difference in uterine cavity 
distension in favour of GIS and stable distension during at least 4 minutes make 
GIS a suitable alternative for SCSH if air bubbles can be prevented. More stable 
filling of the uterine cavity with gel is especially an advantage when performing 
3D ultrasound.  
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In Chapter 3 we studied the reproducibility of niche measurement with 
3D sonography. We evaluated the inter- and intraobserver agreement for 
measurement of niche size and volume, and assessment of shape with the use 
of three-dimensional (3D) ultrasound. Twenty 3D ultrasound volumes of uteri 
with a niche were selected and niche measurements were performed off-line 
twice by one observer and once by another observer in the longitudinal and 
transversal plane. The following measurements were performed: residual 
myometrial thickness (RMT), depth perpendicular to niche base, maximal depth, 
maximal width, width at niche base and the volume of the niche. In addition, we 
assessed the shape of the niche. We have shown that these niche parameters 
can be measured with a high level of agreement, in particular in the longitudinal 
plane. Our results demonstrated low reproducibility for niche shape.  
Part II
Chapter 4 and 5 describe two prospective cohort studies, evaluating the niche 
prevalence and its relation with symptoms. In Chapter 4, 225 women were 
examined with the use of sonography six to twelve months after CS. The 
included women completed a questionnaire and pictorial blood loss assessment 
chart (PBAC). A niche (defined as an anechoic area with a depth of at least 1 mm) 
was present in 24% of women with TVS and 56% with GIS, and was found to be 
associated with postmenstrual spotting. The volume of the niche was significantly 
larger in women with postmenstrual bleeding. We made a classification based 
on the sonographic shape of the niche. Niche shape was not associated with 
abnormal uterine bleeding. In Chapter 5, 263 women were included and 
sonography was performed six to twelve weeks after their CS. Women were 
followed by questionnaire and PBAC at six to twelve weeks, six months and 
twelve months after CS. The prevalence of a niche (defined as an anechoic area 
with a depth of at least 2 mm) was 50% with TVS and 65% with GIS, and women 
with niche had more often complaints of postmenstrual spotting twelve months 
after CS. In addition, the prevalence of postmenstrual spotting was higher in 
women with a RMT <50% of the adjacent myometrium than in women with a RMT 
>50%. Urinary incontinence was not related to the presence of a niche. 
Chapter 6 contains a systematic review of the medical literature on the 
prevalence of a niche using various diagnostic methods, on potential risk factors 
for the development of a niche and on niche-related gynaecological symptoms 
in non-pregnant women. Reported niche prevalence varies depending on 
the method of detection, the criteria used to define a niche and the study 
population. As each study evaluated different risk factors, we classified the risk 
factors into four categories: those related to closure technique, to development 
of the lower uterine segment or location of the incision, to wound healing, and 
Summary| 137
500835-L-bw-Dieleman
138 | Chapter 9
miscellaneous factors. Probable risk factors for the development of a niche are 
single-layer myometrium closure, multiple CSs and uterine retroflexion. Finally, 
we demonstrated with our review that the predominant symptom associated 
with a niche is postmenstrual spotting.  
Part III
We describe our experience with the treatment of four caesarean scar 
pregnancies (CSPs) and provide an overview of the available literature in 
Chapter 7. Based on these cases and the literature, we postulate that transcervical 
needle aspiration of amniotic fluid followed by intra-amniotic injection of 
methotrexate is a good option for the treatment of a CSP, which may prevent 
surgical treatment in a lot of cases. Surgical treatment can still be performed 
if methotrexate fails. A disadvantage of medical treatment in comparison with 
surgical treatment is that it requires more time for the serum ß-HCG levels to 
drop to normal and the pregnancy tissue to resolve completely. 
Chapter 8 provides the main findings of this thesis, a general discussion of the 
results and suggests future research strategies. 
There is a high variance in niche prevalence between studies, which may 
be explained by the heterogeneity of the studied populations and the lack of 
consensus on diagnostic criteria for a niche. The exact mechanism that leads 
to symptoms in women with a niche is still under debate. As a niche does not 
preclude a normal function of the lower uterine segment, with or without 
pregnancy, we prefer to avoid the term ‘defect’.
There are still no universal treatment guidelines for the management of CSP’s. 
We believe that transcervical needle aspiration of the gestational sac and intra-
amniotic injection of methotrexate is a preferable treatment option as surgical 
intervention and the related risk for complications can be prevented in the 
majority of cases. If medical treatment fails, we suggest hysteroscopy in patients 
with a sufficient thick myometrium, and laparoscopic or vaginal removal of the 
pregnancy in case the CSP grows toward the bladder.
Future research on the niche needs a uniform definition and standard method 
for niche assessment. In the absence of evidence for the correct cut-off value for 
niche depth, we propose the following definition for a niche: an indentation of 
at least 1 mm representing myometrial discontinuity at the site of the caesarean 
scar that communicates with the uterine or cervical cavity seen on SHG. Future 
research should demonstrate if this is the correct cut off value. In addition, 
we propose to use the parameters described in our reproducibility study 
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(Chapter 3). At least volume and RMT should be included, as we demonstrated that 
these parameters are related to postmenstrual spotting. In addition, RMT is an 
important factor in the decision to treat with either hysteroscopy or laparoscopy 
in women with gynaecological complaints. The focus for future research should 
be on the aetiology of niche development and related symptoms, and its impact 
on patients functioning, including sexuality. More research is needed to confirm 
if a niche is related to subfertility and/or to uterine dehiscence and rupture in 
a subsequent pregnancy. In addition, well-designed RCT’s are needed to get to 
know the optimal treatment modality of a niche, tailored to niche characteristics 
and symptoms of individual patients. 
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Dit proefschrift gaat over de niche. De niche is een inkeping in de baarmoederwand 
van tenminste 1 mm ter plaatse van het keizersnedelitteken en staat in verbinding 
met de baarmoederholte. De niche kan zichtbaar worden gemaakt door middel 
van echoscopie, en dan vooral met behulp van contrastechoscopie. Deel I van dit 
proefschrift gaat over de diagnostiek van de niche, deel II over gynaecologische 
symptomen als gevolg van de niche en risicofactoren voor een niche, en deel III 
over zwangerschappen in de niche. 
Hoofdstuk 1 is de introductie en beschrijft de achtergronden en doelstellingen 
van dit proefschrift. Het aantal keizersnedes neemt wereldwijd toe en daarmee 
ook de prevalentie van de niche en de interesse hiervoor. Hoewel de niche 
meestal wordt gediagnosticeerd met behulp van echoscopie, bestaat er nog geen 
gouden standaard voor de diagnostiek van een niche. Om die reden is de variatie 
in de gerapporteerde prevalentie van de niche groot. In het eerste deel van dit 
proefschrift wordt ingegaan op de diagnostiek en prevalentie van de niche. 
Niet alle vrouwen ontwikkelen een niche na een keizersnede. Het is van belang 
om te weten te komen welke vrouwen nu een niche ontwikkelen en wat 
risicofactoren zijn voor het ontstaan van een niche. Daarnaast hebben sommige 
vrouwen klachten als gevolg van een niche, zoals spotting na afloop van de 
menstruatie. In het tweede deel van dit proefschrift onderzoeken we welke 
risicofactoren geassocieerd zijn met een niche en de symptomen die bij een 
niche kunnen horen. 
In zeldzame gevallen nestelt een zwangerschap zich in een niche, wat een 
bedreiging vormt voor moeder en kind bij het vorderen van de zwangerschap. In 
het derde deel gaan we in op de behandeling van een zwangerschap in de niche. 
Deel I
Contrastechoscopie is een veel gebruikte onderzoeksmethode voor het in beeld 
brengen van de baarmoederholte, en ook voor het in beeld brengen van de niche. 
De baarmoeder wordt hierbij gevuld met een vloeistof, wat zorgt voor contrast, 
waarna een echo wordt gemaakt. Bij de uitvoering van dit onderzoek kan de 
baarmoederholte worden gevuld met gel (GIS, gel instillation sonohysterography) 
of met een fysiologische zoutoplossing (SCSH, saline contrast sonohysterography). 
In Hoofdstuk 2 hebben we beide methodes vergeleken door bij 65 vrouwen die 
verdacht werden van een afwijking in de baarmoederholte, zoals bijvoorbeeld een 
myoom of een poliep, eerst een contrastecho met fysiologische zoutoplossing 
en vervolgens met gel uit te voeren. Beide methodes werden vergeleken op de 
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volgende punten: distensie van de baarmoederholte, kwaliteit van de echo, het 
in beeld kunnen brengen van een afwijking in de baarmoederholte en pijn. We 
vonden dat de beeldkwaliteit met fysiologische zoutoplossing iets beter was dan 
met gel, wat meest waarschijnlijk werd veroorzaakt door de aanwezigheid van 
luchtbellen in de gel. Aangezien de distensie van de baarmoeder beter was met 
gel en de distensie stabiel bleef gedurende 4 minuten, concludeerden we dat 
gel een goed alternatief is voor fysiologische zoutoplossing als luchtbellen in de 
gel kunnen worden voorkomen. De stabielere vulling met gel is met name een 
belangrijk voordeel bij het maken van 3D-echo’s.
In Hoofdstuk 3 werd de reproduceerbaarheid van het opmeten van de niche 
met behulp van 3D-echografie onderzocht. We hebben de overeenkomst 
tussen de bevindingen van twee onderzoekers onderzocht en tussen de 
herhaalde bevindingen van dezelfde onderzoeker. Twintig 3D-echobeelden 
werden geselecteerd en de metingen werden offline verricht in het 
longitudinale en in het transversale vlak. De volgende metingen werden 
verricht: resterende dikte van de baarmoederwand ter plaatse van de niche, 
de diepte van de niche loodrecht op de basis, de maximale diepte van de 
niche, de maximale breedte van de niche, de breedte ter plaatse van de basis 
van de niche en het volume van de niche. Ook hebben we de vorm van de 
niche bepaald. Onze studie heeft aangetoond dat de reproduceerbaarheid 
van het opmeten van de niche met behulp van 3D-echografie goed is, met 
name in het longitudinale vlak. De reproduceerbaarheid van de bepaling van 
de vorm van de niche bleek slecht te zijn. 
Deel II
Hoofdstuk 4 en 5 beschrijven 2 prospectieve cohortstudies. Beide studies 
hebben de prevalentie van de niche onderzocht en gekeken welke symptomen 
veroorzaakt kunnen worden door een niche. Hoofdstuk 4 beschrijft de studie 
waarbij 225 vrouwen zes tot twaalf maanden na hun keizersnede werden 
onderzocht met behulp van een echo. Alle vrouwen vulden een vragenlijst en 
een menstruatiescorekaart (PBAC; pictorial blood loss assessment chart) in. Een 
niche (gedefinieerd als een inkeping met een diepte van tenminste 1 mm) was 
aanwezig bij 24% van de vrouwen met een normale vaginale echo en bij 56% 
van de vrouwen met GIS (contrastecho met gel). We vonden ook dat vrouwen 
met een niche vaker last hadden van spotting na de menstruatie, en dat het 
volume van de niche groter was bij vrouwen met deze klachten. We hebben 
een classificatie gemaakt gebaseerd op de vorm van de niche die we zagen met 
de echo, maar vonden geen relatie tussen de vorm en menstruatieklachten. In 
het onderzoek van Hoofdstuk 5 werden 263 vrouwen geïncludeerd en werd 
zes tot twaalf weken na de keizersnede een echo gemaakt. Ook deze vrouwen 
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kregen een vragenlijst en menstruatiescorekaart (PBAC; pictorial blood loss 
assessment chart) die op 3 tijdstippen werden ingevuld: zes tot twaalf weken 
na de keizersnede, zes maanden na de keizersnede en twaalf maanden na de 
keizersnede. De prevalentie van de niche (gedefinieerd als een inkeping van 
minstens 2 mm) was in dit onderzoek 50% met een normale vaginale echo en 
65% met GIS (contrastecho met gel). Twaalf maanden na de keizersnede hadden 
vrouwen met een niche vaker klachten van spotting na de menstruatie. Spotting 
na de menstruatie kwam vaker voor bij vrouwen bij wie de resterende dikte 
van de baarmoederwand ter plaatse van de niche minder was dan 50% van de 
volledige dikte van de baarmoederwand (RMT <50%) in vergelijking met vrouwen 
bij wie de resterende dikte meer was dan 50% (RMT >50%). Urine-incontinentie 
bleek niet geassocieerd te zijn met de aanwezigheid van een niche.
Hoofdstuk 6 is een systematisch review van de medische literatuur, waarbij de 
diagnostiek en bijbehorende prevalentie van de niche werden onderzocht, de 
mogelijke risicofactoren voor de ontwikkeling van een niche en de symptomen 
die geassocieerd zijn met een niche bij niet-zwangere vrouwen. Er bleek grote 
variatie te zijn in de gerapporteerde prevalentie van een niche, afhankelijk van 
de gebruikte diagnostische methode, de gebruikte definitie voor een niche en 
de studiepopulatie. Omdat iedere geïncludeerde studie andere risicofactoren 
had onderzocht, werden alle risicofactoren geclassificeerd in 4 categorieën: 
risicofactoren die te maken hebben met hechttechniek, risicofactoren die te 
maken hebben met de ontwikkeling van het onderste uterussegment tijdens de 
bevalling of de locatie van de incisie tijdens de keizersnede, risicofactoren die 
te maken hebben met wondgenezing en overige risicofactoren. Uit ons review 
bleek dat enkellaags hechten van de baarmoederwand tijdens een keizersnede, 
een voorgeschiedenis met meerdere keizersnedes en een baarmoeder in 
retroflexie risicofactoren zijn voor de ontwikkeling van een niche. Ook hebben 
we aangetoond dat spotting na de menstruatie het belangrijkste symptoom is 
dat is geassocieerd met de aanwezigheid van een niche. 
Deel III
In Hoofdstuk 7 beschrijven we onze ervaring met de behandeling van 4 
zwangerschappen in een niche en geven we een overzicht van de literatuur die gaat 
over de behandeling van deze zeldzame zwangerschappen. Gebaseerd op onze 
ervaring en de literatuur concludeerden we in dit hoofdstuk dat opzuigen van het 
zwangerschapsweefsel met een naald via de cervix, gevolgd door het achterlaten 
van Methotrexaat een goede primaire behandeling is van een zwangerschap in 
een niche, waardoor een operatie in veel gevallen kan worden voorkomen. In 
het geval dat Methotrexaat onvoldoende effect heeft, kan dan altijd nog tot een 
operatie worden overgegaan. Een nadeel van deze medicamenteuze behandeling 
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ten opzichte van een operatie is dat het langer duurt totdat het ß-HCG in het 
bloed is gedaald tot normale waarden en het zwangerschapsweefsel volledig is 
verdwenen. 
Hoofdstuk 8 beschrijft de belangrijkste conclusies van dit proefschrift, en de 
sterke en minder sterke methodologische aspecten van alle hoofdstukken. Ook 
bespreken we onze bevindingen in het licht van andere literatuur en doen we 
aanbevelingen voor toekomstig onderzoek.
 
Er is een grote variatie in de gerapporteerde prevalentie van de niche, wat zou 
kunnen worden verklaard door heterogene studiepopulaties en het gebrek aan 
eenduidige diagnostische criteria voor de niche. Het exacte mechanisme waardoor 
vrouwen met een niche klachten krijgen, is nog steeds niet opgehelderd. Wij 
zijn voorstander van het vermijden van de term ‘defect’ als we praten over een 
keizersnedelitteken met een niche, aangezien deze term impliceert dat sprake is 
van een pathologische functie van het onderste uterussegment. Voor dit laatste 
is geen bewijs. 
Er zijn nog steeds geen richtlijnen voor de behandeling van een zwangerschap in 
een niche. Onze voorkeur gaat uit naar het opzuigen van het zwangerschapsweefsel 
met een naald via de cervix, gevolgd door het achterlaten van Methotrexaat, 
zodat een operatie en de bijbehorende mogelijke complicaties kunnen worden 
vermeden in een meerderheid van de gevallen. Als deze medicamenteuze 
behandeling niet slaagt, adviseren wij een hysteroscopische behandeling 
bij patiënten bij wie de baarmoederwand ter plaatse van de zwangerschap 
voldoende dik is, en laparoscopische behandeling of een operatie via de vagina 
bij vrouwen met een dunne baarmoederwand bij wie de zwangerschap richting 
de blaas groeit. 
Voor toekomstig onderzoek is het belangrijk dat een uniforme definitie bestaat 
voor de niche en een gestandaardiseerde methode voor de detectie en het in 
kaart brengen van een niche. Hoewel er nog geen bewijs is voor een bepaalde 
afkapwaarde van de diepte van de niche stellen wij de volgende definitie van de 
niche voor: een inkeping in de baarmoederwand van tenminste 1 mm ter plaatse 
van het keizersnedelitteken, waarbij verbinding is met de baarmoederholte, 
vastgesteld met een contrastecho. Toekomstig onderzoek moet aantonen of 
dit de juiste afkapwaarde is. Ook stellen wij voor om de parameters uit ons 
reproduceerbaarheidsonderzoek (Hoofdstuk 3) te gebruiken. In elk geval moeten 
het volume van de niche en de resterende dikte van de baarmoederwand ter 
plaatse van de niche worden opgemeten, aangezien we hebben aangetoond dat 
deze parameters geassocieerd zijn met spotting na de menstruatie. Daarnaast 
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is de resterende dikte van de baarmoederwand een belangrijke factor voor de 
beslissing ofwel een hysteroscopische ofwel een laparoscopische behandeling 
uit te voeren bij vrouwen die behandeld willen worden voor de klachten als gevolg 
van een niche. De focus van toekomstig onderzoek moet ons inziens liggen op 
de etiologie van de ontwikkeling van een niche en gerelateerde symptomen, en 
de impact hiervan op het functioneren van patiënten (onder andere de impact 
op de sexualiteit). Meer onderzoek is nodig om aan te tonen dat er een relatie is 
tussen een niche en subfertiliteit, en dehiscentie of ruptuur tijdens een volgende 
zwangerschap. RCT’s zijn nodig om te weten te komen wat de beste behandeling 
is van een niche, afgestemd op de individuele karakteristieken van een niche en 
individuele klachten van een patiënt. 
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Dankwoord
Het is eindelijk zover! De afgelopen jaren heb ik steeds met plezier gewerkt aan 
het onderzoek en het opschrijven van de resultaten. Aan dit proefschrift en de 
weg ernaar toe hebben vele mensen bijgedragen, die ik hier wil bedanken. 
Allereerst wil ik alle vrouwen bedanken die hebben deelgenomen aan de SECURE-
studie. Dankzij hen hebben we veel kunnen leren over de niche. Ik was verrast 
door de bereidheid waarmee zij meededen aan het onderzoek. Velen van hen 
waren zelfs bereid deel te nemen aan de vervolgonderzoeken. 
Ik wil mijn promotoren bedanken voor hun hulp bij het tot stand komen van 
dit proefschrift. Prof. dr. H.A.M. Brölmann, beste Hans, ik kan me nog goed 
herinneren dat je me vroeg om naast mijn coschappen een onderzoekje te komen 
doen. Ik deed mijn examen voor het coschap gynaecologie bij ‘de professor’ en 
wilde graag verder in de gynaecologie. Ik nam me voorafgaand aan het examen 
voor dat ik van deze gelegenheid gebruik moest maken om dit kenbaar te maken, 
maar werd tot mijn verrassing door jou gevraagd onderzoek te komen doen. Van 
het een kwam het ander en uiteindelijk begon ik met de opleiding Verloskunde 
en Gynaecologie. Hoewel dat uiteindelijk voor mij niet het juiste vak bleek te zijn, 
heb ik absoluut geen spijt van alle jaren die ik op jouw afdeling heb doorgebracht. 
Ik wil je bedanken voor alle kansen die je mij hebt gegeven. Ik begon als een leek 
in het doen van onderzoek (“Wat is een CRF?”) en ben je erkentelijk voor het vele 
dat ik heb geleerd tijdens mijn onderzoeksjaren. Dank voor het zelfvertrouwen 
dat je mij hebt gegeven in mijn eerste jaren als arts!
Dr. J.A.F. Huirne, beste Judith, dank dat jij er later bij kwam als copromotor. Ik heb 
het enorm gewaardeerd dat jij er altijd was als klankbord en dat ik mijn stukken 
telkens weer per ommegaande terugkreeg met waardevol commentaar. Ik moet 
bekennen dat ik er wel eens van heb gebaald als een stuk erg snel over ‘de 
schutting’ terugkwam voorzien van jouw grondige commentaar; de blijdschap 
ervan af te zijn was dan slechts van korte duur. Het troostte me dat ik wist dat 
het artikel er altijd beter van zou worden! Ik bewonder je om de grote berg werk 
die je verzet en om jouw multitask-kwaliteiten. Ooit belden we op een zaterdag 
toen je aan het werk was en tegelijkertijd koekjes bakte met de kinderen. Dank 
ook voor je persoonlijke interesse en steun!  
Dr. J.W. van der Slikke, beste Hans, bedankt voor de begeleiding tijdens de 
eerste jaren van mijn promotie-onderzoek en niet te vergeten tijdens het 
Madonnaproject. Het was een plezier om samen met jou mijn vuurdoop van het 
spreken op een internationaal congres (in Sint Petersburg) te beleven. 
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Geachte leden van de promotiecommissie, prof. dr. M.Y. Bongers, prof. dr. T. 
Bourne, prof. dr. O. Donnez, dr. W.J.K. Hehenkamp, prof. dr. F.W. Jansen, prof. dr. 
C.B. Lambalk, prof. dr. H. de Vries, hartelijk dank voor uw deelname en voor het 
kritisch beoordelen van het manuscript. 
Alle co-auteurs wil ik bedanken voor hun bijdragen en nuttig commentaar op alle 
conceptversies van de artikelen. 
Beste Lucet, beiden hebben we vele jaren gewerkt aan onderzoek naar de niche. 
Ik hoop dat jouw proefschrift gauw zal volgen. 
Beste echoscopisten, beste Annemieke, Annelieke, Marijke, Monique, Sara en 
Charlotte, van jullie heb ik het maken van echo’s geleerd. Fijn dat jullie altijd 
bereid waren mee te denken en me attendeerden op ‘mooie niches’. 
Alle mede-onderzoekers van het VUmc - Annemarie, Chantal, Dorien, Els, Esther, 
Ingeborg, Iris, Lisette, Lucas, Maaike, Marieke, Mariëlle, Marja-Liisa, Petra, 
Sylvia, Tamar, Ton en Yolanda - wil ik bedanken voor de mooie onderzoeksjaren. 
Kamergenoten, Jacqueline, Afra en Mariëlle, wat hebben we goede tijden beleefd; 
vooral de koffiepauzes om 10.30 uur waren hoogtepuntjes van de soms lange 
onderzoeksdagen. Annemarie en Yolanda, ook al zijn onze wegen gesplitst en is er 
veel gebeurd in de afgelopen tijd, onze ‘gesprekken van de koffiepauze’ gaan nog 
steeds door en ik hoop dat ze nog heel lang door zullen gaan. Yolanda en Petra, 
we hebben mooie tijden beleefd op congressen; bedankt voor jullie gezelligheid! 
Ingeborg, bedankt dat je tijd vrij hebt willen maken om naar echobeelden te 
kijken voor mijn laatste artikel. 
Beste Anne-To Boddeus, Leo van Velzen, Rikste Hinloopen en Willy Lemmen, 
wat een voorrecht dat jullie mijn opleiders in het eerste en derde jaar van de 
huisartsopleiding zijn (geweest). Jullie hebben mij begeleid tijdens de eerste 
stappen in het huisartsenvak - de kennis moest in het begin van ver komen -, mij 
de liefde voor het vak bijgebracht en ervoor gezorgd dat ik straks met een rugzak 
vol kennis en zelfvertrouwen zelf als huisarts aan de slag ga. Ik hoop jullie nog 
regelmatig tegen te komen in huisartsenland! 
Lieve Marieke, Linda en Marja-Liisa, studievriendinnen (letterlijk) van de eerste 
dag. Super dat we elkaar nog steeds met enige regelmaat zien. Dank voor jullie 
vriendschap!
Lieve Femke, Alexandra en Janet, dank voor jullie vriendschap die nu al zeker 20 
jaar (!) bestaat. Door de drukte van het leven zien we elkaar soms wat minder, 
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maar dat doet niet af aan onze vriendschap. Ongetwijfeld volgen er nog veel 
gezellige weekendjes als er even niet wordt gebaard of verhuisd. 
Lieve paranimfen, Inge en Marja-Liisa, dank dat jullie aan mijn zijde willen staan 
tijdens de verdediging van mijn proefschrift. Geen seconde heb ik na hoeven 
denken over mijn keuze voor jullie. Lieve zus, we werken dan wel op totaal 
verschillende terreinen, onze carrières vertonen vele overeenkomsten. Tegelijk 
genoten we van het student zijn, gingen we aan het werk en maakten we mooie 
reizen samen. Hoewel allebei in een andere stad vonden we altijd wel de tijd om 
bij te kletsen. Een tijdje was het vaste prik om even te bellen na middernacht 
als we allebei weer richting huis gingen of dronken we een snelle kop koffie op 
plaatsen waar onze wegen kruisten. Beiden hebben we ons hart gevolgd en een 
carrièreswitch gemaakt, waar we tot op de dag van vandaag nog steeds gelukkig 
mee zijn. Ik hoop dat onze levens nooit te druk zullen zijn voor het bijkletsen 
onder het genot van een kop koffie, en dat Peter en Anne-Sophie veel kunnen 
genieten van hun tante. 
Lieve Marja-Liisa, we hebben elkaar, met Linda en Marieke, ontmoet op dag 1 van 
onze studententijd. We kwamen naast elkaar te wonen en haalden de schotten 
tussen onze balkonnetjes weg, wat het grote Amsterdam net iets kleiner 
maakte. Daarna nam ik jouw studentenkamer over en begonnen we allebei bij 
de Verloskunde en Gynaecologie. Een aantal jaar later kondigden we op dezelfde 
avond allebei aan te switchen naar de huisartsopIeiding; in de beide opleidingen 
en de promotie ging jij mij net een stap voor. Je stond en staat altijd klaar met 
een goed advies. Bedankt daarvoor en ook voor onze fijne vriendschap!
Lieve Jan-Bart, wat leuk om te zien dat jij nu écht je plekje hebt gevonden. Hoewel 
jij in mijn hart mijn kleine broer zult blijven, ging je me voor in het trouwen, kopen 
van een eigen huis en krijgen van kinderen. Ik respecteer je om de manier waarop 
je in het leven staat en je gulle levenshouding! 
Lieve Jacqueline, Hélène, Rien, Edith, Willem, Ruth, Ben en Marianne, dank 
voor jullie meeleven tijdens het schrijven van dit proefschrift. Belangrijker nog, 
bedankt voor alle goede tijden die we als familie met elkaar hebben! 
Lieve pa en ma Dieleman, bedankt dat ik er zulke fijne schoonouders bij ‘kado’ 
heb gekregen. Wat leuk dat ik in uw voetsporen ga treden als huisarts! Bedankt 
dat u altijd voor ons klaar staat! 
Lieve pa en ma, dank voor alle kansen die jullie mij hebben geboden en voor 
jullie onvoorwaardelijke steun! Ik realiseer me steeds meer dat het een groot 
goed is dat ik altijd het gevoel had dat jullie achter me stonden, zelfs als jullie 
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niet onverdeeld blij waren met een voornemen. Wat heerlijk om een stabiele 
thuisbasis te hebben, waar we altijd op terug kunnen vallen! 
Lieve François, Peter en Anne-Sophie, wat ben ik dankbaar voor jullie 
aanwezigheid in mijn leven! François, dankzij jou heeft dit proefschrift enige 
vertraging opgelopen. Ik had me voorgenomen om mijn dankwoord nooit te 
hoeven eindigen met “het proefschrift is nu af, vanaf nu ga ik genieten”. Nee 
liefste, wat hebben wij genoten van de afgelopen jaren samen en ik hoop dat er 
nog velen zullen volgen. Ik hou van je! 
Peter en Anne-Sophie, wat genieten we elke dag van jullie schaterlachen, 
prachtige opmerkingen en dikke knuffels. Lieve Peter, bedankt dat je ’s middags 
af en toe nog een (kort of lang) tukkie deed, dankzij jou is dit proefschrift dan 
toch nog afgekomen. En lieve Anne-Sophie, jij vond het alleen maar gezellig om 
naast mij in je wipstoel te zitten als ik achter mijn computer zat te typen. Geen 
peuter vrolijker dan jij! Jullie zijn onze grootste schatten!
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Marjolein Dieleman-Bij de Vaate werd op 5 juli 1979 geboren te Utrecht. Zij is de 
oudste dochter van J. Bij de Vaate en W. Bij de Vaate-Sterk en groeide samen met 
haar zus en broer op in Zoetermeer. In 1997 behaalde zij haar Gymnasiumdiploma 
aan het Christelijk Gymnasium Sorghvliet te Den Haag. 
Daarop startte zij met de studie Medische Biologie aan de VU in Amsterdam. 
Na drie jaar werd zij ingeloot voor de studie Geneeskunde, die zij volgde aan 
dezelfde universiteit. In 2005 behaalde zij haar doctoraal Medische Biologie en 
in 2006 haar artsexamen. Aansluitend begon zij onder begeleiding van prof. 
dr. H.A.M. Brölmann, en later ook onder begeleiding van dr. J. Huirne, aan het 
promotieonderzoek dat tot dit proefschrift heeft geleid. 
In 2010 begon Marjolein met de opleiding Verloskunde en Gynaecologie in het 
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